,Title,Sentence,Useful
0,Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis Letter to the Editor Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis,"Since January 2020 when it was first isolated in China, coronavirus disease 2019 has spread throughout the world and caused substantial morbidity and mortality.",1
16,Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis Letter to the Editor Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis,The likely explanation for the worse outcomes observed in patients with baseline elevated markers of liver injury could be attributed to compromised immune status.,1
19,Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis Letter to the Editor Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis,Proposed explanations include drug-induced liver injury; direct injury to the liver due to COVID-19 hepatitis; COVID-19 induced myositis; binding of SARS CoV-2 directly to angiotensin-converting enzyme 2 positive rich cholangiocytes and causing liver damage; hepatic congestion due to high levels of positive end expiratory pressure during mechanical ventilation; and aggravation of liver injury by SARS CoV-2 in patients with pre-existing viral hepatitis.,1
32,"NIHR Health Protection Research Unit (HPRU) in Immunisation, London, UK 4","This was subsequently identified and designated as COVID-19, caused by the novel severe acute respiratory syndrome coronavirus 2 , a strain previously unseen in humans.",1
52,"NIHR Health Protection Research Unit (HPRU) in Immunisation, London, UK 4","• requiring admission to hospital and • have either clinical or radiological evidence of pneumonia or • acute respiratory distress syndrome or • influenza like illness , hoarseness, nasal discharge or congestion, shortness of breath, sore throat, wheezing, sneezing Imported cases were defined as cases with travel to countries with known COVID-19 circulation at the time or with contact with a confirmed case whilst abroad within a maximum incubation period of their onset of symptoms.",1
237,"NIHR Health Protection Research Unit (HPRU) in Immunisation, London, UK 4",It is important to note that the predictive values do not necessarily reflect the prevalence of COVID-19 in the population at any particular time.,1
255,Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study,"It is clear that ethnicity is a predictor of a positive SARS-CoV2 result, disease severity and mortality, regardless of age, sex, geographical location, deprivation, smoking status, BMI, co-morbidities and frailty.",1
259,Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study,The novel Severe Acute Respiratory Syndrome Coronavirus-2 which manifests as coronavirus disease 2019 has led to a global pandemic .,1
272,Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study,We considered all patients with confirmed SARS-CoV-2 infection and admitted to the five acute hospitals within Barts Health NHS Trust between 1 st January and 13 th May 2020.,1
275,Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study,"The first emergency admission encompassing the first positive SARS-CoV-2 test, or the first emergency admission within two weeks of positive outpatient testing was defined as the index admission, community diagnoses without an associated emergency hospital admission were excluded.",1
303,Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study,"A total of 1996 patients, aged 16 years and older, with a confirmed SARS-CoV-2 test result with an acute Barts Health admission on or before 13th May 2020 were included in this study .",1
375,Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study,"Importantly, SARS-CoV-2 testing has an appreciable false negative rate and suspected, but not proven, cases are an important group.",1
469,ai-corona: Radiologist-Assistant Deep Learning Framework for COVID-19 Diagnosis in Chest CT Scans,Nucleic acid was extracted from the samples with the QiaSymphony system and SARS-CoV-2 RNA was detected using primer and probe sequences for screening and conformation on the basis of the sequence described by .,1
636,Online COVID-19 diagnosis with chest CT images: Lesion-attention deep neural networks,The novel coronavirus disease 2019 is undergoing an unprecedented global outbreak.,1
641,Online COVID-19 diagnosis with chest CT images: Lesion-attention deep neural networks,The reverse-transcription polymerase chain reaction test is the current standard method for detecting the coronavirus for COVID-19 patients.,1
693,Online COVID-19 diagnosis with chest CT images: Lesion-attention deep neural networks,This lesion-attention mechanism drastically improves the diagnostic accuracy to the level of clinical standards by human experts.,1
768,"Title: Rapid screening of COVID-19 patients by White blood cells scattergrams, a study on 381 patients Revisions are marked in bold red","The novel coronavirus SARS-CoV-2, responsible for COVID-19 confronts the health community with major challenges.",1
805,"Title: Rapid screening of COVID-19 patients by White blood cells scattergrams, a study on 381 patients Revisions are marked in bold red","Based on this retrospective study, we conclude that WDF analysis can be implemented during the SARS-CoV-2 pandemic to quickly categorize symptomatic patients as either COVID-19 probable or improbable, depending on the presence of the plasmacytoid lymphocytes cluster on their scattergram.",1
810,Functional pathways in respiratory tract microbiome separate COVID-19 from community-acquired pneumonia patients,"An impressive number of scientific studies have rapidly been published on the genomics and molecular-level host interactions of the new coronavirus SARS-Cov-2 1 of reported bat origin, 2 responsible for the COVID-19 disease pandemic.",1
816,Functional pathways in respiratory tract microbiome separate COVID-19 from community-acquired pneumonia patients,"8 focused on the SARS-Cov-2 genomes and taxonomic profiling of the microbiomes, here we perform functional profiling to characterize active biological processes.",1
829,Functional pathways in respiratory tract microbiome separate COVID-19 from community-acquired pneumonia patients,Nearly identical results were also obtained when utilizing only the bacterial subset of the database for read matching; the separation is not merely due to COVID-19 sample reads matching SARS-CoV-2 protein domains .,1
830,Functional pathways in respiratory tract microbiome separate COVID-19 from community-acquired pneumonia patients,The sequencing data had varying total number of reads and human content per sample .,1
857,Functional pathways in respiratory tract microbiome separate COVID-19 from community-acquired pneumonia patients,"11 including Trim Galore 19 trimming and bowtie2 20 human read filtering, resulting in 40k to 32M input reads for microbial functional annotation per sample .",1
858,Functional pathways in respiratory tract microbiome separate COVID-19 from community-acquired pneumonia patients,Human reads were already filtered by Shen et al.,1
859,Functional pathways in respiratory tract microbiome separate COVID-19 from community-acquired pneumonia patients,"8 , still we removed additional reads that mapped to human with the bowtie 2 local alignment mode.",1
946,Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study,"Excess deaths from the coronavirus disease 2019 pandemic might arise both in those infected , as well as those affected by altered access to health services; the physical, psychological, and social effects of distancing; and economic changes.",1
968,Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study,"Evidence before this study We searched PubMed, medRxiv, bioRxiv, arXiv, and Wellcome Open Research for peer-reviewed articles, preprints, and research reports on mortality and comorbidities at baseline in coronavirus disease 2019 , using the search terms ""coronavirus"", ""COVID-19"", and similar terms, and ""mortality"", up to March 21, 2020.",1
1127,Characteristics of COVID-19 infection in Beijing,We compared the epidemic features between COVID-19 and 2003 SARS for learn lessons and control the outbreak.,1
1129,Characteristics of COVID-19 infection in Beijing,"The measures to prevent transmission was very successful at early stage, the next steps on the COVID-19 infection should be focused on early isolation of patients and quarantine for close contacts in families and communities in Beijing and China.",1
1135,Characteristics of COVID-19 infection in Beijing,"Additionally, Beijing experienced the outbreak of SARS in 2003.",1
1136,Characteristics of COVID-19 infection in Beijing,"For learn lessons and control the outbreak, we compare the epidemic features between COVID-19 and 2003 SARS.",1
1139,Characteristics of COVID-19 infection in Beijing,The features were compared between COVID-19 and 2003 SARS.,1
1141,Characteristics of COVID-19 infection in Beijing,"A confirmed case was defined as a suspected case with the laboratory test for the COVID-19 from the respiratory specimens show positive result by the real-time reverse-transcription-polymerasechain-reaction assay, while a suspected case was defined as a case that fulfilled both the following criteria: have fever, radiographic evidence of pneumonia, low or normal white-cell count or low lymphocyte count in clinic; and have a travel to Wuhan or direct contact with patients from Wuhan who have fever or respiratory symptoms within 14 days before illness in the epidemic history according to the new coronavirus pneumonial prevention and control program, and the new coronavirus pneumonial diagnosis and treatment program which were published by the National Health Commission of China.",1
1164,Characteristics of COVID-19 infection in Beijing,"The median time from contact symptomatic case to illness onset, which is called the incubation period, was 6.7 days, from illness onset to visit hospital was 4.5 days, from visit hospital to defined confirmed case was 2.1 days.",1
1174,Characteristics of COVID-19 infection in Beijing,"From May 1st, the new confirmed case of SARS started to decline, but the COVID-19 confirmed cases was still moving in the mainland of China until Feb 10, 2020.",1
1175,Characteristics of COVID-19 infection in Beijing,China has experienced SARS in 2003 and MERS in 2012 of the coronavirus outbreak.,1
1176,Characteristics of COVID-19 infection in Beijing,"11 As prof. Drazen said, the SARS shows that when confronted by a common enemy, we can forget our differences and work together fruitfully.",1
1177,Characteristics of COVID-19 infection in Beijing,"This was the most important lesson from SARS, let us hope that we can all benefit from it.",1
1182,Characteristics of COVID-19 infection in Beijing,"Therefore, to identify and control the non-pneumonia and asymptomatic cases are the important measures to prevent transmission on the COVID-19.",1
1188,Characteristics of COVID-19 infection in Beijing,"The most common symptoms of illness onset were fever, cough, fatigue, and headache, severe cases with dyspnea, the results were consistent with the new coronavirus pneumonial diagnosis and treatment program published by the National Health Commission of China.",1
1189,Characteristics of COVID-19 infection in Beijing,9 The median time of incubation period was 6.7 days.,1
1194,Characteristics of COVID-19 infection in Beijing,"Therefore, Beijing was successful in preventing and controlling on the COVID-19 infection, it benefits from the correct leadership and experience of SARS in 2003.",1
1195,Characteristics of COVID-19 infection in Beijing,"From the perspective of death of SARS, as of May 11, 2003 , the fatality of the SARS was 5.0%, while the COVID-19 was 2.4% in the whole national, there was no significant with the fatality between SARS and the COVID-19 infection in the early stage, but different in the later, the fatality rate of SARS was up to 10% at last.",1
1200,Characteristics of COVID-19 infection in Beijing,"Last, the official data of 2003 SARS is a month later than the outbreak, its epidemic development curve is not precise.",1
1205,Pediatric Blood & Cancer Pediatric cancer research: Surviving COVID-19,"Importantly, industry has a vital role in supporting pediatric cancer research through drug discovery, laboratory research, and codevelopment of and support for clinical trials.",1
1209,Pediatric Blood & Cancer Pediatric cancer research: Surviving COVID-19,"19 Interestingly, immune dysregulation and hyperinflammation as measured by whole blood transcription profiles have also been shown to correlate with severe respiratory syncytial virus disease in infants, 20 who also have higher viral loads and more protracted viral decay than infants with mild RSV.",1
1210,Pediatric Blood & Cancer Pediatric cancer research: Surviving COVID-19,21 27 and adaptive immune responses.,1
1211,Pediatric Blood & Cancer Pediatric cancer research: Surviving COVID-19,"28 As adults have a more proinflammatory background, they may be predisposed to more severe COVID-19 via a hyperinflammatory response to SARS-CoV-2.",1
1212,Pediatric Blood & Cancer Pediatric cancer research: Surviving COVID-19,Adults and children also differ in their immune response to viral challenge.,1
1215,Pediatric Blood & Cancer Pediatric cancer research: Surviving COVID-19,"38 Furthermore, both cancer and infectious pathogens use similar strategies to avoid immune recognition.",1
1217,Pediatric Blood & Cancer Pediatric cancer research: Surviving COVID-19,"Therefore, immune profiling of SARS-CoV-2 infection may elucidate pathways involved in oncogenesis or inflammation that could be targeted with novel or repurposed cancer or supportive therapies.",1
1220,Pediatric Blood & Cancer Pediatric cancer research: Surviving COVID-19,"42 Given its development as an ABL kinase inhibitor, imatinib has been shown to block coronavirus membrane fusion, inhibiting viral entry into cells.",1
1221,Pediatric Blood & Cancer Pediatric cancer research: Surviving COVID-19,"43 Similarly, the Janus kinase 1/2 inhibitor, ruxolitinib, and the blocking monoclonal IL-6 antibody, tocilizumab, may inhibit SARS-CoV-2-induced hyperinflammation 19 in addition to their use in steroid-refractory graft-versus-host disease following allogeneic hematopoietic cell transplant 44 and cytokine storm following chimeric antigen receptor T cell therapy, 45 respectively.",1
1224,Pediatric Blood & Cancer Pediatric cancer research: Surviving COVID-19,"Given its high prevalence, high transmissibility, and lack of established therapeutic and preventative agents, SARS-CoV-2 will likely infect the majority of adults and children.",1
1225,Pediatric Blood & Cancer Pediatric cancer research: Surviving COVID-19,"Therefore, defining potential associations of SARS-CoV-2 with future cancer risk, especially in minority populations, 48 continue to impact many more millions of people, given the need to restructure life in response to an evolving pandemic.",1
1239,Journal Pre-proof Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2? Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2?,"The papular-purpuric gloves and socks syndrome, for example, was initially described in patients with parvovirus B19 infection, but a similar clinical appearance was then reported with many other viruses: Epstein-Barr virus, cytomegalovirus, hepatitis B, measles, varicella, human herpes virus 6, HIV, and others.",1
1250,Journal Pre-proof Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2? Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2?,"One basic difference between a classic viral eruption and a paraviral eruption is that the skin lesions result from a direct interaction between the virus and the skin in the former, and they are a consequence of an immune reaction triggered by the virus in the latter.",1
1258,Journal Pre-proof Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2? Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2?,"Unfortunately, the mere publication has immediately led to discontinuation of major clinical trials.",1
1268,Journal Pre-proof Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2? Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2?,"In many patients, SARS-CoV-2 could be demonstrated by nasopharyngeal swabs.",1
1287,Journal Pre-proof Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2? Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2?,"Many of them did not develop specific anti-SARS-CoV-2 antibodies suggest that they might have a natural resistance to the virus, as I have hypothesized elsewhere .",1
1288,Journal Pre-proof Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2? Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2?,"These findings suggest that their innate immune system rejects the virus and that the adaptive immune system does not need to intervene, explaining the lack of specific antibodies.",1
1289,Journal Pre-proof Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2? Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2?,"Interestingly, children with rare monogenic disorders leading to an enhanced anti-viral innate immune response also develop chilblains, supporting this hypothesis.",1
1293,Journal Pre-proof Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2? Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2?,It will be up to them to determine the association with SARS-CoV-2 and the meaning of the findings in term of viral vs paraviral.,1
1295,Journal Pre-proof Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2? Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2?,"Some signs are the direct consequence of the virus interacting with an organ, while others are the consequence of activation of the immune system.",1
1296,Journal Pre-proof Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2? Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2?,"Obviously, therapy and care of the patients will not be the same whether the target is the virus or the immune system.",1
1298,Journal Pre-proof Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2? Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2?,1 monomorphic papulovesicular and excoriated mildly pruritic rash in a 54-year-old man with positive SARS-CoV-2 nasopharyngeal swab.,1
1303,Elevations of serum cancer biomarkers correlate with severity of COVID-19,The coronavirus disease 2019 pandemic has become a global threat to public health.,1
1306,Elevations of serum cancer biomarkers correlate with severity of COVID-19,4 Severe acute respiratory syndrome coronavirus 2 is the causative organism for COVID-19.,1
1307,Elevations of serum cancer biomarkers correlate with severity of COVID-19,"5 Betacoronavirus, which is based on the most conserved sequence of coronavirus genome, that is, the open reading frame 1a/1b responsible for replicases encoding.",1
1308,Elevations of serum cancer biomarkers correlate with severity of COVID-19,"6 The RNA genome has 29,891 nucleotides and share 79% sequence identity with SARS-COV and 50% sequence identity with Middle East respiratory syndrome coronavirus .",1
1309,Elevations of serum cancer biomarkers correlate with severity of COVID-19,"6, 7 The phylogeny of this Accepted Article coronavirus show that it is most close to the bat coronavirus RaTG13, with 96.3% sequence identity.",1
1310,Elevations of serum cancer biomarkers correlate with severity of COVID-19,3 The SARS-COV2 Spike protein is thought to mediate the virus entering host cells via surface angiotensin converting enzyme 2 .,1
1312,Elevations of serum cancer biomarkers correlate with severity of COVID-19,The incubation period for symptomatic development in COVID-19 is approximately 4-7 days.,1
1320,Elevations of serum cancer biomarkers correlate with severity of COVID-19,We posit that SARS-CoV-2-induced acute lung injuries may be associated with elevations of some cancer biomarkers.,1
1375,"CD4+T, CD8+T counts and severe COVID-19: A meta-analysis",CD4+T and CD8+T play a vital role in maintaining immune function and viral clearance in the body.,1
1379,"CD4+T, CD8+T counts and severe COVID-19: A meta-analysis","We searched PubMed, EMBASE and Web of Sciences, using the keywords as ""CD4"", ""CD8"", ""COVID-19"", ""Severe 2019-nCoV"", and ""SARS-CoV-2"" without date or language restrictions.",1
1393,"CD4+T, CD8+T counts and severe COVID-19: A meta-analysis",COVID-19 is an acute inflammatory infectious disease caused by severe acute respiratory syndrome coronavirus 2 .,1
1394,"CD4+T, CD8+T counts and severe COVID-19: A meta-analysis",SARS-CoV-2 has a genome sequence 79.6% identical to the SARS-CoV .,1
1396,"CD4+T, CD8+T counts and severe COVID-19: A meta-analysis","It has been reported that low counts of CD4+T and CD8+T were associated with adverse outcome in patients with SARS, and the counts would rise dramatically when clinical symptoms improved .",1
1399,"CD4+T, CD8+T counts and severe COVID-19: A meta-analysis","It appears that, unlike SARS, CD8+T may be a more sensitive predictor of clinical outcome than CD4+T in COVID-19 patients.",1
1508,National Smoking Rates Correlate Inversely with COVID-19 Mortality,"To our knowledge, the only other respiratory virus for which smoking has been suggested to have a protective effect is the closely related SARS-CoV.",1
1510,National Smoking Rates Correlate Inversely with COVID-19 Mortality,"While it was found that smokers were more than four-fold underrepresented in this group of SARS patients, when confounds were considered this dropped to only 1.7-fold --and the effect was not significant.",1
1518,National Smoking Rates Correlate Inversely with COVID-19 Mortality,"In the case of SARS-CoV, a study showed it down-regulates the ACE2 and that this was directly implicated in the development of severe lung disease.",1
1525,National Smoking Rates Correlate Inversely with COVID-19 Mortality,43 Evidence also points to antiviral activity with SARS-CoV.,1
1529,National Smoking Rates Correlate Inversely with COVID-19 Mortality,"45 Smoking is associated with inflammation in the respiratory tract and creates a host of changes to the immune system, and it is possible that some of these changes might make for an inhospitable environment for SARS-CoV-2 infection.",1
1530,National Smoking Rates Correlate Inversely with COVID-19 Mortality,A comprehensive review of immune changes associated with smoking concluded that these effects were almost always harmful rather than beneficial.,1
1531,National Smoking Rates Correlate Inversely with COVID-19 Mortality,"46 As noted, the exceptions may involve SARS-CoV and SARS-CoV-2, and it could be informative to understand what is so different about how these viruses act, and to develop treatments based on this understanding.",1
1538,National Smoking Rates Correlate Inversely with COVID-19 Mortality,"https://doi.org/10.1101/2020.06.12.20129825 doi: medRxiv preprint Fever is an evolutionarily conserved function in all vertebrates, 49 it is generally believed to play a role in the body is defense against viruses, 50, 51 and enhances a host of immune functions, including productions of heat shock proteins, 50,51 Importantly, COVID-19 patients that are admitted to the hospital without fever have been found to have greatly elevated risk of poor outcomes.",1
1543,National Smoking Rates Correlate Inversely with COVID-19 Mortality,"Though the evidence was deemed inconclusive in a Cochrane review, 57 several controlled trials 58-60 were cited of various heat treatments showing successful reduction of symptoms or duration of colds, another illness sometimes caused by a coronavirus.",1
1558,Serum Mycoplasma pneumoniae IgG in COVID-19: A Protective Factor,"Ever since its initial outbreak in Wuhan, Hubei province, China, in December 2019, the 2019 novel coronavirus disease has quickly spread around the world.",1
1571,Serum Mycoplasma pneumoniae IgG in COVID-19: A Protective Factor,Patients with prior exposure to Mycoplasma pneumoniae showed stronger resistance and better recovery from the SARS-CoV-2 viral infection than patients without exposure.,1
1572,Serum Mycoplasma pneumoniae IgG in COVID-19: A Protective Factor,"Of particular note, the immune response rendered against the virus was noted to be stronger in the IgG positive group, evident through an overall higher leukocyte count.",1
1573,Serum Mycoplasma pneumoniae IgG in COVID-19: A Protective Factor,This can partially be explained by reprogrammed immune cells.,1
1577,Short Communication Single Center Trends in Acute Coronary Syndrome Volume and Outcomes During the COVID-19 Pandemic,"The coronavirus disease 2019 pandemic has greatly affected healthcare delivery across the world, and many cardiac catheterization laboratories in the USA have scaled down the number of cases in accordance with regulatory and societal guidelines .",1
1592,Short Communication Single Center Trends in Acute Coronary Syndrome Volume and Outcomes During the COVID-19 Pandemic,Initial markers of cardiac injury were not significantly higher in the COVID-19 era than the pre-COV-ID-19 era .,1
1621,Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic,"The Coronavirus disease 2019 pandemic has prompted reflections and statements on the management of endocrine and metabolic disorders, including diabetes mellitus, obesity, adrenal insufficiency , as well as on the way COVID-19 outbreak might affect our daily clinical practice after the pandemic will be over .",1
1660,Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic,"Although intravenous glucocorticoid therapy for GO does not seem to be associated with secondary adrenal insufficiency , patients who recently finished the intravenous glucocorticoid treatment, and more obviously, those who completed a long-term course of oral glucocorticoids for GO, should be considered at risk of potentially having an acute adrenal crisis if they get infected by Coronavirus.",1
1666,Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic,"Informed consent Informed consent is not needed, because this article does not contain any original research on either animals or human subjects.",1
1667,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,"The coronavirus disease 2019 pandemic is a major burden on healthcare systems and is imposing a change in practice in multiple disciplines, including interventional cardiology.",1
1671,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,"The severe acute respiratory syndrome coronavirus-2 has the same stability in aerosols and on surfaces as SARS-CoV-1, but the rate of transmission is higher.",1
1717,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,"Whenever SARS-CoV-2 testing can be obtained before an invasive procedure, this strategy should be prioritized.",1
1754,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,"2 To that end, and in the absence of previous SARS-CoV-2 testing, all STEMI patients should be managed as if they are COVID-19 positive.",1
1759,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,"23 As a general rule, all patients with NSTE-ACS should undergo testing for SARS-CoV-2 as soon as possible following first medical contact, irrespective of treatment strategy, in order to allow HCWs to implement adequate protective measures and management pathways .",1
1767,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,"For these patients, a medical strategy aimed at stabilization and prompt execution of a SARS-CoV-2 test is recommended, whilst planning an early invasive strategy.",1
1769,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,"In the case of a positive SARS-CoV-2 test, patients should be transferred for invasive management to a COVID-19 hospital.",1
1771,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,"For these patients, a medical strategy aimed at stabilization and prompt execution of the SARS-CoV-2 test is recommended.",1
1774,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,"When there is a positive SARS-CoV-2 test, patients should be transferred for invasive management to a COVID-19 hospital.",1
1777,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,A SARS-CoV-2 test is also recommended in these patients.,1
1808,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,"Human or logistic resources may be shared amongst institutions, especially when a hub is temporarily put into quarantine.",1
1836,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,All patients admitted to the cardiovascular emergency triage for ACS should receive SARS-CoV-2 testing.,1
1837,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,"Patients with STEMI or very high risk NSTEMI should be immediately referred to the cathlab, while those in the other NSTEMI risk categories should be referred to a dedicated chest pain unit before SARS-CoV-2 testing results are available.",1
1838,EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic Interventional cardiology Abbreviations ACS = acute coronary syndrome ED = emergency department HCWs = healthcare workers NSTEMI = non-ST-elevation myocardial infarction PCI = percutaneous coronary intervention PPE = personal protective equipment STEMI = ST-elevation myocardial infarction,Patients should be further managed according to SARS-CoV-2 testing.,1
1900,Journal Pre-proof,"Given the seemingly ubiquitous presence but the heterogeneous incidence and impact of COVID-19, demographic information, and questions regarding the current prevalence of Journal Pre-proof J o u r n a l P r e -p r o o f COVID-19 in the respondent is area were obtained to determine how specific factors influenced practice pattern changes as well as COVID-19 infection testing and infection rates.",1
1921,Journal Pre-proof,"They indicated the highest level of concern for the following: 107 for delay in care, 93 for access to medical supplies, 70 for access to oncology treatments, 59 for access to blood products, 49 for quality of care, and 30 for access to medications.",1
1945,Journal Pre-proof,Access to clinical trials is being limited according to 132 of those surveyed.,1
2031,COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images,"The COVID-19 pandemic continues to have a devastating effect on the health and well-being of the global population, caused by the infection of individuals by the severe acute respiratory syndrome coronavirus 2 .",1
2033,COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images,"The main screening method used for detecting COVID-19 cases is reverse transcriptase-polymerase chain reaction testing, which can detect SARS-CoV-2 RNA from respiratory specimens .",1
2035,COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images,"An alternative screening method that has also been utilized for COVID-19 screening has been radiography examination, where chest radiography imaging or computed tomography imaging) is conducted and analyzed by radiologists to look for visual indicators associated with SARS-CoV-2 viral infection.",1
2060,COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images,"In this study, a human-machine collaborative design strategy is leveraged to create COVID-Net, where humandriven principled network design prototyping is combined with machine-driven design exploration to produce a network architecture tailored for the detection of COVID-19 cases from CXR images.",1
2062,COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images,"The first stage of the human-machine collaborative design strategy employed to create the proposed COVID-Net is a principled network design prototyping stage, where an initial network design prototype is constructed based on human-driven design principles and best practices.",1
2066,COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images,The second stage of the human-machine collaborative design strategy employed to create the proposed COVID-Net is a machine-driven design exploration stage.,1
2067,COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images,"More specifically, at this stage, the initial network design prototype, data, along with human specific design requirements, act as a guide to a design exploration strategy to learn and identify the optimal macroarchitecture and microarchitecture designs with which to construct the final tailor-made deep neural network architecture.",1
2068,COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images,"Such a machine-driven design exploration stage enables much greater granularity and much greater flexibility than is possible through manual human-driven architecture design, while still ensuring that the resulting deep neural network architecture satisfies domain-specific operational requirements.",1
2070,COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images,"In this study, we leverage generative synthesis as the machine-driven design exploration strategy, which is based on an intricate interplay between a generator-inquisitor pair that work in tandem to garner insights and learn to generate deep neural network architectures that best satisfies human specified design requirements.",1
2071,COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images,"More specifically, the following human specified design requirements were employed in this study to enable the generative synthesis process to learn and identify the optimal macroarchitecture and microarchitecture designs for the final COVID-Net network architecture: COVID-19 sensitivity ≥ 80%, and COVID-19 positive predictive value ≥ 80%.",1
2125,COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images,"It can be observed that, based on the interpretation produced by GSInquire, the proposed COVID-Net primarily leverages areas in the lungs in the CXR images as the main critical factors in determining whether a CXR image is of a patient with a SARS-CoV-2 viral infection, as shown in red in Fig.",1
2132,COVID-Net: A Tailored Deep Convolutional Neural Network Design for Detection of COVID-19 Cases from Chest X-Ray Images,"The critical factors leveraged by the proposed COVID-Net could potentially help clinicians discover new insights into the key visual indicators associated with SARS-CoV-2 viral infection, which they can then leverage to improve screening accuracy.",1
2138,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,Infection with severe acute respiratory syndrome coronavirus 2 causes coronavirus disease 2019 .,1
2146,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,There has been significant interest in modulating the systemic immune response in an effort to prevent or treat respiratory failure in patients with COVID-19.,1
2147,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,More than one hundred clinical trials are currently registered at clinicaltrials.gov to evaluate the efficacy of inflammatory cytokine blocking medications or interventions such as cytokine filtration as potential treatments for respiratory failure in COVID-19 patients.,1
2150,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"In order to evaluate the etiology of respiratory failure in COVID-19 patients, we undertook a comparative investigation of inflammatory responses in a cohort of influenza patients with severe illness collected during 2019 and 2020, which allowed us to characterize the immune response in patients with severe COVID-19 specifically in the context of the more widely studied immune responses seen during influenza disease.",1
2151,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,We enrolled a total of 79 symptomatic subjects who tested positive for SARS-CoV-2 RNA using an FDA-approved clinical PCR test.,1
2159,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,We initially characterized circulating immune cells by quantifying the absolute number of CD4 + and CD8 + T lymphocytes and CD19 + B cells.,1
2163,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"However, when compared with either influenza or control subjects, COVID-19 subjects exhibited significantly reduced numbers of circulating monocytes, including all three common classifications of human monocytes .",1
2168,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"Plasma cytokine levels were measured from 27 patients with confirmed influenza virus infection, 79 patients with SARS-CoV-2 infection, and 8 healthy controls.",1
2169,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"Among the SARS-CoV-2 patients, two response profiles were immediately apparent.",1
2201,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"Immune suppression can often occur as a negative feedback from immune activation, so we sought further resolution of the immune state of severe COVID-19 patients to understand the dominant regulatory signals determining their trajectory.",1
2217,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,We furthermore noted significant decreases in a number of interferon-induced genes known to play important roles in the innate immune response to viral insults .,1
2219,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,Understanding the complexities of the systemic inflammatory response to SARS-CoV-2 infection is critical to determining the most appropriate treatment for this condition.,1
2221,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,Two forms of COVID-19 immune dysregulation were observed: a cytokine storm phenotype in a small proportion of patients and a far more common phenotype characterized by targeted immunosuppression.,1
2224,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"At the cellular level, dramatic reductions in overall cellularity and particularly in the monocyte compartment were observed, with phenotypic and transcriptional evidence that monocytes were less activated.",1
2227,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"The elevated plasmablast frequencies in COVID-19 patients may reflect the abundance of viral antigens, which is consistent with the reported persistence of viral RNA in nasal swabs for up to 15 days after onset of symptoms .",1
2232,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,Excessive GC production is an attractive hypothesis to account for the observed immune dysregulation and disease manifestations in COVID-19.,1
2238,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,Another potential source of cortisol production unique to SARS-CoV-2 infection is through its modulation of ACE2 levels.,1
2239,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"ACE2 is the receptor for virus entry, and while it is still unclear the extent to which its levels are modulated by infection, experience from SARS-CoV-1 and other data suggest that ACE2 expression or activity are lowered.",1
2242,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"Beyond considering the potential impacts of increased GC production on the development of the immunosuppressed phenotype we characterized in the vast majority of COVID-19 patients in this study, we must also consider the possibility that GCs modulate the immune microenvironment differently in the context of distinct viral encounters.",1
2243,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"There are known but underappreciated immunosuppressive features of influenza ; coronaviruses are similarly known to utilize a number of nonstructural proteins to disrupt host gene expression and protein synthesis , with the potential for profound impacts on various immune signaling pathways .",1
2244,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"Although the details of these mechanisms in the context of COVID-19 immune dysregulation remain to be fully elucidated, our own analyses demonstrate enhanced GC signaling in cells from COVID-19 patients, consistent with an enhanced production of GCs or enhanced sensitivity to GCs after infection.",1
2245,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"Together these data suggest a feedforward amplification of IL-6 and GC signaling, paired with a profound suppression of other potentially protective immune functions through GC-induced apoptosis and suppression of key antiviral pathways.",1
2247,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,The direct and indirect effects of SARS-CoV-2 is unique biology may determine this pathological outcome.,1
2253,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,Inclusion criteria required that subjects were symptomatic and had a physicianordered SARS-CoV-2 test performed in the course of their normal clinical care.,1
2254,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,Some subjects were enrolled prior to the return of the SARS-CoV-2 test result.,1
2255,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,Enrolled subjects who tested negative for SARS-CoV-2 are not included in the current manuscript.,1
2265,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"We enrolled most influenza subjects during the course of the 2019-2020 influenza season, immediately before the spread of COVID-19 disease in the Saint Louis region.",1
2276,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,Plasma obtained from subjects was frozen at -80°C and subsequently analyzed using a human magnetic cytokine panel providing parallel measurement of 35 cytokines .,1
2281,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"Individual libraries were processed using CellRanger with the accompanying human reference , which was modified to include the influenza A, influenza B, and COVID-19 genomes.",1
2299,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"Flow Cytometry Lymphocyte subsets were compared across healthy, influenza, and SARS-CoV-2 subjects using Mann-Whitney U tests.",1
2302,Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease,"Cytokines Cytokine levels were natural safe-log transformed prior to analysis and compared across healthy, influenza, and SARS-CoV-2 subjects using Kruskal-Wallis tests.",1
2347,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis","COVID-19 is caused by a novel strain of coronavirus, the severe acute respiratory syndrome coronavirus 2 .",1
2349,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis","Although the symptoms and clinical presentation of COVID-19 is similar to SARS and MERS, the rate of spread is greater .",1
2398,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis","Our main outcomes show that the prevalence of COPD in COVID-19 patients was low, but that the risk of severity and mortality were high, which indicates COPD patients with confirmed COVID-19 are at a greater risk of severe complications and death.",1
2400,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis","We report a low prevalence of COPD patients in COVID-19 case series compared to the latest COPD prevalence rate in China, which was 13.6% and the global prevalence of COPD .",1
2404,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis","Having a reliable estimate of the prevalence of COPD in COVID-19 cases, and likely outcomes, is crucial to ensure specific successful global preventive and treatment strategies for COPD patients.",1
2438,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis","For the first time, we conducted a meta-analysis using a random effects model to calculate the pooled prevalence of COPD in confirmed COVID-19 and examined outcomes.",1
2448,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis","We strongly advocate public awareness campaigns concentrating on ways to achieve smoking cessation among smokers, and it is possible that an improvement in cessation rates will help to reduce the spread of SARS-CoV-2.",1
2456,Cutaneous signs in COVID-19 patients: A review,"Since the severe acute respiratory syndrome coronavirus 2 induced infectious disorder named coronavirus disease pandemic started in Wuhan city in Central China at the end of 2019, a total of 3.5 million patients have been tested positive worldwide with >240 000 related death recorded.",1
2459,Cutaneous signs in COVID-19 patients: A review,"The primary target of SARS-CoV-2 is the upper respiratory mucosa, and angiotensin-converting enzyme 2 acts as a functional receptor for the viral spikes and eventually viral entry into host cells.",1
2460,Cutaneous signs in COVID-19 patients: A review,2 Expression of the SARS-CoV-2 cell receptor gene ACE2 has been demonstrated in a number of human tissues including skin and adipose tissue.,1
2462,Cutaneous signs in COVID-19 patients: A review,SARS-CoV-2 induces pulmonary fibrosis in a tumor growth factor-beta /Smad-dependent pathway.,1
2474,Cutaneous signs in COVID-19 patients: A review,"9 With a closer involvement of dermatologist in the battle against the latest pandemic, the interest on cutaneous signs of SARS-CoV-2 infection increased.",1
2530,Cutaneous signs in COVID-19 patients: A review,Both were tested positive for SARS-CoV-2-RNA.,1
2547,Cutaneous signs in COVID-19 patients: A review,It lasted for about 9 days and was associated with a more severe course of the coronavirus infection.,1
2557,Cutaneous signs in COVID-19 patients: A review,RT-PCR was positive for SARS-CoV-2 RNA.,1
2563,Cutaneous signs in COVID-19 patients: A review,Urticaria with pyrexia has diagnostic significance since this combination is an early symptom of an otherwise not confirmed SARS-CoV-2 infection.,1
2567,"Journal Pre-proof Lung, Heart, Vascular, and Diaphragm Ultrasound Examination of COVID-19 Patients: A Comprehensive Approach Lung, Heart, Vascular, and Diaphragm Ultrasound Examination of COVID-19 Patients: A Comprehensive Approach",From the Wuhan district in Chinawhere the first cases of novel coronavirus disease-2019 were isolated in early January 2020the coronavirus called SARS-CoV-2 quickly spread to many other countries around the world.,1
2569,"Journal Pre-proof Lung, Heart, Vascular, and Diaphragm Ultrasound Examination of COVID-19 Patients: A Comprehensive Approach Lung, Heart, Vascular, and Diaphragm Ultrasound Examination of COVID-19 Patients: A Comprehensive Approach","2 Although SARS-CoV-2 also affects other body systems, 3 the pulmonary involvement of COVID-19 is of particular concern, since the leading cause of COVID-19 related death is severe acute respiratory failure.",1
2611,"Journal Pre-proof Lung, Heart, Vascular, and Diaphragm Ultrasound Examination of COVID-19 Patients: A Comprehensive Approach Lung, Heart, Vascular, and Diaphragm Ultrasound Examination of COVID-19 Patients: A Comprehensive Approach","That said, given the high pre-test probability of infection in a pandemic context, like that for SARS-CoV-2, the specificity of the LU signs becomes much higher, but is still low and often not sufficient to confirm the diagnosis alone.",1
2629,"Journal Pre-proof Lung, Heart, Vascular, and Diaphragm Ultrasound Examination of COVID-19 Patients: A Comprehensive Approach Lung, Heart, Vascular, and Diaphragm Ultrasound Examination of COVID-19 Patients: A Comprehensive Approach","As mentioned above, the specificity of the signs detected by LU in relation to SARS-CoV-2 infection is not very high.",1
2639,"Journal Pre-proof Lung, Heart, Vascular, and Diaphragm Ultrasound Examination of COVID-19 Patients: A Comprehensive Approach Lung, Heart, Vascular, and Diaphragm Ultrasound Examination of COVID-19 Patients: A Comprehensive Approach","As reported in table 2, cardiac involvement may occur in these patients, either as a direct effect of the SARS-CoV-2 virus or as a consequence of lung disease and ventilatory management.",1
2696,POCOVID-Net: AUTOMATIC DETECTION OF COVID-19 FROM A NEW LUNG ULTRASOUND IMAGING DATASET (POCUS),"To date, SARS-CoV-2 has infected several millions and killed hundreds of thousands around the globe.",1
2699,POCOVID-Net: AUTOMATIC DETECTION OF COVID-19 FROM A NEW LUNG ULTRASOUND IMAGING DATASET (POCUS),"Alternatively, fast serology tests are in early stages of development, and are based on antibodies that the immune system only produces in an advanced stage of the disease.",1
2703,POCOVID-Net: AUTOMATIC DETECTION OF COVID-19 FROM A NEW LUNG ULTRASOUND IMAGING DATASET (POCUS),"In this context, biomedical imaging techniques have great potential to complement the conventional diagnostic techniques of COVID-19 such as molecular biology and immune assays.",1
2712,POCOVID-Net: AUTOMATIC DETECTION OF COVID-19 FROM A NEW LUNG ULTRASOUND IMAGING DATASET (POCUS),"Although literature on the applicability of ultrasound for COVID-19 is still scarce, a growing body of evidence for disease-specific patterns in US has lead to advocacy for an amplified role of US in the research community .",1
2725,POCOVID-Net: AUTOMATIC DETECTION OF COVID-19 FROM A NEW LUNG ULTRASOUND IMAGING DATASET (POCUS),It is crucial to note that medical doctors must be trained thoroughly to reliably differentiate COVID-19 from pneumonia and that the relevant patterns are hard to discern for the human eye .,1
2856,POCOVID-Net: AUTOMATIC DETECTION OF COVID-19 FROM A NEW LUNG ULTRASOUND IMAGING DATASET (POCUS),"We believe that POCUS can provide a quick, easy and lowcost method to assess the possibility of a SARS-CoV-2 infection.",1
2874,POCOVID-Net: AUTOMATIC DETECTION OF COVID-19 FROM A NEW LUNG ULTRASOUND IMAGING DATASET (POCUS),[ Cov-grepmed-blinespocus-.mp4,1
2879,Journal Pre-proofs The Use of Ibuprofen to Treat Fever in COVID-19: A Possible Indirect Asso- ciation with Worse Outcome? The Use of Ibuprofen to Treat Fever in COVID-19: A Possible Indirect Association with Worse Outcome? The Use of Ibuprofen to Treat Fever in COVID-19: A Possible Indirect Association with Worse Outcome?,The concern related to ibuprofen use has centered on the pharmacological property of the drug and whether inhibition of the release of prostaglandins will interfere with the adaptive immune system .,1
2893,Journal Pre-proofs The Use of Ibuprofen to Treat Fever in COVID-19: A Possible Indirect Asso- ciation with Worse Outcome? The Use of Ibuprofen to Treat Fever in COVID-19: A Possible Indirect Association with Worse Outcome? The Use of Ibuprofen to Treat Fever in COVID-19: A Possible Indirect Association with Worse Outcome?,Febrile temperatures have been shown to work as a systemic alert system activating the immune system during a challenge by invading pathogens .,1
2901,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,"The disease was designated as coronavirus disease 2019 by the World Health Organization in February 2020 and the pathogen was shown to be a novel coronavirus, namely severe acute respiratory syndrome coronavirus 2 .",1
2903,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,"Although first cases of COVID-19 in China seemed to be related to a seafood wholesale market, rapid evidence for human-to-human transmission emerged with increasing number of cases .",1
2908,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,"Although most of the morbidity in COVID-19 seems to be related to presence of viral pneumonia, cases with mild disease are thought to be responsible for majority of the spread of SARS-CoV-2 infection in the population .",1
2909,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,Even asymptomatic patients with SARS-CoV-2 infection have been demonstrated to be able to transmit disease which may explain why prevention of COVID-19 in the population proved to be challenging: WHO have declared COVID-19 to be a pandemic on 11 th March 2020 .,1
2913,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,The viral load and genetic characteristics of the infecting SARS-CoV-2 strain have also been proposed as factors affecting disease susceptibility and severity .,1
2916,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,Genetic factors have been implicated in a genetically related family cluster of SARS-CoV pneumonia with very poor outcomes .,1
2918,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,"We sought to determine the clinical characteristics relevant to the clinical course of COVID-19 by comparing the family cluster to unrelated patients with SARS-CoV-2 infection so that the presence of Accepted Article potential determinants of disease severity, other than traditional risk factors previously reported, could be investigated.",1
2924,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,COVID-19 was diagnosed when patients met the criteria suggested by WHO Interim Guidance Document and Turkish Ministry of Health COVID-19 Guideline: patients suspected with infection on clinical grounds were tested for the presence of SARS-CoV-2 infection .,1
2926,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,"In accordance with COVID-19 diagnostic algorithms, patients who were suspected of having SARS-CoV-2 infection after triage were further questioned for additional symptoms and data regarding comorbidities like DM, HT, CHD, chronic respiratory disease, malignancy on admission, along with smoking history were collected.",1
2930,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,Oropharyngeal and nasopharyngeal swab specimens from the upper respiratory tract as described elsewhere were sent to a nation-wide central laboratory for real-time reverse-transcriptase-polymerase-chain-reaction and SARS-CoV-2 infected individuals were identified by the successful amplification of virus .,1
2968,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,There were no differences between the groups with respect to medications inhibitors and Angiotensin Receptor blockers and anti-thrombotic agents) that the patients used for comorbid chronic conditions when they presented to the ER with COVID-19 symptoms.,1
2976,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,"On the other hand, any potential contributors to prognosis like demographic characteristics, cardiovascular risk factors, co-morbid chronic illnesses, concomitant medications and drugs used for treatment of COVID-19 were compared.",1
3010,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,have demonstrated that hydroxycholoroquine administration to the SARS-COV-2 positive population was associated with an increased need for escalation of respiratory support .,1
3012,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,"There has been some concern regarding the use of ACE inhibitors and Angiotensin Receptor Blockers in COVID-19 because ACE2, an enzyme that physiologically counters Renin-Angiotensin-Aldosterone System activation, is the functional receptor to SARS-CoV-2 .",1
3013,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,Upregulation of the ACE2 due to RAS blocker use was hypothesized to impact susceptibility to SARS-CoV-2 infection and clinical course of COVID-19 whereas no clinical data to back-up this possibility have been published .,1
3015,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,"In this study, there were no differences between the groups with respect to antihypertensive medications including ACE inhibitors and Angiotensin Receptor blockers that the patients used when they presented to the ER with COVID-19 symptoms.",1
3018,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,have reported a COVID-19 cluster of five cases of from the same family in which transmission of COVID-19 via close contact with asymptomatic carriers during the incubation period has been suggested as a reason for the formation of family clusters .,1
3030,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,"Patients may have particular predisposition to SARS-CoV-2 infection or severe illness, possibly variations in their immunological and inflammatory responses possibly mediated in at least in part by RAS system .",1
3031,''Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?'' Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?,A recent report has offered structural variations in human ACE2 influencing its binding with SARS-CoV-2 spike protein as a candidate for a mechanism by which host susceptibility to COVID-19 may be mediated .,1
3040,Journal Pre-proof Proposed guidelines for screening of hyperglycemia in patients hospitalized with COVID-19 in low resource settings Title Proposed Guidelines for Screening of Hyperglycemia in Patients Hospitalized with COVID- 19 in Low Resource Settings Running title Screening for Hyperglycemia in COVID-19 patients Corresponding Author Funding None Proposed Guidelines for Screening of Hyperglycemia in Patients Hospitalized with COVID-19 in Low Resource Settings,The coronavirus disease 2019 pandemic has resulted in an unprecedented rise in admissions in dedicated COVID facilities.,1
3066,"Journal Pre-proof Herbal Medicine for the management of COVID-19 during the medical observation period: A review of guidelines Lin Ang (Methodology) (Writing -original draft), Hye Won Lee (Conceptualization) (Data curation) (Writing -original draft), Anna Kim (Methodology) (Data curation) (Writing -review and editing), Myeong Soo Lee (Conceptualization) (Writing -review and editing) (Supervision) Herbal Medicine for the management of COVID-19 during the medical observation period: A review of guidelines",The recent emergence of a novel coronavirus has caused a pandemic and sickened more than 2.5 million people in at least 177 countries.,1
3067,"Journal Pre-proof Herbal Medicine for the management of COVID-19 during the medical observation period: A review of guidelines Lin Ang (Methodology) (Writing -original draft), Hye Won Lee (Conceptualization) (Data curation) (Writing -original draft), Anna Kim (Methodology) (Data curation) (Writing -review and editing), Myeong Soo Lee (Conceptualization) (Writing -review and editing) (Supervision) Herbal Medicine for the management of COVID-19 during the medical observation period: A review of guidelines","1, 2 This novel strain of coronavirus which caused coronavirus disease 2019 also belonged to the same family of viruses that cause severe acute respiratory syndrome and Middle East respiratory syndrome in the past.",1
3070,"Journal Pre-proof Herbal Medicine for the management of COVID-19 during the medical observation period: A review of guidelines Lin Ang (Methodology) (Writing -original draft), Hye Won Lee (Conceptualization) (Data curation) (Writing -original draft), Anna Kim (Methodology) (Data curation) (Writing -review and editing), Myeong Soo Lee (Conceptualization) (Writing -review and editing) (Supervision) Herbal Medicine for the management of COVID-19 during the medical observation period: A review of guidelines",5 A recent publication also showed that the actual intervals of transmission are shorter than the incubation period which suggests that pre-symptomatic transmission is more substantial than expected.,1
3088,"Journal Pre-proof Herbal Medicine for the management of COVID-19 during the medical observation period: A review of guidelines Lin Ang (Methodology) (Writing -original draft), Hye Won Lee (Conceptualization) (Data curation) (Writing -original draft), Anna Kim (Methodology) (Data curation) (Writing -review and editing), Myeong Soo Lee (Conceptualization) (Writing -review and editing) (Supervision) Herbal Medicine for the management of COVID-19 during the medical observation period: A review of guidelines","17 Studies also showed that the herb Citri Reticulatae Pericarpium has anti-inflammatory and anti-asthmatic properties which may relieve fever, soothe cough and dyspnea, stimulate appetite, as well as enhance the immune system.",1
3101,"Journal Pre-proof Herbal Medicine for the management of COVID-19 during the medical observation period: A review of guidelines Lin Ang (Methodology) (Writing -original draft), Hye Won Lee (Conceptualization) (Data curation) (Writing -original draft), Anna Kim (Methodology) (Data curation) (Writing -review and editing), Myeong Soo Lee (Conceptualization) (Writing -review and editing) (Supervision) Herbal Medicine for the management of COVID-19 during the medical observation period: A review of guidelines",No ethics committee approval was required as no human or animal research was conducted.,1
3104,A systematic review to evaluate the clinical outcomes in COVID -19 patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers Authors,"Severe acute respiratory syndrome coronavirus 2 causes coronavirus disease , a potentially fatal disease that is of immense global public health concern.",1
3111,A systematic review to evaluate the clinical outcomes in COVID -19 patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers Authors,"This could theoretically result in an upregulation of ACE2 in the epithelial cells of the lung, intestine, kidney, and blood vessels, which is an active binding target for SARS-CoV-2 virus .",1
3112,A systematic review to evaluate the clinical outcomes in COVID -19 patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers Authors,"Although this raised concerns regarding the use of these drugs in COVID-19 patients, several animal studies presented conflicting findings regarding increased ACE2 expression due to ACEI and ARB in animal studies and the previous human studies suggested that administration of ACEI/ARBs does not increase ACE2 expression .",1
3116,A systematic review to evaluate the clinical outcomes in COVID -19 patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers Authors,"Literature search was conducted on the PubMed/MEDLINE database using key words, viz., ""ACE inhibitors AND coronavirus.""",1
3117,A systematic review to evaluate the clinical outcomes in COVID -19 patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers Authors,"and ""ARB AND coronavirus.""",1
3136,A systematic review to evaluate the clinical outcomes in COVID -19 patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers Authors,"Although ACEI and ARB are commonly prescribed to treat some of these comorbidities, the fact that ACE2 receptor is the main binding site for entry of SARS-CoV-2, caused concerns regarding the use of ACEI and ARB in such patients .",1
3150,A systematic review to evaluate the clinical outcomes in COVID -19 patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers Authors,Individuals with ACE2 polymorphisms have an increased genetic predisposition for an increased risk of SARS-CoV-2 infection and may have harmful effects of ACEI/ARB .,1
3170,A systematic review to evaluate the clinical outcomes in COVID -19 patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers Authors,"** Mortality rates for patients with hypertension # Among the 78 patients, 40 were classified as having mild disease , and 38 were classified as severe condition according to New Coronavirus Pneumonia Prevention and Control Program published by the National Health Commission of China + Other regimens $ Primary endpoint primary endpoint being death or transfer to a critical care unit for organ support within 7-days of symptom onset.",1
3196,A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response Special Articles,"Infection with SARS-CoV-2 can result in myocardial injury, HF, and arrhythmias, and putative treatments can have interactions with the cardiovascular system.",1
3234,A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response Special Articles,"If these patients are hemodynamically stable, we recommend close monitoring of hemodynamics and telemetry, diuresis , and guidelinedirected therapy, except for new initiation of ACEi, ARB, or ARNI outside of clinical trials.",1
3258,A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response Special Articles,"The mainstay of treatment for COVID-19 infection remains supportive therapy, but clinical trials have proliferated in response to this pandemic.",1
3259,A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response Special Articles,Patients with COVID-19 who suffer a cardiovascular complication are high-risk patients and should be screened for enrollment in clinical trials.,1
3298,Breath-borne VOC Biomarkers for COVID-19,its SARS-CoV-2 safety.,1
3347,Breath-borne VOC Biomarkers for COVID-19,"8 Likewise, when people are infected by SARS-CoV-2, characteristic protein and metabolite changes were observed; and more than 100 lipids were reported to be down-regulated in their blood sera.",1
3354,Breath-borne VOC Biomarkers for COVID-19,"Higher levels of both butyraldehyde and ethyl butanoate likely result from 5 infections by other pathogens, but not by SARS-CoV-2.",1
3358,Breath-borne VOC Biomarkers for COVID-19,"11 Here, we observed a decline of breath-borne acetone level, and an increase in ethyl butanoate, which could be due to the changes of metabolites resulting from SARS-CoV-2 15 infections as reported.",1
3362,Breath-borne VOC Biomarkers for COVID-19,"Such a metabolism abnormality resulting from the SARS-CoV-2 20 infection is likely contributing to the cytokine storms in which levels of protein biomarkers substantially increased, e.g., interleukin -2, IL-7, macrophage inflammatory protein 1-α, tumour necrosis factor-α, C-reactive protein and interleukin-6 .",1
3365,Breath-borne VOC Biomarkers for COVID-19,"Isopropanol-1, emitted also by healthy controls, was shown to inactivate SARS-CoV-2 by at least 5.9 Log10 within 30 s at 75% .",1
3366,Breath-borne VOC Biomarkers for COVID-19,"15 Thus, isopropanol-1 produced by the COVID-19 patients, which however varied greatly , was used as a selfdefense to inactivate SARS-CoV-2 or other pathogens.",1
3367,Breath-borne VOC Biomarkers for COVID-19,Whether breath-borne SARS-CoV-2 can 30 be efficiently inactivated depended on the level of isopropanol-1 emitted from a particular patient.,1
3368,Breath-borne VOC Biomarkers for COVID-19,"Accordingly, the isopropanol-1 level might to some extent affect the viability of SARS-CoV-2 emitted by COVID-19 patients.",1
3369,Breath-borne VOC Biomarkers for COVID-19,COVID-19 patients with low levels of isopropanol-1 might serve as a super-spreader of viable SARS-CoV-2.,1
3370,Breath-borne VOC Biomarkers for COVID-19,"Previously, we have shown that COVID-19 patients emitted millions of SARS-CoV-2 per hour during the earlier stages of the 35 disease.",1
3371,Breath-borne VOC Biomarkers for COVID-19,"4, 6 Accordingly, some of those emitted SARS-CoV-2 could have been inactivated by breath-borne isopropanol-1.",1
3375,Breath-borne VOC Biomarkers for COVID-19,"The larger sample size of COVID-19 patients was desired, but impacted by both biosafety concerns and lab constraints due to the highly infectious nature of SARS-CoV-2.",1
3408,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"Coronavirus disease 2019 is the third coronavirus infection in two decades that was originally described in Asia, after severe acute respiratory syndrome and Middle East respiratory syndrome .",1
3410,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"Many lessons can be learnt from the cumulative experience of Asian ICUs dealing with the COVID-19, SARS, and MERS outbreaks.",1
3414,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"2 By comparison, the SARS epidemic infected 8096 people in 29 countries from November, 2002, to July, 2003, and had a case fatality rate of 9·6%, 3 whereas the MERS outbreak infected 2494 people in 27 countries from April, 2012, to November, 2019, and had a case fatality rate of 34·4%.",1
3420,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"9, 10 Critically ill patients with COVID-19 are older and have more comorbidities, including hypertension and • Clinical features of coronavirus disease 2019 are non-specific and do not easily distinguish it from other causes of severe community-acquired pneumonia • As the pandemic worsens, intensive care unit practitioners should increasingly have a high index of suspicion and a low threshold for diagnostic testing for COVID-19 • Many questions on clinical management remain unanswered, including the significance of myocardial dysfunction, and the role of non-invasive ventilation, high-flow nasal cannula, corticosteroids, and various repurposed and experimental therapies • ICU practitioners, hospital administrators, governments, and policy makers must prepare early for a substantial increase in critical care capacity, or risk being overwhelmed by the pandemic • Surge options include the addition of beds to a pre-existing ICU, provision of intensive care outside ICUs, and centralisation of intensive care in designated ICUs, while considering critical care triage and rationing of resources should surge efforts be insufficient • Preparations must focus not just on infrastructure and supplies, but also on staff, including protection from nosocomial transmission and promotion of mental wellbeing diabetes, than do non-critically ill patients.",1
3435,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,Diagnosis is based on RT-PCR assays for severe acute respiratory syndrome coronavirus 2 .,1
3445,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"Epidemiological data suggest that NIV was associated with nosocomial transmission of SARS; 34 however, human laboratory data suggest that NIV does not generate aerosols.",1
3451,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"Extrapolating from SARS, intubation of patients with COVID-19 also poses a risk of viral transmission to healthcare workers, and intubation drills are crucial.",1
3460,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"Although outcome data on prone A global shortage of medical masks and respirators threatens efforts to prevent transmission Consider reuse between patients and use beyond the manufacturer-designated shelf life N95 respirators that do not fit facial contours might not provide the necessary protection Conduct regular fit testing, preferably before outbreaks Self-contamination often happens during removal of PPE Surges in numbers of critically ill patients with COVID-19 can occur rapidly Implement national and regional modelling of needs for intensive care Low-income and middle-income countries have insufficient ICU beds in general, and even highincome countries will be put under strain in an outbreak like COVID-19 Consider whether increasing intensive care provision is an appropriate use of resources; if so, make plans for an increase in capacity, including providing intensive care in areas outside ICUs and centralising intensive care in designated ICUs Increasing ICU capacity requires more equipment , consumables, and pharmaceuticals, which might be in short supply Pay close attention to logistical support and the supply chain; reduce the inflow of patients who do not urgently require intensive care Ventilators are in short supply Consider transport, operating theatre, and military ventilators Increasing ICU bed numbers and workload without increasing staff could result in increased mortality Make plans for augmentation of staff from other ICUs or non-ICU areas, and provision of appropriate training Risk of loss of staff to illness, medical leave, or quarantine after unprotected exposure to COVID-19, with a potentially devastating effect on morale, is high Minimise risk of infection; consider segregation of teams and physical distancing to limit unprotected exposure of multiple team members, and travel restrictions to limit exposure to COVID-19, which is now global 15 ) are currently lacking, the tendency for SARS-CoV-2 to affect the peripheral and dorsal areas of the lungs provides the ideal conditions for a positive oxygenation response to prone positioning.",1
3467,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"11,13,15,16,23 This incidence might be due to strong binding affinity of the SARS-CoV-2 spike protein to human angiotensin converting enzyme 2 , a membrane-bound receptor crucial for host cell entry that is expressed in the heart and lungs, among other organs.",1
3476,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"57 Although the benefits of immunosuppression are unproven and the role of corticosteroids in COVID-19 remains unclear, a systematic review of observational studies of corticosteroids for SARS found no impact on mortality but possible harms, including avascular necrosis, psychosis, diabetes, and delayed viral clearance.",1
3481,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,Transfer of patients out of the ICU for investigations such as CT scans risks Severe acute respiratory illness and any of the following: recent travel to or residence in a location reporting community transmission; recent contact with a confirmed or probable COVID-19 case; or no alternative diagnosis that fully explains the clinical presentation spreading SARS-CoV-2 and can be minimised with alternatives such as point-of-care ultrasound.,1
3487,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"No proven therapy for COVID-19 exists, but several candidates-some previously used against SARS-CoV and MERS-CoV-have been used empirically and are undergoing investigation.",1
3489,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"88, 89 Admittedly, therapies for which efficacy is not supported by strong evidence-not in COVID-19, and not even in SARS and MERS-are being administered in the hope of improving outcomes, before or in parallel with clinical studies.",1
3492,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"90 During the SARS outbreak, however, ribavirin was widely used, but was subsequently found to be at best ineffective and at worst harmful.",1
3498,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"Although some clinicians have suggested the additional use of powered air-purifying respirators -given accounts of health-care workers acquiring SARS despite wearing N95 respirators, and available albeit limited evidence that PAPRs result in less contamination of health-care workers 43 -their use comes with significant logistical challenges.",1
3506,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"98 Not efficacious for Ebola virus disease compared with other investigational therapies; 67 superior activity compared with lopinavirritonavir in mice with MERS-CoV; 68 effectively inhibited SARS-CoV-2, MERS-CoV, and SARS-CoV in vitro 69, 70 No peer-reviewed, published safety data available for SARS-CoV-2; in the PALM trial, only 1 of 175 patients randomised to remdesivir had a potentially serious adverse event 67 Second candidate identified for rapid implementation in clinical trials, alone or in combination with interferon beta, by WHO; 66 Studies ongoing in patients with COVID-19; 75 in vitro studies of chloroquine on SARS-CoV and SARS-CoV-2 76, 77 According to a news briefing, 75 chloroquine slowed the progression of pneumonia and accelerated SARS-CoV-2 clearance and recovery in >100 patients with COVID-19, but results have not been published in the peer-reviewed literature and caution is advised in interpreting these findings; 75 in-vitro antiviral effects reported for both SARS-CoV and SARS-CoV-2 76, 77 No peer-reviewed, published safety data available for SARS-CoV-2, but concerns include the possibility of QT prolongation 78 Open label, non-randomised trial in 36 patients with COVID-19 ; 79 in-vitro studies of hydroxychloroquine on SARS-CoV-2 80 Reduced SARS-CoV-2 load in the nasopharynx of patients with COVID-19, especially when combined with azithromycin; 79 more potent than chloroquine in inhibiting SARS-CoV-2 in vitro 80 No peer-reviewed, published safety data available for SARS-CoV-2, but concerns include the possibility of QT prolongation 78 Phase 1 trial of human polyclonal immunoglobulin G in healthy participants; 81 Might reduce mortality in severe acute respiratory infections due to SARS-CoV and influenza; 83 associated with reduction in viral load and improvement in fever, oxygenation, and chest imaging in a case series, but study limited by small sample size, multiple possible confounders, and absence of controls 85 No peer-reviewed, published safety data available for SARS-CoV-2, but studies of SARS-CoV have not reported serious adverse events 83 Licensed for cytokine release syndrome; hypothesised to work against cytokine storm with raised ferritin and interleukin-6 levels due to SARS-CoV-2 57, 86 No peer-reviewed, published efficacy data available for SARS-CoV-2 No peer-reviewed, published safety data available for SARS-CoV-2 Hypothesised to have an antiviral action on SARS-CoV-2 ; multiple clinical studies underway for SARS-CoV-2 87 No peer-reviewed, published efficacy data available for SARS-CoV-2; preliminary, unpublished trial data suggest a more potent antiviral action with favipiravir compared with lopinavir-ritonavir, but caution is advised in interpreting these results 87 No peer-reviewed, published safety data available for SARS-CoV-2; preliminary, unpublished trial data suggest fewer adverse events with favipiravir compared with lopinavir-ritonavir, but caution is advised in interpreting these results 87 Building a safety culture and encouraging staff to point out protocol errors were useful to reduce nosocomial SARS transmission.",1
3508,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"Viable SARS-CoV-2 persists on inanimate surfaces such as plastic and stainless steel for up to 72 h. 27 Because more than one-third of health-care workers' mobile phones might be contaminated with common viral pathogens, 100 these should be cleaned regularly or wrapped with specimen bags that are discarded after contact with patients or daily.",1
3509,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,Environmental contamination by SARS-CoV-2 was detected on furniture and equipment within a patient is room and toilet in Singapore.,1
3510,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"101 During the MERS outbreak in South Korea, viable coronavirus was detected on doorknobs, bed guardrails, air exhaust dampers, and elevators.",1
3511,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,102 Immediate and proper disposal of soiled objects is also warranted as SARS-CoV-2 might be transmitted faecally.,1
3516,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"During the SARS outbreak in Singapore, negative pressure ventilation was created by mounting industrial exhaust fans.",1
3549,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,Staffing of ICUs must take into account the risk that health-care workers might become infected with SARS-CoV-2.,1
3555,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,118 Staff who worked in high-risk SARS units continued to suffer from post-traumatic stress disorder years later.,1
3565,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"5 A search of WHO is International Clinical Trials Registry Platform on March 31, 2020, revealed 667 registered trials on COVID-19.",1
3569,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"Data on the effectiveness of NIV and HFNC, and the associated risk of viral transmission, remain scarce.",1
3572,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"11, 13, 15, 16, 23 The role of ECMO is unclear.",1
3578,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"For example, several interventions against SARS-CoV-2 are being incorporated into the Randomized, Embedded, Multi-factorial Adaptive Platform Trial for Community-Acquired Pneumonia , a pre-approved platform trial for severe community-acquired pneumonia.",1
3584,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"China is rapid sharing of the SARS-CoV-2 genetic code had an Review immediate impact on case identification, isolation, and the spread of the virus.",1
3590,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"Even if SARS-CoV-2 infects a small proportion of the 7·8 billion people on Earth, many thousands will still become critically ill and require ICU care.",1
3599,Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations,"We identified the references for this Review through searches of PubMed for articles published between Jan 1, 1950, and March 22, 2020, using combinations of the terms ""coronavirus"", ""COVID-19"", ""SARS-CoV-2"", ""nCoV"", ""severe acute respiratory syndrome"", ""SARS"", ""Middle East respiratory syndrome"", ""MERS"", ""outbreak"", ""epidemic"", ""pandemic"", ""acute respiratory distress syndrome"", and ""intensive care"".",1
3628,Open Peer Review COVID-19 in-patient hospital mortality by ethnicity [version 1; peer review: 2 approved] Reviewer Status 1 2 report report,"It also sheds no light on variations by ethnicity in exposure to, risk of coronavirus infection or the severity of COVID-19 illness in the community.",1
3636,R E V I E W A R T I C L E,WHAT IS A CORONAVIRUS?,1
3637,R E V I E W A R T I C L E,"Based on genome sequencing, all known human coronaviruses have emerged from animal reservoirs.",1
3638,R E V I E W A R T I C L E,1 Comparisons of the current COVID-19 outbreak are being made to 2 recently emerged coronaviruses from zoonotic spillover events; SARS- On Multiple reports have confirmed human-to-human transmission of the COVID-19.,1
3639,R E V I E W A R T I C L E,"8 When person-to-person spread has occurred with MERS-CoV and SARS-CoV, it is thought to have happened mainly via respiratory droplets produced when an infected person coughs or sneezes, similar to how Influenza and other respiratory pathogens spread.",1
3642,R E V I E W A R T I C L E,11 This development raises concerns that the COVID-19 may be similar to other viruses such as chickenpox and measles in that transmission may be possible during the incubation period or by patients with mild disease.,1
3645,R E V I E W A R T I C L E,"9,10 For comparison, MERS and SARS exhibited CFRs of 35% and 15%, respectively.",1
3648,R E V I E W A R T I C L E,"To date, the average incubation period is estimated to be a median of 5 days with a range between 2 and 14 days.",1
3653,R E V I E W A R T I C L E,Infection prevention guidance or COVID-19 is based upon guidance previously developed for MERS and SARS as well as interim guidelines provided by the WHO and CDC.,1
3670,Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis,"Coronavirus Disease 2019 is a viral respiratory disease caused by the 2019 novel coronavirus , which has caused the pneumonia epidemic in the world .",1
3731,Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis,"Our search strategy included terms for ""2019-nCoV"" or ""Coronavirus"" or ""COVID-19"" or ""SARS-CoV-2"" or ""2019-nCoV"" or ""Wuhan Coronavirus.""",1
3832,Journal Pre-proof A Novel Cohorting and Isolation Strategy for Suspected COVID-19 Cases during a Pandemic A Novel Cohorting and Isolation Strategy for Suspected COVID-19 Cases during a Pandemic,These individuals were effectively shielded from SARS-CoV-2 exposure and risk of healthcare associated transmission during their admission.,1
3855,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,"The pathogen had typical features of the coronavirus family and therefore was classified in the subgenus Sarbecovirus, Orthocoronavirinae subfamily .",1
3856,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,"This virus has been named ""severe acute respiratory syndrome coronavirus 2"" , and the disease it causes has been named ""coronavirus disease 2019"" .",1
3857,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,"It is the third epidemic coronavirus that has emerged in the human population in the Twenty-first century, following the severe acute respiratory syndrome coronavirus outbreak in 2002, and the Middle East respiratory syndrome coronavirus outbreak in 2012 .",1
3858,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,Coronavirus is one of the main causes of human respiratory disease owing to frequent crossspecies infections.,1
3859,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,The emerging virus rapidly became a challenge for global public health due to it spreading through human-to-human transmission.,1
3861,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,"However, human-to-human transmission has frequently occurred, and the epidemic has been gradually growing .",1
3864,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,The number of infected individuals is far surpassing that of SARS and MERS.,1
3865,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,"SARS-CoV-2 can cause severe and even fatal respiratory diseases, such as acute respiratory distress syndrome.",1
3866,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,"It has been reported that SARS-CoV-2 is more likely to affect older males with comorbidities, suggesting that age, and comorbidity may be risk factors for poor outcomes .",1
3903,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,Our result does not support a previous report that SARS-CoV-2 generally affects more males than females in the epidemic .,1
3924,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,Age has been reported as the independent predictor of an adverse outcome in SARS and MERS.,1
3925,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,Comorbidities and low immune function in older people might be the major cause of a higher mortality of coronaviruses .,1
3926,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,Prompt administration of antibiotics to prevent infection and the strengthening of immune support treatment might reduce the mortality of seniors .,1
3945,Age-Dependent Risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China,Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements.,1
3947,Hazardous Postoperative Outcomes of Unexpected COVID-19 Infected Patients: A Call for Global Consideration of Sampling all Asymptomatic Patients Before Surgical Treatment,"In December 2019, a novel coronavirus was identified as the cause of many pneumonia cases in Wuhan, China .",1
3948,Hazardous Postoperative Outcomes of Unexpected COVID-19 Infected Patients: A Call for Global Consideration of Sampling all Asymptomatic Patients Before Surgical Treatment,"The new virus, now known as severe acute respiratory syndrome coronavirus 2 , led to the outbreak of coronavirus disease 2019 , first in China and then worldwide, causing an international emergency.",1
3967,Hazardous Postoperative Outcomes of Unexpected COVID-19 Infected Patients: A Call for Global Consideration of Sampling all Asymptomatic Patients Before Surgical Treatment,The following search terms were used: COVID-19 or novel coronavirus or SARS-CoV-2 or 2019 nCoV and surgery or surgical or operation or perioperative or postoperative or anesthesia.,1
4007,Hazardous Postoperative Outcomes of Unexpected COVID-19 Infected Patients: A Call for Global Consideration of Sampling all Asymptomatic Patients Before Surgical Treatment,"The rationale behind knowing the COVID-19 status of any surgical candidate is ensuring patient safety, reduction of postoperative complications and potential transmission of the novel coronavirus from an unknown carrier to medical staff or to other patients .",1
4026,Hazardous Postoperative Outcomes of Unexpected COVID-19 Infected Patients: A Call for Global Consideration of Sampling all Asymptomatic Patients Before Surgical Treatment,"But since our global overarching goal is to continue providing compassionate, safe care for surgical patients and for medical staff, we believe that preoperative screening for COVID-19 baseline status and detection of asymptomatic surgical candidates during the COVID-19 incubation period is an acceptable requirement.",1
4032,Mutated COVID-19 may foretell a great risk for mankind in the future,"Novel coronavirus disease 19 first emerged on 31 December 2019 in Wuhan city, China.",1
4036,Mutated COVID-19 may foretell a great risk for mankind in the future,Comparison of the lipid rafts of coronaviruses has indicated that the new strain COVID-19 has 80% identity with severe acute respiratory syndrome coronavirus .,1
4041,Mutated COVID-19 may foretell a great risk for mankind in the future,"Over the past two decades, outbreaks of coronavirus have been observed-SARS-CoV in 2003 and Middle-East respiratory syndrome -CoV-and have been described as major public health threats.",1
4043,Mutated COVID-19 may foretell a great risk for mankind in the future,"To date, it seems that the mortality rate of COVID-19 is lower than those of SARS or MERS.",1
4046,Mutated COVID-19 may foretell a great risk for mankind in the future,"Some countries face an outbreak crisis and are trying to prevent the spread of COVID-19 through preventing human gatherings, imposing a curfew in cities, preventing travel between countries and closing land borders, all of which may reduce the outbreaks.",1
4047,Mutated COVID-19 may foretell a great risk for mankind in the future,"The main transmission of COVID-19 starts with human-tohuman contact, including relatives and friends who have intimate contact with patients or incubating carriers.",1
4049,Mutated COVID-19 may foretell a great risk for mankind in the future,COVID-19 is related to the beta-coronavirus that infects humans and probably developed from bat coronaviruses.,1
4050,Mutated COVID-19 may foretell a great risk for mankind in the future,"Structural analysis shows that COVID-19 probably derives from a bat SARS-like coronavirus, which has mutated in the spike glycoprotein and nucleocapsid N protein The positive-sense RNA genomes of COVID-19 differ from SARS-CoV and MERS-CoV, being approximately 29.9 kb, 27.9 kb and 30.1 kb, respectively .",1
4052,Mutated COVID-19 may foretell a great risk for mankind in the future,"Sequence analysis revealed that COVID-19 has > 80% identity with SARS-CoV and 50% with MERS-CoV, which originated in bats .",1
4057,Mutated COVID-19 may foretell a great risk for mankind in the future,"COVID-19 and COVID-19 , bat-SL-CoVZC45 and SARS-CoV BJ182b showed alignment identities of 99%, 89% and 82%, respectively.",1
4061,Mutated COVID-19 may foretell a great risk for mankind in the future,Seven complete genomes have been aligned for different coronavirus strains .,1
4068,Mutated COVID-19 may foretell a great risk for mankind in the future,COVID-19 also possesses accessory proteins that interfere with the host is innate immune response .,1
4071,Mutated COVID-19 may foretell a great risk for mankind in the future,"Nucleocapsid phosphoprotein COVID-19 was aligned with NP COVID-19 and showed similarity of 100%; against NP SARS CoV CUHK-L2 and bat COV HKU5 similarities were 85% and 61%, respectively .",1
4073,Mutated COVID-19 may foretell a great risk for mankind in the future,"ORF7a protein COVID-19 aligned with NS7a Bat CoV RaTG13 showed 99% similarity, aligned with hypothetical protein SARS 7 CoV it showed 89% similarity and aligned with putative uncharacterized protein 4 SARS CoV it showed 68% similarity .",1
4074,Mutated COVID-19 may foretell a great risk for mankind in the future,"Alignment of ORF8 protein COVID-19 with ORF8 protein COVID-19 , hypothetical protein Bat SARS CoV Rs806/2006 and hypothetical protein Bat SARS CoV HKU3-8 showed similarities of 99%, 76% and 84%, respectively .",1
4075,Mutated COVID-19 may foretell a great risk for mankind in the future,"ORF6 protein COVID-19 was aligned with ORF6 protein COVID-19 , protein 7 Rhinolophus affinis CoV and NSP 6 SARS CoV ExoN1 and showed similarities of 98%, 88% and 86%, respectively .",1
4076,Mutated COVID-19 may foretell a great risk for mankind in the future,"Alignment of envelope protein COVID-19 with EP COVID-19 showed 98% similarity, with Chain A Envelope small membrane protein SARS CoV showed 90% similarity and with envelope protein Hypsugo Bat CoV HKU25 showed 56% similarity .",1
4078,Mutated COVID-19 may foretell a great risk for mankind in the future,There are obvious differences compared with other species in the coronavirus family.,1
4079,Mutated COVID-19 may foretell a great risk for mankind in the future,This may indicate that COVID-19 originated from mutations within the coronavirus family.,1
4081,Mutated COVID-19 may foretell a great risk for mankind in the future,We are unable to give reasonable explanations for the significant number of amino acid substitutions between COVID-19 and SARS-CoV or MERS-CoV due to very limited knowledge of this novel virus.,1
4082,Mutated COVID-19 may foretell a great risk for mankind in the future,The incubation period of the virus may vary with age and immune status.,1
4083,Mutated COVID-19 may foretell a great risk for mankind in the future,"In general, it has been assumed that the incubation period is between 2 and 14 days, although cases have been observed up to 23 days after exposure.",1
4091,Mutated COVID-19 may foretell a great risk for mankind in the future,This period depends on the age and immune status of the individual and is shorter in those <70 years old .,1
4105,Mutated COVID-19 may foretell a great risk for mankind in the future,"COVID-19 RNA has been isolated from human saliva, nasopharynx and lower respiratory tract.",1
4115,Mutated COVID-19 may foretell a great risk for mankind in the future,Clinical trials of hydroxychloroquine treatment for COVID-19 pneumonia have shown positive preliminary outcomes in China.,1
4117,Mutated COVID-19 may foretell a great risk for mankind in the future,Scientists have made progress in characterizing the new coronavirus but there are still many questions to be answered.,1
4127,Title: Outcomes from COVID-19 across the range of frailty: excess mortality in fitter older people,"While it is clear that mortality from SARS-CoV-2 infection increases with age , the association between frailty and mortality is not well understood .",1
4131,Title: Outcomes from COVID-19 across the range of frailty: excess mortality in fitter older people,Patients admitted to an urban teaching hospital aged ≥70 were included if they tested positive for SARS-CoV-2 by combined throat and high-nasal swab on reverse-transcriptase polymerase chain reaction or if there was high clinical suspicion for COVID-19 up until 23 rd April 2020.,1
4132,Title: Outcomes from COVID-19 across the range of frailty: excess mortality in fitter older people,"During the pandemic, the index of suspicion for SARS-CoV-2 infection was very high, so each older person needing hospitalisation was systematically assessed for COVID-19.",1
4180,Title: Outcomes from COVID-19 across the range of frailty: excess mortality in fitter older people,"In general, the pathophysiology described in COVID-19 patients in critical care indicates substantial immune hyperactivation .",1
4181,Title: Outcomes from COVID-19 across the range of frailty: excess mortality in fitter older people,"However, given survival in the CFS range 7-9 was similar in cases and controls, this may reflect death from COVID-19 is occurring in the same way as for other common illness and immune hyperactivation is unlikely to be a significant feature in this group.",1
4182,Title: Outcomes from COVID-19 across the range of frailty: excess mortality in fitter older people,One might speculate that older people with frailty have pre-existing immunesenescence such that they are unable to mount excess immune responses and may be otherwise by dying from the direct effects of viral infection.,1
4203,Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment,"The outbreak of Severe Acute Respiratory Syndrome Coronavirus-2 causing the Coronavirus Disease pandemic in 2020 was identified in December, 2019.",1
4212,Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment,"11 To evaluate this, we used a flash survey to determine whether there was current evidence that pediatric patients with cancer in SARS-CoV-2 affected areas had been tested for this virus or had developed severe COVID-19 disease.",1
4218,Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment,"Briefly, of more than 200 patients who were tested for SARS-CoV-2 in these PH/O departments, which care for close to 10,000 at-risk patients, only eight cases of proven infection were identified.",1
4236,Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment,"To our knowledge, this is the first survey of pediatric oncology centers in SARS-CoV-2 affected areas.",1
4238,Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment,"The low rate of identified infection is somewhat surprising, as it is reasonable to assume that the pediatric patients with cancer would be at least as susceptible to infection with SARS-CoV-2 infection as their healthy peers.",1
4239,Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment,"The SARS-CoV-2 does infect children in general, although lower severity of the infection makes children prone to be underreported 3, 6 .",1
4240,Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment,"Thus, at least in the countries with high COVID-19 incidence, either the transmission of SARS-CoV-2 was prevented by standard infection prevention measures, or cases remained undiagnosed as the course of the infection did not raise a suspicion of COVID-19.",1
4247,Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment,"The participating countries are gradually strengthening general preventative measures, usually aiming at social distancing, quarantines for the infected and contacts, clean hands and surfaces and cautious checking for possible symptoms -similarly to measures successfully applied in Hong Kong during the SARS epidemic in 2003 13 .",1
4261,Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment,Children with respiratory symptoms are screened for SARS-CoV-2 before entering PH/O units.,1
4264,Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment,"Although these infection prevention measures might reduce the risk of SARS-CoV-2 transmission, they can also directly or indirectly complicate patient care.",1
4268,Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment,More research is needed to better understand the epidemiology of SARS-CoV-2 infection and COVID-19 in pediatric patients with cancer or other immunocompromised children.,1
4322,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","The ongoing pandemic due to the novel coronavirus, SARS-CoV-2, has now affected over 7 million people worldwide with at least 400,000 people having died with COVID-19 1 .",1
4327,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","This has led to speculation that treatments for respiratory disease, specifically inhaled corticosteroids , may have a protective effect against SARS-CoV-2.",1
4330,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","In-vitro evidence indicates that the ICS ciclesonide can suppress SARS-CoV-2 replication 12 , and budesonide combined with glycopyrronium and formoterol inhibits the production of cytokines in cells exposed to HCoV-229E, another human coronavirus 13 .",1
4333,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","A recent systematic review of the role of ICS in SARS-CoV-2, SARS-CoV-1, and MERS found no studies investigating the impact of prior ICS use on outcomes in any of these infections 10 .",1
4342,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","It includes pseudonymised data such as coded diagnoses, medications and physiological parameters.",1
4345,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","We excluded people with prior diagnoses of other chronic respiratory conditions, or with asthma in the three years before the index date 21 , and those receiving nebulised COPD medications in the twelve months before the index date or a leukotriene receptor antagonist in the four months before the index date.",1
4429,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","To fully explain the lower bound of the 95% CI in the COPD cohort , or for the highdose ICS association in the asthma cohort , an unmeasured confounder would need to be associated with either exposure or outcome by at least risk ratio 1.37 and with both exposure and outcome by at least RR 1.08 found no other epidemiological studies or randomised controlled trials assessing the role of ICS in COVID-19.",1
4430,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis",Two ongoing RCTs investigating the role of ICS in people hospitalised with laboratory confirmed COVID-19 and mild COVID-19 respectively are due to complete later this year.,1
4435,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","It may be that features other than ICS use, such as shielding, influence the risk of acquiring SARS-CoV-2 among asthmatics.",1
4436,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","Studies investigating the causal effect of chronic respiratory disease, including COPD, and asthma on SARS-CoV-2 infection risk and COVID-19 disease, ideally taking into account the relatively large degree of heterogeneity that exists within each of these diagnostic categories, are urgently needed to help inform about levels of risk for these patients.",1
4460,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","Although we report a small harmful association, the pattern of results we observed suggests this could readily be explained by differences in underlying health between people receiving ICS and those receiving other respiratory medications.",1
4473,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","https://doi.org/10.1101/2020.06.19.20135491 doi: medRxiv preprint Evidence before this study At the start of the global coronavirus outbreak, Inhaled Corticosteroids were hypothesised to offer some protection against either infection with SARS-CoV-2 or against severe outcomes from COVID-19, such as acute respiratory distress syndrome and respiratory failure 9 , despite these medications being known to increase the risk of pneumonia and other respiratory tract infections 17, 33 .",1
4475,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","Most recently, ICS exposure has been found to correlate with a lower expression of ACE2 and TMPRSS2, the entry receptors used by SARS-CoV-2, in sputum cells 34 .",1
4476,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","A recent systematic review evaluating whether administration of ICS was associated with clinical outcomes in COVID-19, SARS or MERS identified no relevant studies 10 .",1
4484,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis",We also cannot recommend that ICS be used specifically to treat people with COVID-19 outside of the context of clinical trials.,1
4485,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis","Future observational research is likely to be subject to similar issues around unmeasured confounding, and evidence from RCTs will provide more definitive answers regarding the role of ICS in COVID-19 later this year.",1
4525,The unique characteristics of COVID-19 coagulopathy,"While ACE2 helps to mediate anticoagulant properties of the vascular endothelium in the healthy state, binding of SARS-CoV-2 to ACE2 aggravates cell damage, upregulates tissue factor expression, and downregulates the protein C system .",1
4527,The unique characteristics of COVID-19 coagulopathy,"Hemophagocytic syndrome or hemophagocytic lymphohistiocytosis is a hyperinflammatory syndrome characterized by the excessive activation of immune cells such as macrophages, natural killer cells, and cytotoxic T cells.",1
4532,The unique characteristics of COVID-19 coagulopathy,"In bacterial sepsis, immune cells such as monocyte and macrophages are activated by pathogen-associated molecular patterns and hostderived damage-associated molecular patterns .",1
4533,The unique characteristics of COVID-19 coagulopathy,The immune cells initiate coagulation cascades through expressing tissue factor and releasing extracellular vesicles .,1
4543,The unique characteristics of COVID-19 coagulopathy,"Direct SARS-CoV-2 infection in the lung epithelial cells followed by the damage to the lung capillary endothelial cells, and subsequent fibrin deposition with upregulated fibrinolysis by u-PA in the alveoli, may contribute to differences between COVID-19 and HPS/HLH .",1
4552,The unique characteristics of COVID-19 coagulopathy,"In COVID-19, SARS-CoV-2 occupies ACE2 and the angiotensin II level increases, which result in vasoconstriction and decreased blood flow.",1
4575,The unique characteristics of COVID-19 coagulopathy,"SARS-CoV-2 infection of the endothelial cells may stimulate the release of these components, with levels increasing independently from ADAMTS13 levels.",1
4576,The unique characteristics of COVID-19 coagulopathy,"Dengue virus, an RNA virus similar to coronavirus, is known to stimulate endothelial cells to release VWF , and an association between elevated circulating levels of VWF and stroke has been reported in dengue .",1
4584,The unique characteristics of COVID-19 coagulopathy,"Though studies of the complement system in COVID-19 are sparse, MERS-CoV is known to increase the levels of C5a and C5b-9 in the blood and lung tissues in a murine model .",1
4602,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,The outbreak of the novel Severe Acute Respiratory Syndrome Coronavirus in December 2019 has had significant impacts on healthcare systems globally .,1
4603,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,The coronavirus disease 2019 outbreak was declared a Public Health Emergency of International Concern on the 30th of January 2020 by the World Health Organization .,1
4616,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,"The Pharmacy Department provides a wide range of services via inpatient pharmacy, outpatient pharmacy, compounding pharmacy, clinical pharmacy, clinical trials and special access scheme pharmacy and pharmacy stores.",1
4622,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,"The COVID pharmacist attends ward rounds, practices partnered charting and has faced challenges such as anticipated medical staff shortages, the storage of medications bought in by COVID-19 infected patients, the limited availability of clinical trial medications, intentionally limiting contact between infected, or potentially infected patients, and clinical healthcare workers and significant language barriers.",1
4630,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,The pharmacist promotes medications with longer half-lives in order to reduce nursing contact frequency such as atenolol versus metoprolol and once daily ceftriaxone for the treatment of pneumonia and urosepsis.,1
4632,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,Interacting medications may be dispensed in a separate medication cup and the patient advised by nursing staff to separate from their meal.,1
4633,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,Inpatients are usually encouraged to bring their patient own medications for use during their hospital stay and as a source for medication reconciliation.,1
4634,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,"These medications are locked in a centralised medication room in each ward, away from the patient.",1
4635,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,"Conversely, COVID-19 confirmed or suspected patients are advised to leave their medications at home.",1
4659,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,"In order to minimise pharmacist attendance in COVID-19 areas, the COVID pharmacist collaborates with specialist palliative care, haematology and transplant pharmacists to ensure that specialised medications can be prescribed via partnered charting.",1
4661,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,The challenges of conducting non-contact medication reviews are compounded by language barriers and patient is own medications which may not be available in Australia.,1
4663,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,The COVID pharmacist is responsible for advising on therapeutic substitution of locally available therapeutic alternatives when prescribed medications are not available.,1
4668,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,"National guidelines do not support the use of antivirals and other disease-modifying treatments in treating COVID-19 patients due to lack of evidence, however, do promote their use in context of clinical trials .",1
4669,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,"The state-wide antimicrobial stewardship body recommended in a position statement publicised to all WA healthcare institutions, that medications which have been publicised as having antiviral in vitro activity against SARS-CoV-2 such as hydroxychloroquine and lopinavir/ ritonavir should not be used for off-label pharmacotherapy unless the patient is enrolled in an approved, randomised, controlled clinical trial such as The Australasian COVID-19 trial trial or the Randomised, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia trial At our institution, COVID-19 related clinical trials are managed on the ward by the clinical investigators specific for each trial with support from the pharmacy department clinical trial team.",1
4671,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,"The COVID pharmacist is responsible for ensuring the availability of time-critical medications on our dedicated COVID-19 ward areas, including medicines required for rapid intubation.",1
4672,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,"A 'COVID Airway -System Kit' was prepared in conjunction with the Department of Anaesthesia, consisting of a pre-populated list of medications that the COVID pharmacist and nurses can readily access via the ward automated medication dispensing system for use by an anaesthetist.",1
4683,The role of a Coronavirus disease 2019 pharmacist: an Australian perspective,"Table 2 List of COVID Airway Medications available as a pre-populated list on the ward is automated medication dispensing system to enable efficient removal COVID airway medications 1 × Adrenaline 1 in 10,000 ampoule 1 × Atropine 600 microg/mL ampoule 1 × Ephedrine 30 mg/mL ampoule 1 × Fentanyl 500 microg/10 mL ampoule 1 × Ketamine 200 mg/2 mL vial 2 × Metaraminol 2.5 mg/5 mL prefilled syringes 1 × Propofol 200 mg/20 mL vial 1 × Propofol 500 mg/50 mL vial 4 × Rocuronium 50 mg/5 mL vial",1
4684,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"A novel coronavirus, SARS-CoV-2, has developed into a global pandemic, resulting in more than 7.6 million cases worldwide with over 427,000 deaths as we write 1 .",1
4685,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"Contextually this pandemic is likely to surpass the SARS-CoV-1 2003 pandemic by 1000-fold whereby SARS-CoV-1 resulted in 8,098 cases, took 12 months to contain and had a 9.6% mortality rate .",1
4686,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"The novel SARS-CoV-2 virus, the causative agent for COVID-19 disease, is highly communicable and despite urgent and resourceintensive efforts globally, we have no vaccine or efficacious treatment in sight 2 .",1
4687,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"COVID-19 clearly shares some immunological features with other viral responses, such as interferon activation, simultaneous repression of immune cells, and changes in metabolism including glucose and iron regulation as shown by cytokine and cytometry studies .",1
4695,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"We simultaneously compiled a database of clinical viral infections from 23 studies of > 1,800 samples to represent the conserved immune response to a broad range of viral infections including influenza, RSV, HRV, SARS-CoV-1, ebola, and dengue.",1
4696,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,We here report on the results of a comparison of host responses to SARS-CoV-2 and other viruses.,1
4702,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,18.20131326 doi: medRxiv preprint A total of 76 adult patients with SARS-CoV-2 pneumonia were prospectively enrolled from April 1 st to May 4 th by department participating in the Hellenic Sepsis Study Group using the inclusion criteria already described elsewhere 22 .,1
4704,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,SARS-Cov-2 was detected by positive molecular testing of respiratory secretions.,1
4706,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"Exclusion criteria were infection by the human immunodeficiency virus, neutropenia, and any previous intake of immunosuppressive medication .",1
4731,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,https://doi.org/10.1101/2020.06.18.20131326 doi: medRxiv preprint Transcriptomic data of clinical respiratory infections caused by viruses other than SARS-CoV-2 were surveyed from Gene Expression OmniBus and ArrayExpress for inclusion to define a conserved host response signature for non-COVID-19 viral infection.,1
4768,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,The human transcriptome reference is used as background and the p-values from the hypergeometric test were adjusted using the Benjamini-Hochberg method 32 .,1
4770,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"A statistical deconvolution method was used to estimate the percentage of 25 immune cell types in the peripheral blood transcriptome data 34, 35 .",1
4774,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"Here, immunoStates was used as a basis matrix because it has been shown to reduce the effect of the biological and technical heterogeneity in transcriptome data on statistical deconvolution and identify robust changes in immune cell proportions .",1
4782,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"The 30 most significant pathways for 771 over-expressed genes included neutrophil activation, innate immune response, immune response to viral infection, type-I interferon signing and cytokine production , and for 1,231 under-expressed genes include lymphocyte differentiation and T cell activation and regulation .",1
4783,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,These results suggest that in response to SARS-CoV-2 infection T cells are suppressed whereas neutrophils are activated as a hallmark of its overwhelming host response represented in the transcriptomic changes.,1
4785,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"Based on our previous results 14 , we hypothesized that there is a conserved immune response to respiratory viral infections irrespective of age and genetic background of a patient or a virus.",1
4795,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"Second, we investigated whether the non-COVID-19 viral signature is observed in other severe viral infections including ebola, dengue, and SARS-CoV-1 in five independent studies .",1
4799,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"We found that non-COVID-19 viral score separated patients with COVID-19 from HCs with an AUC of 0.96 , similar to SARS-CoV-1 .",1
4803,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"https://doi.org/10.1101/2020.06.18.20131326 doi: medRxiv preprint Comparison of COVID-19 profile with non-COVID-19 viral infection profile Next, we investigated similarities and differences in host response to SARS-CoV-2 and other respiratory viruses by comparing change in expression with respect to healthy controls across 9,818 genes that were present across all datasets.",1
4804,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"When considering the entire transcriptome, there was high correlation between change in expression in response to SARS-CoV-2 or other respiratory viruses .",1
4821,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,We expanded our comparison of significant pathways in response to SARS-CoV-2 versus non-COVID-19 viruses by including all pathways instead of only 30 most significant pathways.,1
4829,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,We estimated proportions of 25 immune cell types in bulk gene expression in blood samples from patients with COVID-19 or non-COVID-19 viral infections using immunoStates.,1
4830,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"In patients with COVID-19, we found immune cells from myeloid-lineage increased significantly , and lymphoid cells decreased significantly during viral infection .",1
4837,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"Although change in memory B cells was not statistically significant, the direction of change is expected as patients with non-COVID-19 infection are highly likely to have memory to those viruses, whereas SARS-CoV-2 is a novel coronavirus with no pre-existing memory in the population.",1
4843,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,Here we take a host response transcriptomics approach using peripheral blood transcriptomics of the immune response to COVID-19 compared to 652 non-COVID-19 viral infections spanning 6 viruses.,1
4844,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"While the vast majority of the host immune response appears to be similar between COVID-19 and other viruses, our study highlights some key differences.",1
4848,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,Prior reports suggest that both genes may be involved in viral replication and immune evasion.,1
4862,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,In SARS-CoV-1 infections it was determined that viral nsp1 disrupts ribosomal function 52 .,1
4863,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"The inverse cluster of pathways that are high in non-COVID-19 viral infections and low in COVID-19 positively regulate cell-cell adhesion, cell activation, leukocyte activation, immune response-activating cell surface receptor signaling, perhaps suggesting a more dysregulated immune response.",1
4864,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"While the host response to SARS-CoV-2 in essence is highly similar to other viral infections, it does clearly have some molecular differences.",1
4866,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"Interestingly, the consistency in the change in the immune cell proportions are mostly consistent across COVID-19 and non-COVID-19 datasets.",1
4868,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"Expansion of CD56 bright NK cells is common in many viral infections, as part of recognizing and killing virally infected cells while orchestrating adaptive immune responses 53 .",1
4878,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,"However, in general, monocytotropic viruses including SARS-CoV-1 have evolved mechanisms to interfere with effective macrophage polarization, favoring the M2 population for immune evasion.",1
4880,Transcriptomic Similarities and Differences in Host Response between SARS-CoV-2 and Other Viral Infections,This shift we see in the proportion of M2 macrophages in COVID-19 versus non-COVID-19 viral infections indicate that this novel pathogen may be executing these immune evasion techniques with a high degree of success.,1
4923,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,"In Wuhan, China pneumonia cases of a new pathogen, which was subsequently named severe acute respiratory syndrome coronavirus 2 , were identified in December 2019 .",1
4924,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,"In the meanwhile, the coronavirus diseases 2019 was declared a pandemic by the World Health Organization .",1
4926,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,"To fight the COVID-19 pandemic, a number of clinical trials were initiated or are in planning to investigate novel therapies, diagnostics and vaccines.",1
4930,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,"In order to effectively protect patient safety in these trials during the COVID-19 pandemic, across the world, clinical trials answering important healthcare questions were stopped, or temporarily paused to possibly re-start later, some with important modifications.",1
4935,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,"Missed treatments due to the interruptions, but also due to acquiring the SARS-CoV-2 virus may not be random and require a different approach than based on the intention-to-treat principle.",1
4939,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,Regulatory authorities have produced guidance on implications of COVID-19 on methodological aspects of ongoing clinical trials .,1
4950,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,"This has also been recognized by Anker et al in the context of clinical trials in heart failure, a chronic condition.",1
4952,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,In Section 2 four ongoing clinical trials are introduced which are all impacted by the COVID-19 pandemic.,1
4957,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,Clinical trials are affected in many different ways by the COVID-19 pandemic.,1
4979,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,"Due to the coronavirus pandemic, recruitment to the study was delayed by the cancellation of elective surgery in UK hospitals.",1
4985,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,The ATALANTE 1 trial: Premature study discontinuation not to endangering sensitive patients during the COVID-19 pandemic The ATALANTE 1 clinical trial aimed at evaluating and comparing the medicinal product tedopi to standard treatment as second and third line therapy in HLA-A2 positive patients with advanced NSCLC after failure of immune checkpoint inhibitor.,1
4995,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,"As SARS-CoV-2 pneumonia was not an exclusion criterion of CAPE-Cod, centers started to include COVID-19 infected patients into the study.",1
5006,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,In the introduction an outline of the potential challenges for clinical trials by the COVID-19 pandemic was provided.,1
5019,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,"Although the current situation of clinical trials being conducted in the setting of a global pandemic is without precedent, the particular question of adding interim analyses to a trial is not a new one.",1
5027,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,"For ongoing clinical trials initially planned with interim analyses, the impact of the COVID-19 pandemic may lead to a desire to modify the timing of the planned analyses.",1
5110,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,Inter-patient heterogeneity as well as intra-patients heterogeneity are both very common in clinical trials.,1
5216,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,"The COVID-19 pandemic affects all clinical trials, with implications for studies intended for drug regulation well beyond statistical aspects .",1
5233,Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?,"COVID-19 affects ongoing clinical trials in many different ways, which in turns affects many aspects of statistical inference, which are best described in the estimand framework laid out by ICH .",1
5288,COVID-19 not detected in peritoneal fluid: a case of laparoscopic appendicectomy for acute appendicitis in a COVID-19-infected patient,"Since the time of SARS-CoV-2003, there existed convincing evidence that aerosol-generating procedures could potentially result in a wider human-to-human coronavirus droplet transmission radius .",1
5329,COVID-19 not detected in peritoneal fluid: a case of laparoscopic appendicectomy for acute appendicitis in a COVID-19-infected patient,Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.,1
5331,Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2,"As recent studies described , severe coronavirus disease 2019 is commonly complicated with coagulopathy, markedly elevated D-dimer was associated with poor prognosis of severe COVID-19.",1
5332,Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2,"The effect of SARS-CoV2 infection on pulmonary coagulation and fibrinolysis is considered to be regulated by various proinflammatory cytokines, and similar to pneumonia induced by other pathogens .",1
5336,Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2,"The medications and outcomes were monitored up to March 13, 2020.",1
5337,Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2,The diagnosis of COVID-19 was confirmed by RNA detection of the SARS-CoV-2.,1
5340,Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2,"Exclusion criteria were hospital stay < 7 days, lack of information about coagulation parameters and medications, and age < 18 years for both of COVID and Non-COVID groups.",1
5379,Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2,"In conclusion, patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS-CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant therapy mainly with LMWH.",1
5384,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis Authors contributions","COVID-19 is caused by a novel strain of coronavirus, the severe acute respiratory syndrome coronavirus 2 .",1
5386,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis Authors contributions","Although the symptoms and clinical presentation of COVID-19 is similar to SARS and MERS, the rate of spread is greater .",1
5464,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis Authors contributions","Our main outcomes show that the prevalence of COPD in COVID-19 patients was low, but that the risk of severity and mortality were high, which indicates COPD patients with confirmed COVID-19 are at a greater risk of severe complications and death.",1
5466,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis Authors contributions","We report a low prevalence of COPD patients in COVID-19 case series compared to the latest COPD prevalence rate in China, which was 13.6% and the global prevalence of COPD .",1
5468,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis Authors contributions","Having a reliable estimate of the prevalence of COPD in COVID-19 cases, and likely outcomes, is crucial to ensure specific successful global preventive and treatment strategies for COPD patients.",1
5503,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis Authors contributions","For the first time, we conducted a meta-analysis using a random effects model to calculate the pooled prevalence of COPD in confirmed COVID-19 and examined outcomes.",1
5517,"Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis Authors contributions","We strongly advocate public awareness campaigns concentrating on ways to achieve smoking cessation among smokers, and it is possible that an improvement in cessation rates will help to reduce the spread of SARS-CoV-2.",1
5527,Early Detection and Assessment of Covid-19,"Coronavirus 2 , caused the current global pandemic .",1
5530,Early Detection and Assessment of Covid-19,"For the health services providers, it became a challenge to make rapid forward planning to evaluate the transmission rate of SARS-Cov-2 without ready access to diagnostic techniques and future planning based on the sustainability of healthcare systems to cope with the outbreak .",1
5531,Early Detection and Assessment of Covid-19,"Pragmatic understanding of the novel pathogen SARS-Cov-2 revealed an essential genetic sequencing similarity to the previously known pathogen, SARS .",1
5532,Early Detection and Assessment of Covid-19,A mean incubation period of 5.2 days of SARS-Cov-2 has been reported to cause the onset of symptoms and a mean 12.5 days for hospitalization from day of infection .,1
5534,Early Detection and Assessment of Covid-19,emphasized the time interval during the incubation of SARS-Cov-2 to hold crucial information on pathogenesis and asserted the need to understand it to design an effective containment policy .,1
5535,Early Detection and Assessment of Covid-19,Current understanding of Covid-19 pathogenesis focuses on the Angiotensin Converting Enzyme 2 based SARS-Cov-2 cell entry that infects lung epithelial cells and synergistic entry through endosome proteases cell prime entry that infects the host cell .,1
5536,Early Detection and Assessment of Covid-19,Novel coronavirus also infects T-lymphocytes .,1
5538,Early Detection and Assessment of Covid-19,"Currently, Covid-19 is detectable with Reverse Transcriptase Polymerase Chain Reaction , which detects presence of genetic fragments of SARS-Cov-2 within secretions from nasal and pharyngeal epithelial mucus membrane.",1
5560,Early Detection and Assessment of Covid-19,Clinical manifestations of SARS-Cov-2 appeared variable as compared to influenza.,1
5615,Early Detection and Assessment of Covid-19,"The formula contains a maximum of 39 scores, out of long incubation period .",1
5616,Early Detection and Assessment of Covid-19,A longer incubation period means certain opportunities to get prepared and prompt early action against Covid-19 to be opted.,1
5630,Early Detection and Assessment of Covid-19,Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements.,1
5633,Obesity as a Predictor for a Poor Prognosis of COVID-19: A 1 Systematic Review,"33 Obesity has been associated with impaired immune system, increasing the 34 susceptibility for 2019-nCoV infection.",1
5635,Obesity as a Predictor for a Poor Prognosis of COVID-19: A 1 Systematic Review,36 Coronavirus disease-2019 / COVID-19 is a new emerging pandemic.,1
5637,Obesity as a Predictor for a Poor Prognosis of COVID-19: A 1 Systematic Review,"Per 25 April 2020, the total confirmed coronavirus cases 58 globally reached 2,902,708 along with 202,179 death .",1
5679,Commentary to QJM: An International Journal of Medicine Title: Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in,'What should I do for the preparation of the second wave of the coronavirus disease pandemic in the future?',1
5684,Commentary to QJM: An International Journal of Medicine Title: Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in,"Herein, we initiated a clinical program of measurement of the severe acute respiratory syndrome coronavirus 2 -specific IgG antibody using the point-of-care test kit to assess the magnitude of COVID-19 in the community clinic setting under the approval of the institutional review board .",1
5689,Commentary to QJM: An International Journal of Medicine Title: Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in,"Delay in the expansion of the capacity for the diagnostic PCR test to detect SARS-CoV-2 in Japan has made difficulties in evaluating the COVID-19 pandemic, in turn, caused obstacles planning the recovery measures .",1
5692,Commentary to QJM: An International Journal of Medicine Title: Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in,The primary issues are the false-negative due to low sensitivity and false-positive due to crossreaction to past coronavirus infection.,1
5701,Commentary to QJM: An International Journal of Medicine Title: Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in,The 'Immune Passport' or 'Immune License' is an idea to utilize the results of the antibody test at a personal level although the concept has not been established yet .,1
5703,Commentary to QJM: An International Journal of Medicine Title: Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in,"The longitudinal investigation to see the incidence of the COVID-19 infection in the SRAS-CoV-2 IgG-positive cohort compared to those negative would provide evidence of Immune Passport or In conclusion, the antibody test of COVID-19 have benefits to understand the spreading of the virus in individual regions or communities although there are several issues to overcome such as reliability of the test, selection bias for the interpretation of the positive ratio and biological meaning of the existence of IgG antibody especially for the risk of the second infection.",1
5706,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"Coronavirus disease 2019 has been declared as a pandemic by Word Health Organization on March 11, 2020, as soon as it satisfied the epidemiological criteria .",1
5713,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"We have systematically searched the PubMed medical database up till March 27, 2020 using MeSH key words that include Covid-19, coronavirus, hypertension, diabetes, cardiovascular disease, angiotensin receptor blockers, angiotensin converting enzyme inhibitors.",1
5733,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,There has been a growing concern that this association with hypertension and or CVD may be confounded by the treatment with certain antihypertensive medications such as RASB.,1
5735,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,The entry of coronavirus into the cell is facilitated by the spike protein.,1
5737,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,The S proteins of different coronaviruses may utilise different receptors; MERS utilises CD26 while SARS CoV and SARS CoV2 utilise Angiotensin Converting Enzyme-2 .,1
5740,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,The major outbreak of SARS CoV occurred in 2002e2003 with a minor localised outbreak with mild symptoms in 2003e2004.,1
5741,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"It was observed that the S-protein of SARS CoV in the 2002e2003 outbreak bound to ACE-2 receptor much more efficiently than that of SARS CoV in the 2003e2004 outbreak, consistent with the absence of human-to-human transmission during the latter outbreak.",1
5742,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"Several molecular changes in the S-protein influence the binding with human ACE-2; for example, the substitution of threonine by serine at position 487 in S protein reduces the binding .",1
5745,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"Recently, S-protein of SARS CoV2 has been shown to be similar to that of SARS CoV, barring a few gains of function mutations.",1
5746,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"The most important of these is a glutamine at position 493 at the receptor binding domain, which explains its increased transmissibility compared to SARS CoV .",1
5747,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"b) Changes in ACE-2 Receptor: With regard to MERS-CoV, which employs CD26 as its receptor for cellular entry, there are naturally-occurring polymorphisms in DPP4 that impact cellular entry of MERS-CoV and might thus modulate MERS development in infected patients .",1
5749,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"Polymorphisms of ACE-2 gene have been identified; however, there is no evidence that they affect susceptibility to or severity of SARS CoV2 infection .",1
5750,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"A recent study found differential ACE-2 gene expression in human lung tissue with no racial/gender differences, but a higher gene expression in lungs of smokers compared to non-smokers, which could explain the higher risk of infection in smokers .",1
5751,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,The role of ACE-2 on vascular bed is opposite to that of angiotensin converting enzyme .,1
5754,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,Downregulation of ACE-2 was observed in animal models of lung injury induced by SARS CoV .,1
5755,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"Recombinant ACE-2 improved pulmonary blood flow and oxygenation in animals with lung injury, indicating that ACE-2 may be the main determinant of lung injury caused by SARS CoV .",1
5756,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"However, there is lack of human data except a small study in 10 patients with acute respiratory distress syndrome which showed that recombinant ACE-2 was well tolerated and led to an increase in angiotensin .",1
5757,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,There has been considerable interest regarding the role of RAS blockers in COVID-19 infection.,1
5770,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"b) Rationale and Evidence for Benefit: As discussed above, increasing ACE-2 levels in coronavirus infection could reduce lung injury.",1
5773,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"Similarly, severe lung injury and pulmonary edema were prevented by both recombinant human ACE-2 infusions or losartan in ACE2-knockout mice .",1
5774,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,Mice with coronavirus induced lung injury showed improvement when treated with losartan .,1
5777,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,The exact mechanism of apparent benefit of these drugs in coronavirus infection is not yet clear.,1
5781,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"Camostat mesylate, which is a TMPRSS2 inhibitor, has been shown to inhibit cellular entry of SARS CoV2 and could be a potential therapeutic option .",1
5783,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"Increased ACE-2 expression on the cell membrane may also lead to increased soluble ACE-2 in blood, which may actually bind to most of SARS CoV2 and prevent its interaction with the membrane bound receptor.",1
5786,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"The interaction of ACE-2 with angiotensin II could induce a conformational change in the receptor binding domain of ACE-2, limiting its ability to bind with SARS CoV2 .",1
5793,Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers,"Collectively, relationship between RAS activity and use of RASB in SARS CoV2 infection is very scarce.",1
5804,Clinical and historical features associated with severe COVID-19 infection: a systematic review,"Although data surrounding the novel coronavirus are rapidly evolving, initial estimates depict a dire situation: between 15% and 20% of infections lead to severe or critical disease.",1
5834,Clinical and historical features associated with severe COVID-19 infection: a systematic review,All publications in the World Health Organization is Database of Publications on Coronavirus Disease were also included.,1
5852,Clinical and historical features associated with severe COVID-19 infection: a systematic review,The novelty of SARS-CoV-2 infection has led to many hypotheses regarding potentially significant predictors of patient illness.,1
5867,Clinical and historical features associated with severe COVID-19 infection: a systematic review,"Due to the novelty of SARS-CoV-2 infection, there are currently no scoring systems validated for COVID-19 illness severity assessment either at the initial point of entry to the healthcare system or during admission.",1
5870,Clinical and historical features associated with severe COVID-19 infection: a systematic review,"oxygen and mechanical ventilation -and human resources necessary to oversee such interventions in a timely, appropriate manner for the rapidly increasing volume of COVID-19 patients.",1
5932,"Table: HScore for secondary HLH, by clinical parameter","8 A multicentre, randomised con trolled trial of tocilizumab , has been approved in patients with As of March 12, 2020, coronavirus disease 2019 has been con firmed in 125 048 people worldwide, carrying a mortality of approximately 3·7%, 1 compared with a mortality rate of less than 1% from influenza.",1
5958,"Table: HScore for secondary HLH, by clinical parameter","Perhaps unique to pandemics, these include considerable international coordination and collaboration in providing aid to affected countries, recruiting the necessary resources for promoting research on medications and vaccines, and developing complex risk communication.",1
5966,Prevalence and mortality of Lung Comorbidities Among Patients with COVID-19: A systematic review and meta-analysis Authors,"The novel coronavirus also termed as COVID-19 discovered in late 2019 in Wuhan, China has been established to be the main cause of a cluster of pneumonia cases which have disrupted the world order today .",1
5968,Prevalence and mortality of Lung Comorbidities Among Patients with COVID-19: A systematic review and meta-analysis Authors,"Given the rapid spread of COVID-19 and driven by international concern, the WHO declared coronavirus as a global pandemic .",1
5969,Prevalence and mortality of Lung Comorbidities Among Patients with COVID-19: A systematic review and meta-analysis Authors,"Caused by a new strain of the virus, COVID-19 belongs to the family of the class of coronavirus that included viruses associated with the outbreak of Middle East Respiratory in 2012 and severe acute respiratory syndrome in 2002 .",1
5974,Prevalence and mortality of Lung Comorbidities Among Patients with COVID-19: A systematic review and meta-analysis Authors,"In addition to symptoms associated with pneumonia, COVID-19 has been shown to cause damage to other organs including heart, liver, and kidneys as well as blood and immune system .",1
6096,Prevalence and mortality of Lung Comorbidities Among Patients with COVID-19: A systematic review and meta-analysis Authors,The microbial structure of coronavirus is characterized by transmembrane glycoproteins namely S1 and S2 .,1
6098,Prevalence and mortality of Lung Comorbidities Among Patients with COVID-19: A systematic review and meta-analysis Authors,Recent studies have shown that ACE2receptors provide a binding site for SARS-COV-2 i.e.,1
6104,Prevalence and mortality of Lung Comorbidities Among Patients with COVID-19: A systematic review and meta-analysis Authors,"Finally, patients with asthma have shown to have a weakened immune system including a deficiency and delay in lung cell interferon -α, IFN-β and IFN-λ leading to asthma exacerbations and risk of viral infections, quantifying these cytokines might be helpful to further elucidate underlying mechanisms for progression of disease and COVID-19 and develop potential therapeutic targets .",1
6107,Prevalence and mortality of Lung Comorbidities Among Patients with COVID-19: A systematic review and meta-analysis Authors,Cancer predisposes an individual to a heightened risk of viral and bacterial infections due to weakened immune system.,1
6114,Prevalence and mortality of Lung Comorbidities Among Patients with COVID-19: A systematic review and meta-analysis Authors,"https://doi.org/10.1101/2020.06.01.20119271 doi: medRxiv preprint Due to the complexity of multiple factors surrounding cancer patients including patients' clinical and demographic characteristics like age, gender, site, and stage as well as treatment and comorbidity history, certain groups recommend that baseline SARS-CoV-2 testing for all patients affected by lung cancer should be recommended and practiced .",1
6144,Psychological Sciences cite as,"Motivated by the rapid spread of the coronavirus disease 2019 pandemic, this research examines whether younger and older men and women differ in their COVID-19 related worries and behavior changes.",1
6154,Psychological Sciences cite as,Worry also predicted favorable health behavior changes during the SARS epidemic .,1
6163,Psychological Sciences cite as,Questions were based in part upon studies testing the psychological impact of SARS .,1
6172,Psychological Sciences cite as,"We also assessed other behaviors that had less clear health benefits: eaten a more balanced diet in an effort to avoid contracting COVID-19, taken additional vitamins or supplements in an effort to avoid contracting COVID-19, purchased extra food, and purchased extra medical supplies, including medications.",1
6198,Psychological Sciences cite as,COVID-19 = coronavirus disease 2019.,1
6211,Psychological Sciences cite as,COVID-19 = coronavirus disease 2019.,1
6221,Psychological Sciences cite as,COVID-19 = coronavirus disease 2019.,1
6241,Psychological Sciences cite as,"Consistent with this, Yeung and Fung examined the emotional responses of Hong Kong residents to the SARS epidemic.",1
6256,Psychological Sciences cite as,COVID-19 = coronavirus disease 2019.,1
6262,The estimations of the COVID-19 incubation period: a systematic review of the literature,"At the start of 2020, a new form of coronavirus was found to be the source of infection responsible for an epidemic of viral pneumonia in Wuhan, China, a region in which the first patients began to show symptoms in December 2019.",1
6264,The estimations of the COVID-19 incubation period: a systematic review of the literature,"The novel virus, causing severe acute respiratory disease, is thought to be from the same family as Middle East Respiratory Syndrome coronavirus and Severe Acute Respiratory Syndrome coronavirus, but it is unique in its own right.",1
6265,The estimations of the COVID-19 incubation period: a systematic review of the literature,"This means that central epidemiological parameters, which includes the incubation period, are being urgently researched in real-time from case reports while the epidemic is continuing .",1
6266,The estimations of the COVID-19 incubation period: a systematic review of the literature,The incubation period of a virus represents the time span from the probable earliest contact with a source of transmission and the earliest recognition of the first symptoms.,1
6267,The estimations of the COVID-19 incubation period: a systematic review of the literature,Accurately estimating the length of incubation period is essential for effective contemporary public health measures to be taken .,1
6268,The estimations of the COVID-19 incubation period: a systematic review of the literature,If health authorities know what the incubation period is then they will know for how long a healthy individual has to be monitored and have their movement restricted .,1
6269,The estimations of the COVID-19 incubation period: a systematic review of the literature,"Correctly estimating the incubation period will also help us to comprehend how infectious COVID-19 is, make estimations of the size of the pandemic, and decide on the best course of action .",1
6270,The estimations of the COVID-19 incubation period: a systematic review of the literature,"With insufficient data available to definitively state what the incubation period for this virus is, the World Health Organisation is working with a broad range of 0-14 days, the European Centre for Disease Prevention and Control is working with a range of 2-14 days, and a number of studies have made the assumption that the incubation period is similar to that of the MERS and SARS coronaviruses .",1
6272,The estimations of the COVID-19 incubation period: a systematic review of the literature,"Nevertheless, for some infectious diseases, we are relatively certain about the incubation period.",1
6276,The estimations of the COVID-19 incubation period: a systematic review of the literature,Accurately determining the incubation period will significantly influence controls to prevent transmission of the disease and official policy regarding it.,1
6277,The estimations of the COVID-19 incubation period: a systematic review of the literature,"Nevertheless, determining the incubation period for COVID-19 is no simple matter, due to the fact that there is no consistency in the quality of the available data.",1
6278,The estimations of the COVID-19 incubation period: a systematic review of the literature,"One reason for this is that generally we can only discover the times when the patient was in contact with persons carrying the virus, and then assume that the incubation period runs from the earliest date of exposure to the appearance of clinical symptoms or medical diagnosis.",1
6279,The estimations of the COVID-19 incubation period: a systematic review of the literature,This way of calculating the incubation period may well be responsible for overestimation.,1
6280,The estimations of the COVID-19 incubation period: a systematic review of the literature,This paper represents a systematic review of the literature in order to answer the essential question of what length the COVID-19 incubation period is.,1
6281,The estimations of the COVID-19 incubation period: a systematic review of the literature,"Due to the fact that no method currently exists that can make an accurate estimation of the incubation period, the only option is to draw lessons from past experience/practice.",1
6284,The estimations of the COVID-19 incubation period: a systematic review of the literature,"It comprises more than 55,000 academic articles, and more than 44,000 of them have some reference to COVID-19, SARS-CoV-2, and other forms of coronavirus.",1
6294,The estimations of the COVID-19 incubation period: a systematic review of the literature,"""what is the incubation period of COVID/normal coronavirus/SARS-CoV-2/nCoV"".",1
6299,The estimations of the COVID-19 incubation period: a systematic review of the literature,"Each of the 29 papers have been read thoroughly, causing nine articles to be excluded from the list for the following reasons: one was simply a report of earlier studies into incubation periods, one related to techniques for estimating incubation periods, two were letters to editors, one was a literature review regarding the genometric features of SARS-CoV-2, one was a perspective paper, and the other four were either irrelevant or redundant.",1
6301,The estimations of the COVID-19 incubation period: a systematic review of the literature,"Backer J.et al employed travel histories and symptom onsets for 88 confirmed cases discovered beyond the boundaries of Wuhan, China, in the early stage of the coronavirus outbreak.",1
6302,The estimations of the COVID-19 incubation period: a systematic review of the literature,These authors made an estimation that the incubation period ranged from 2.1 to 11.1 days and that the mean incubation period was 6.4 days .,1
6304,The estimations of the COVID-19 incubation period: a systematic review of the literature,"The researchers employed three parametric forms related to the distribution of the incubation period: lognormal distribution, gamma distribution, and the Weibull distribution.",1
6308,The estimations of the COVID-19 incubation period: a systematic review of the literature,Et al examined COVID-19 is epidemiological characteristics and incubation period.,1
6313,The estimations of the COVID-19 incubation period: a systematic review of the literature,"The outcomes of this research concluded that the incubation period falls into a range of 2-14 days , with the mean being approximately five days as found by employing best-fit lognormal distribution.",1
6315,The estimations of the COVID-19 incubation period: a systematic review of the literature,"On the basis of the 95 th percentile estimate for the incubation period, the researchers recommended that exposed individuals should be quarantined for a minimum of 14 days.",1
6320,The estimations of the COVID-19 incubation period: a systematic review of the literature,"Jiang X et al undertook research making a comparison between incubation periods for MERS, SARS, and SARS-CoV-2.",1
6321,The estimations of the COVID-19 incubation period: a systematic review of the literature,"The researchers reported that SARS-CoV-2 has an extended incubation period, which has led to modifications in official policy for control and screening.",1
6323,The estimations of the COVID-19 incubation period: a systematic review of the literature,"Nevertheless, by analyzing a large dataset for this research, researchers report that no identifiable difference exists between incubation times for SARS-CoV-2, severe acute respiratory syndrome coronavirus , and the Middle East respiratory syndrome coronavirus , which highlights the requirement for more extensive and better-annotated datasets.",1
6324,The estimations of the COVID-19 incubation period: a systematic review of the literature,"This research covered 49 patients with SARS-CoV-2 who had definite dates for first exposure, end of exposure and beginning of symptoms, 153 patients with SARS-CoV, and 70 MERS-CoV patients; this data was amalgamated from seven separate papers.",1
6325,The estimations of the COVID-19 incubation period: a systematic review of the literature,"The results indicated that MERS incubates on average 5.8 days , SARS-CoV 4.7 days , and SARS-CoV2 4.9 days .",1
6326,The estimations of the COVID-19 incubation period: a systematic review of the literature,"This demonstrates that the longest incubation period is MERS-CoV, with SARS-CoV2 second longest.",1
6327,The estimations of the COVID-19 incubation period: a systematic review of the literature,Lauer Stephen et al researched the COVID-19 incubation period by looking at diagnosed cases that have been publicly reported.,1
6328,The estimations of the COVID-19 incubation period: a systematic review of the literature,The aim of the study was to ascertain COVID-19 is incubation period and to detail its implications for public health.,1
6330,The estimations of the COVID-19 incubation period: a systematic review of the literature,"The research covered 181 subjects diagnosed with SARS-CoV-2 infection outwith Hubei province, China by examining press releases and news reports from 50 different provinces, regions, and nations.",1
6334,The estimations of the COVID-19 incubation period: a systematic review of the literature,This research adds to the evidence that COVID-19 is similar to SARS in having a median incubation period of around five days.,1
6336,The estimations of the COVID-19 incubation period: a systematic review of the literature,"Li Q. et al researched the early data regarding transmission dynamics for the virus in Wuhan, estimating the mean incubation period at 5.2 days , with the distribution is 95 th percentile being 12.5 days.",1
6338,The estimations of the COVID-19 incubation period: a systematic review of the literature,Their preliminary estimate of distribution of the incubation period offers strong support for the case that exposed subjects should be quarantined or put under medical observation for 14 days.,1
6347,The estimations of the COVID-19 incubation period: a systematic review of the literature,This research gave an estimation of mean incubation period as 7.2 days.,1
6349,The estimations of the COVID-19 incubation period: a systematic review of the literature,The researchers used transmission clusters for estimations of serial interval distribution and incubation period.,1
6351,The estimations of the COVID-19 incubation period: a systematic review of the literature,Interval censoring was employed ) for making parametric estimations of the distribution of the incubation period.,1
6359,The estimations of the COVID-19 incubation period: a systematic review of the literature,"The researchers found a median incubation period of six days; eight patients incubated between 14 and 17 days, and eight patients incubated between 18 and 30 days.",1
6362,The estimations of the COVID-19 incubation period: a systematic review of the literature,The timeline they uncovered implies that the coronavirus could have been passed on by this asymptomatic carrier.,1
6364,The estimations of the COVID-19 incubation period: a systematic review of the literature,"This patient initially produced a negative return for the RT-PCR test; RT-PCR is a common test for diagnostic virology and does not often return false positives, so her second result from this test was probably not a false positive, and so it was assumed that she was infected with the coronavirus that is responsible for COVID-19.",1
6365,The estimations of the COVID-19 incubation period: a systematic review of the literature,Wei Xia et al undertook research into how the coronavirus was transmitted in incubation periods in 2019.,1
6367,The estimations of the COVID-19 incubation period: a systematic review of the literature,They assessed the possibilities of transmission in the course of the incubation period for 50 clusters of infection; these included 124 cases outwith Wuhan/Hubei province.,1
6369,The estimations of the COVID-19 incubation period: a systematic review of the literature,"This research found that the mean incubation period for COVID-19 was 4.9 days , with a range of 0.8 to 11.1 days .",1
6372,The estimations of the COVID-19 incubation period: a systematic review of the literature,Robust workable countermeasures are required for the prevention or mitigation of the virus being transmitted asymptomatically amongst high-risk populations in the course of the incubation period.,1
6381,The estimations of the COVID-19 incubation period: a systematic review of the literature,"For the whole period, mean incubation period was calculated at 5.2 days with the mean serial interval being 5.1 days .",1
6382,The estimations of the COVID-19 incubation period: a systematic review of the literature,Shaoqing et al undertook research investigating the clinical characteristics and outcomes for patients submitting to surgery in the COVID-19 incubation period.,1
6383,The estimations of the COVID-19 incubation period: a systematic review of the literature,"The researchers undertook analysis of clinical data for 34 subjects submitting to elective surgery during the COVID-19 incubation period at four Chinese hospitals in Wuhan between January 1 and February 5, 2020.",1
6390,The estimations of the COVID-19 incubation period: a systematic review of the literature,The time gap between hospital admission and surgery is less than the median incubation period of 5.2 days found in patients with laboratory-confirmed infections in Wuhan ; it is also less than the general incubation time in hospitals in China ).,1
6392,The estimations of the COVID-19 incubation period: a systematic review of the literature,Guan et al undertook research into coronavirus' clinical characteristics within China.,1
6397,The estimations of the COVID-19 incubation period: a systematic review of the literature,There was found to be a median incubation period of four days .,1
6425,The estimations of the COVID-19 incubation period: a systematic review of the literature,This research found a median incubation period for COVID-19 of four days .,1
6432,The estimations of the COVID-19 incubation period: a systematic review of the literature,92% of patients did not have an incubation period in excess of 14 days.,1
6434,The estimations of the COVID-19 incubation period: a systematic review of the literature,Table 1 : overview of articles investigating and reporting on the incubation period of COVID-19.,1
6435,The estimations of the COVID-19 incubation period: a systematic review of the literature,Method for estimating the incubation period.,1
6439,The estimations of the COVID-19 incubation period: a systematic review of the literature,Throughout human history epidemics have been a disrupter of human civilizations and caused staggering amounts of mortality and illness for both humans and animals .,1
6443,The estimations of the COVID-19 incubation period: a systematic review of the literature,"On the basis of this research, it appears that the only means of estimating the incubation period for COVID-19 at present is logarithm normal distribution.",1
6451,The estimations of the COVID-19 incubation period: a systematic review of the literature,"The systematic review undertaken by this research has demonstrated that the current published estimations have offered empirical evidence that the virus' incubation period is approximately a median of 5.01 and a mean of 7.8 days, which falls into the 2 to 12 days assumption of the ECDC and the 0 to 14 days of the WHO .",1
6453,The estimations of the COVID-19 incubation period: a systematic review of the literature,"offered evidence that it is possible for symptoms to appear once patients have left a 14 day period of quarantine or active monitoring; the authors suggest that the median incubation time is around five days, similar to SARS.",1
6458,The estimations of the COVID-19 incubation period: a systematic review of the literature,"Out of 291 patients with an average age of 47, the incubation period was 4.0 days, for five patients with an average age of 49.5 years it was 4.5 days, for 44 patients with an average age of 60 years it was 4.99 days, and for two patients with an average age of 47 years, it was 4.5 days.",1
6461,The estimations of the COVID-19 incubation period: a systematic review of the literature,states that COVID-19 has a mean incubation period lower than MERS coronavirus but higher than SARS coronavirus.,1
6475,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"The coronavirus-19-disease pandemic caused by the severe acute respiratory syndrome coronavirus 2 has surpassed four million cases world-wide , causing more than 283,000 deaths in 215 countries .",1
6476,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"While asymptomatic in some, SARS-CoV-2 infection can cause viral pneumonia that progresses to acute respiratory distress syndrome , and even multi-organ failure, in severe cases .",1
6477,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"Reports have shown that SARS-CoV-2 has the ability to productively infect lung epithelium, gut enterocytes and endothelium .",1
6478,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"It is unclear whether disease severity is caused by the viral infection, the host response, or both, emphasizing the urgent need to understand the immune perturbations induced by SARS-CoV-2 .",1
6481,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"Immune profiling studies to date have been conducted as single case reports or focused only on moderate, severe or recovered COVID-19 with limited numbers of individuals , and have not necessarily reflected the range of comorbidities globally associated with severe COVID-19.",1
6482,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"Studies of peripheral blood mononuclear cells by mass cytometry or single cell RNA sequencing have provided valuable insights into possible immune perturbations in COVID-19 but have not assessed the contributions of granulocytic populations, or, in the case of scRNAseq, defined expression or modulation of cellular proteins .",1
6484,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"To address these issues, we conducted a comprehensive analysis of the overall immunologic state of 42 individuals with different trajectories of SARS-CoV-2 infection and COVID-19 , compared with 12 healthy donors using whole blood to capture the full breadth of immunological perturbations and activation occurring in circulating lymphocytes and major granulocyte populations.",1
6485,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"We further explored modulation of the B cell repertoire, its associations with the establishment of a SARS-CoV-2-specific humoral response, and activation of T cells relative to disease severity.",1
6486,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"Together our results reveal a potential platform for assessing disease trajectory, and identify distinct immune perturbation patterns in severe COVID-19 that merit consideration for therapeutic immunomodulation strategies to ameliorate disease severity and organ failure.",1
6507,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"To assess the general landscape of immune responses and their perturbation during severe COVID- 19 , we performed extensive immunophenotyping to characterize the frequencies of circulating immune subsets in HD, or in moderate, severe and recovered COVID-19 individuals .",1
6528,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"Similar to observations in the immune atlas of recovered COVID-19 donors , expanded plasmablasts were not found in this group .",1
6538,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,Previous work has suggested that the SARS-CoV-2 IgG levels could be associated with disease severity .,1
6541,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,We then quantified IgM and IgG specific for the spike receptor binding domain of the SARS-CoV-2.,1
6544,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"Together these data indicate an exacerbated plasmablast response in severe COVID-19, as well as the development of a strong SARS-CoV-2-specific humoral response.",1
6550,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"Donors with severe COVID-19 had an unusually high proportion of large clones comprising the majority of their circulating antibody repertoire, with the fraction occupied by the top 20 ranked clones the highest compared to the healthy and moderate SARS-CoV-2 infected patients The D20 rank measure in moderate and severe disease also correlated positively with the plasmablast fraction .",1
6564,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"Acknowledging the characteristic differences in innate cell subset frequencies in severe COVID-19 individuals , we further assessed the phenotype of innate immune cells.",1
6572,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"The monocyte CD16 expression level tended to decrease with disease severity Altogether, these findings indicate a substantial perturbation of the innate immune system in severe COVID-19.",1
6586,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"These data indicate a heightened status of immune activation and frequency of cytotoxic CD8+ T cells during severe COVID-19, not observed in moderate or recovered disease.",1
6587,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"Finally, we performed an unbiased analysis to determine if the immune cells in severe COVID-19 disease cohort could be differentiated from the healthy, moderate, and recovered cohorts.",1
6588,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"We included all analyzed immune phenotype parameters described thus far, including the expression of activation markers within specific CD4+ and CD8+ T cell memory subsets .",1
6596,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"Taken as a whole, our analysis reveals a characteristic immune phenotype in severe COVID-19, distinct not only from HD but also from other COVID-19 individuals with moderate or recovered disease.",1
6600,Title: Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Authors,"While their size, somatic mutation status and association with the plasmablast fraction are suggestive of active participation in the immune response to SARS-CoV-2, it is unknown if these clones can recognize the virus, confer protection, or contribute to immunopathology.",1
6655,What Are People Asking About COVID-19? A Question Classification Dataset,"Finally, to minimize occurrences of questions that trivially differ, we remove all punctuation and replace synonymous ways of saying COVID, such as ""coronavirus,"" ""COVID-19,"" and ""COVID19,"" with ""covid.""",1
6762,What Are People Asking About COVID-19? A Question Classification Dataset,"Comparison ""How are COVID and SARS-COV similar?""",1
6770,What Are People Asking About COVID-19? A Question Classification Dataset,"""What is the genus of the SARS-COVID?""",1
6773,What Are People Asking About COVID-19? A Question Classification Dataset,"""How long is the incubation period for COVID?""",1
6779,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,"There were many reports related to a live-animal and seafood market, supporting that the pathogens were transferred from animals to humans, rapidly evolving into transmission from human to human.",1
6787,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,"2019-nCoV can attach to the human angiotensin-converting enzyme 2 , which is the same entry receptor for SARS-CoV.",1
6788,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,"2019-nCoV can also attach to the ACE-2 receptor from human, bat, pig and civet cat, cells, but it cannot attach to any cells in the absence of ACE-2 .",1
6798,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,"According to results from genetic and epidemiologic studies, the COVID-19 outbreak began with a single transmission from animal to human and then followed by ongoing human-to-human spread .",1
6803,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,"While symptomatic COVID-19 patients are the primary transmission source, the latest findings indicate that asymptomatic patients and patients in the incubation period are also carriers of 2019-nCoV.",1
6811,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,"The average incubation period for COVID-19 has been projected to be 5 to 6 days, although there is evidence that it can last as long as 14 days, which is now the widely accepted length for medical monitoring and quarantine of potentially exposed individuals .",1
6815,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,It suggests that the advent of summer and rainy season in the northern hemisphere will drastically decrease the COVID-19 transmission.,1
6826,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,"There are at least three different pathways for 2019-nCoV existence in saliva as follows : 1-2019-nCoV in the lower and upper respiratory tract entering the oral cavity along with the liquid droplets regularly exchanged by these organs 2-2019-nCoV in the blood entering the mouth through crevicular fluid 3-Infection of the major and minor salivary glands with subsequent release of particles into saliva through salivary ducts It is necessary to note that salivary gland epithelial cells may be affected with SARS-CoV shortly after infection in rhesus macaque, indicating that salivary gland cells can be a key source for this virus in saliva .",1
6827,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,"Furthermore, the development of SARS-CoV-specific Secretory Immunoglobulin A in the animal models' saliva has been previously demonstrated .",1
6836,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,The preventive and therapeutic advantage of CP is related to the potential source of particular antibodies of human origin .,1
6837,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,"Nevertheless, it is still hard to determine the effectiveness of CP treatment due to the lack of high-quality randomized clinical trial studies and the specific action process of plasma treatment.",1
6868,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,The British Medical Journal prescribed acetaminophen as analgesia instead of ibuprofen for COVID-19 infected patients because ibuprofen can interfere with the immune system function .,1
6877,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,"Protective glasses and face shields: There is clinical proof that since infectious droplets could readily attack the epithelium of human conjunctival, COVID-19 can be transferred by contact with the mucous membranes lining the eyes.",1
6886,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,"Although the pre-procedural mouthrinse impact on coronavirus is still uncertain, CHX is efficient against some infectious viruses such as human immunodeficiency virus , herpes simplex virus , and hepatitis B virus .",1
6902,Journal Pre-proofs Title Title: What Dentists Need to Know about COVID-19,Human coronavirus may live up to 9 days at room temperature on an inert surface with a higher preference for humid situations.,1
6918,Diabetes increases the mortality of patients with COVID-19: a meta-analysis,"Nowadays, the ongoing pandemic of COVID-19 caused by the novel coronavirus Syndrome-Coronavirus-2 is an emerging, rapidly evolving situation .",1
6920,Diabetes increases the mortality of patients with COVID-19: a meta-analysis,"Although SARS-CoV-2 and SARS-CoV share similarities in phylogeny and clinical trials, the new type of coronavirus seems to have a higher spread and lower mortality .",1
6921,Diabetes increases the mortality of patients with COVID-19: a meta-analysis,A study reported that SARS-CoV-2 invades into the cells through its predicated receptor angiotensin converting enzyme 2 .,1
6928,Diabetes increases the mortality of patients with COVID-19: a meta-analysis,"Therefore, this meta-analysis first aims to explore the possible clinical mortality between diabetes and COVID-19, analyze if diabetes patients infected with SARS-CoV-2 are exposed to the worst clinical prognostic risk, and to evaluate the reliability of the evidence.",1
6931,Diabetes increases the mortality of patients with COVID-19: a meta-analysis,"We determined to include studies involving in COVID-19, SARS-CoV-2, or diabetes.",1
6933,Diabetes increases the mortality of patients with COVID-19: a meta-analysis,"We first screened both titles and abstracts of the articles, and publications which may involve in data concerning COVID-19, SARS-CoV-2, or diabetes.",1
6974,Diabetes increases the mortality of patients with COVID-19: a meta-analysis,"According to the reports, diabetes and high blood glucose levels are important predictors of the severity and death of patients infected with different viruses, involving SARS-CoV and MERS-CoV .",1
6978,Diabetes increases the mortality of patients with COVID-19: a meta-analysis,A previous study suggested that SARS coronavirus uses ACE2 as a receptor to enter and damage islet cells that cause acute diabetes .,1
6979,Diabetes increases the mortality of patients with COVID-19: a meta-analysis,"Until now, there was no relevant study exploring the role of ACE2 in COVID-19 diabetic patients.",1
6980,Diabetes increases the mortality of patients with COVID-19: a meta-analysis,A recent meta-analysis retrieved the data of 2108 Chinese patients diagnosed with SARS-Cov-2 infection and found the prevalence of diabetes is 10.3% .,1
6994,Diabetes increases the mortality of patients with COVID-19: a meta-analysis,"First, due to the inadequate data, we do not have access to information such as diabetes duration, time of diagnoses, diabetes type, diabetes medications and complications, and thus we cannot conduct risk stratification in the subgroup analysis within the diabetic population.",1
6995,Diabetes increases the mortality of patients with COVID-19: a meta-analysis,"Second, we only obtained the information regarding the age and gender of COVID-19 patients, but other factors might influence the accuracy of results, such as BMI , measurements, and instruments for the detection of SARS-CoV-2.",1
7008,The impact of believing you have had COVID-19 on behaviour: Cross-sectional survey COPYRIGHT COMPETING INTEREST STATEMENT TRANSPARENCY DECLARATION AUTHOR CONTRIBUTION STATEMENT WHAT IS ALREADY KNOWN ON THIS TOPIC,"• Those who think they have had COVID-19 were more likely to think they were immune to COVID-19, and less likely to adhere to social distancing measures.",1
7017,The impact of believing you have had COVID-19 on behaviour: Cross-sectional survey COPYRIGHT COMPETING INTEREST STATEMENT TRANSPARENCY DECLARATION AUTHOR CONTRIBUTION STATEMENT WHAT IS ALREADY KNOWN ON THIS TOPIC,"People who believe they have had COVID-19 may be more likely to think they are completely immune, stop engaging in protective behaviours such as handwashing and reduce their social distancing measures.",1
7023,The impact of believing you have had COVID-19 on behaviour: Cross-sectional survey COPYRIGHT COMPETING INTEREST STATEMENT TRANSPARENCY DECLARATION AUTHOR CONTRIBUTION STATEMENT WHAT IS ALREADY KNOWN ON THIS TOPIC,"We hypothesised that people who think they have had COVID-19 are: more likely to believe that they are immune to COVID-19; less likely to adhere to social distancing measures; less worried about COVID-19; and perceive a lower risk of COVID-19 to themselves, but no difference in perceived risk of COVID-19 to others.",1
7037,The impact of believing you have had COVID-19 on behaviour: Cross-sectional survey COPYRIGHT COMPETING INTEREST STATEMENT TRANSPARENCY DECLARATION AUTHOR CONTRIBUTION STATEMENT WHAT IS ALREADY KNOWN ON THIS TOPIC,"Having had COVID-19 Participants were asked ""Do you think you have already had coronavirus?""",1
7040,The impact of believing you have had COVID-19 on behaviour: Cross-sectional survey COPYRIGHT COMPETING INTEREST STATEMENT TRANSPARENCY DECLARATION AUTHOR CONTRIBUTION STATEMENT WHAT IS ALREADY KNOWN ON THIS TOPIC,"Possible answers included ""yes, the results showed I did have coronavirus"", ""yes, the results showed I did not have coronavirus"" and ""no, I have not been tested"".",1
7041,The impact of believing you have had COVID-19 on behaviour: Cross-sectional survey COPYRIGHT COMPETING INTEREST STATEMENT TRANSPARENCY DECLARATION AUTHOR CONTRIBUTION STATEMENT WHAT IS ALREADY KNOWN ON THIS TOPIC,"To measure perceived immunity to COVID-19, we asked participants to what extent they agreed or disagreed with the statement ""I think I have some immunity to coronavirus"" on a five-point Likert scale .",1
7048,The impact of believing you have had COVID-19 on behaviour: Cross-sectional survey COPYRIGHT COMPETING INTEREST STATEMENT TRANSPARENCY DECLARATION AUTHOR CONTRIBUTION STATEMENT WHAT IS ALREADY KNOWN ON THIS TOPIC,"To assess the likelihood of misdiagnosis, we asked participants what they thought ""the most common symptoms of coronavirus"" were from a list of thirteen items .",1
7130,The impact of believing you have had COVID-19 on behaviour: Cross-sectional survey COPYRIGHT COMPETING INTEREST STATEMENT TRANSPARENCY DECLARATION AUTHOR CONTRIBUTION STATEMENT WHAT IS ALREADY KNOWN ON THIS TOPIC,Older participants were less likely to think they had had coronavirus.,1
7132,The impact of believing you have had COVID-19 on behaviour: Cross-sectional survey COPYRIGHT COMPETING INTEREST STATEMENT TRANSPARENCY DECLARATION AUTHOR CONTRIBUTION STATEMENT WHAT IS ALREADY KNOWN ON THIS TOPIC,"Those who have a child were more likely to report having had coronavirus perhaps linked to greater exposure, or perceived exposure, among this group.",1
7161,The impact of believing you have had COVID-19 on behaviour: Cross-sectional survey COPYRIGHT COMPETING INTEREST STATEMENT TRANSPARENCY DECLARATION AUTHOR CONTRIBUTION STATEMENT WHAT IS ALREADY KNOWN ON THIS TOPIC,Graph depicting the percentage of people who: strongly agree that they are immune to COVID-19; went out to buy groceries/pharmacy on two or more days in the last seven days; went out to buy items other than groceries/pharmacy once or more in the last seven days; met up with friends and/or family they do not live with once or more in the last seven days; reported total out-of-home activity of eight or more ; are not worried at all about COVID-19; perceive no risk at all to themselves from COVID-19; perceive no risk at all to people in the UK from COVID-19; did not identify cough and high temperature / fever as common symptoms of COVID-19 in those who think they have and have not had COVID-19.,1
7166,Risks of Novel Coronavirus Disease (COVID-19) in Preg- nancy; a Narrative Review,Coronaviruses are among the main human and animal pathogens .,1
7171,Risks of Novel Coronavirus Disease (COVID-19) in Preg- nancy; a Narrative Review,"On February 12, 2020, WHO named the disease caused by the novel coronavirus ""Coronavirus Disease 2019"" .",1
7175,Risks of Novel Coronavirus Disease (COVID-19) in Preg- nancy; a Narrative Review,"With the spread of the coronavirus, concerns have been raised about its intrauterine transmission from mother to fetus in pregnant women .",1
7183,Risks of Novel Coronavirus Disease (COVID-19) in Preg- nancy; a Narrative Review,"In this review, we searched for all articles published in various databases including PubMed, Scopus, Embase, Science Direct and Web of Science using MeSH-compliant keywords including COVID-19, Pregnancy, vertical transmission, Coronavirus 2019, SARS-CoV-2 and 2019-nCoV from December 2019 to March 11 2020 and then reviewed them.",1
7206,Risks of Novel Coronavirus Disease (COVID-19) in Preg- nancy; a Narrative Review,No antiviral medications were given to mothers during pregnancy.,1
7209,Risks of Novel Coronavirus Disease (COVID-19) in Preg- nancy; a Narrative Review,"Samples were taken from neonate is throat, umbilical cord, amniotic fluid, stool, neonatal blood samples and breast milk of mother immediately after birth for screening of SARV-19 infection via SARS-CoV2 RT-PCR.",1
7222,Risks of Novel Coronavirus Disease (COVID-19) in Preg- nancy; a Narrative Review,• There is limited knowledge regarding coronavirus infections that occur during pregnancy.,1
7223,Risks of Novel Coronavirus Disease (COVID-19) in Preg- nancy; a Narrative Review,• Previous experiences with coronavirus infections in pregnancy indicate that these agents are capable of causing adverse clinical outcomes.,1
7228,Risks of Novel Coronavirus Disease (COVID-19) in Preg- nancy; a Narrative Review,This finding is in line with the results of a previous study on SARS-CoV-1 that was done by Wong and colleagues .,1
7236,Risks of Novel Coronavirus Disease (COVID-19) in Preg- nancy; a Narrative Review,"Previously published studies have demonstrated that being affected with SARS during perinatal period is associated with a high prevalence of harmful maternal and neonatal side effects including disseminated intravascular coagulopathy, abrupt abortion, preterm childbirth, intrauterine growth retard, neonatal intubation and need of newborn to be admitted to neonatal intensive care unit, and organ failure .",1
7237,Risks of Novel Coronavirus Disease (COVID-19) in Preg- nancy; a Narrative Review,"Generally, our review of literature showed that pregnant women infected with COVID-19 and their newborns had less problems than would be anticipated for those with SARS-CoV-1 infection.",1
7239,Risks of Novel Coronavirus Disease (COVID-19) in Preg- nancy; a Narrative Review,"Also, the clinical manifastations reported in pregnant women with positive COVID-19 are similar to those reported for non-pregnant women infected with COVID-19 and relatively good clinical outcomes have been reported for COVID-19 infection in pregnant women compared with SARS-CoV-1 infection .",1
7247,Adults at high-risk of severe coronavirus disease-2019 (Covid-19) in Brazil 2,"The World Health Organization suggests that most people infected with the virus may develop mild or uncomplicated coronavirus disease 2019 , while the remaining 20% may develop its severe variation, requiring hospitalization or intensive care unit 1 .",1
7251,Adults at high-risk of severe coronavirus disease-2019 (Covid-19) in Brazil 2,"As of April 12, 2020, the number of SARS-CoV-2 infections was above 1.8 million, reported in 185 countries/regions of the world 11 .",1
7297,Adults at high-risk of severe coronavirus disease-2019 (Covid-19) in Brazil 2,"These findings and methods to identify high-risk settings may be useful to plan and manage prevention strategies in Brazil and other low-to middle-income settings with routinely collected data from population-based surveys, but limited testing capacity for SARS-CoV-2.",1
7316,Adults at high-risk of severe coronavirus disease-2019 (Covid-19) in Brazil 2,"We argue that these results support broad social isolation measures, particularly while testing capacity for SARS-CoV-2 is limited.",1
7345,Asian Journal of Psychiatry,Clinicians need to have indepth understanding of these interactions when treating a COVID-19 positive patient who is also on psychotropic medications.,1
7351,Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review,"Human coronavirus infections are known to remain mild, as opposed to the ""Middle East Coronavirus"" and ""Severe Acute Respiratory Syndrome"" coronavirus, which occurred in the past two decades, and were grave .",1
7353,Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review,"An outbreak of SARS-CoV-2 in the near past has been declared a pandemic and it is predicted to be at its peak in USA, Europe and many other developing countries around the end of April, or in first two weeks of May 2020.",1
7369,Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review,"The search strategy used in this paper is based on key terms such as ""pregnant women"" or ""protection"" AND ""Coronavirus 2019"", or ""COVID-19"" with the English language.",1
7402,Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review,"A recent study has shown that the SARS-COV2 virus is not detected in the breast milk, amniotic fluid and cord blood in women who have been infected with SARS-COV2.",1
7404,Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review,"During the ""severe acute respiratory syndrome coronavirus"" epidemic, the virus disease remained lower in neonates as compared to adults.",1
7435,Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review,has an evidence of our claim that there is no vertical transmission of coronavirus in pregnant women.,1
7439,Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review Protection Challenges of Pregnant Women against Vertical Transmission during COVID-19 Epidemic: A Narrative Review,The immune system of pregnant women keeps stabilizing the balance of hormones from earlier stages to the trimester stage of pregnancy.,1
7446,A systematic review of convalescent plasma treatment for COVID19,"Passive immunization using convalescent plasma containing neutralizing antibodies, obtained from individuals that have recovered from the infection, was used during the SARS-CoV-1 and MERS-CoV outbreaks 7,8 , and has also been proposed as a treatment option for COVID-19 9, 10 .",1
7447,A systematic review of convalescent plasma treatment for COVID19,CP therapy may be most effective when given early during coronavirus infection and may actually cause harm to the patient if the plasma used has low antibody titers and the infusion is given late in the disease progression 11 .,1
7453,A systematic review of convalescent plasma treatment for COVID19,"Initially, the literature search revealed 3,864 peer-reviewed articles on treatment strategies, therapeutic procedures, and vaccine development for SARS-CoV-2 infection and COVID-19 treatment .",1
7454,A systematic review of convalescent plasma treatment for COVID19,"A total of 232 articles were identified that addressed the potential use of CP therapy for COVID-19, mostly by reviewing CP therapy results 13 from previous infectious disease outbreaks such as influenza 14, 15 , Ebola 16 as well as SARS-CoV-1 17 and MERS-CoV 8 .",1
7467,A systematic review of convalescent plasma treatment for COVID19,Recovery was defined as the first consecutive negative result for SARS-CoV-2 RNA from mouth/nasal swab of the patient.,1
7468,A systematic review of convalescent plasma treatment for COVID19,"If viral RNA results were not reported, we used the hospital discharge time point as a proxy for SARS-CoV-2 clearance.",1
7473,A systematic review of convalescent plasma treatment for COVID19,"To evaluate the effect of immune plasma antibody treatment for COVID-19, our literature search identified ten studies , which met our systematic literature review criteria, and reported results for CP therapy treatment for patients with confirmed COVID-19.",1
7481,A systematic review of convalescent plasma treatment for COVID19,Transfusion of SARS-CoV-2 neutralizing antibody containing immune plasma was administered as a one-day treatment for 52 patients with a total of between 200mL and 500mL of CP for each patient.,1
7485,A systematic review of convalescent plasma treatment for COVID19,Donors had been diagnosed with COVID-19 and had a SARS-CoV-2 infection confirmed by RT-PCR from nasopharyngeal specimens.,1
7486,A systematic review of convalescent plasma treatment for COVID19,Donors tested negative for SARS-CoV-2 RNA after recovery and prior to .,1
7490,A systematic review of convalescent plasma treatment for COVID19,"Other respiratory infections, Hepatitis B, hepatitis C, human immunodeficiency virus and syphilis were reported to have been tested following standard blood banking practices at the time of blood donation.",1
7500,A systematic review of convalescent plasma treatment for COVID19,"Across the studies, antiviral treatment was mostly given until the SARS-CoV-2 RNA was not detected in the nasopharyngeal/throat swab sample.",1
7514,A systematic review of convalescent plasma treatment for COVID19,The most robust measure to estimate the CP treatment response of the COVID-19 patients across the ten studies was deemed to be the RT-PCR of SARS-CoV-2 RNA from nasopharyngeal and throat swab samples.,1
7515,A systematic review of convalescent plasma treatment for COVID19,"Even so, for a number of cases the viral RNA results were not available 30 , and hence, for those we used the reported patients hospital discharge time as a proxy for expected clearance of SARS-CoV-2 RNA.",1
7521,A systematic review of convalescent plasma treatment for COVID19,"Particularly, all COVID-19 patients reviewed here received in parallel antiviral and other medications, and thus, these concomitant treatments prevented direct estimations of the likely benefits or harms of CP treatment.",1
7528,A systematic review of convalescent plasma treatment for COVID19,"Another ongoing study of 5000 COVID-19 patients treated with convalescent plasma also emphasize that the treatment is safe, as thus far, they report only two patients with severe adverse effects certainly related to the CP transfusion 35 Importantly, however, previous experience with CP therapy for coronavirus-related severe pneumonic disease, such as SARS-CoV-1 and MERS-CoV, already pointed a note of caution for the treatment and argued that CP therapy may be most effective when given soon after onset of the disease 8 .",1
7529,A systematic review of convalescent plasma treatment for COVID19,"In agreement, an improved intervention outcome was observed among SARS patients who received CP within the first two weeks of disease onset 38 .",1
7531,A systematic review of convalescent plasma treatment for COVID19,"An important concern, however, has been recently addressed that COVID-19 clinical trials may be currently implemented largely due to urgent treatment needs but at the expense of rigorous scientific and ethical standards 43, 44 .",1
7544,A systematic review of convalescent plasma treatment for COVID19,"A massive number of large scale clinical trials are ongoing, but preliminary data is still not available 33- 36, 46 .",1
7547,A systematic review of convalescent plasma treatment for COVID19,"Moreover, we re-analyzed our data after excluding the study lacking RT-PCR results for SARS-CoV-2 RNA post-transfusion 30 .",1
7549,A systematic review of convalescent plasma treatment for COVID19,Most available intervention results of CP transfusion with high titer SARS-CoV-2 antibody to treat COVID-19 disease is limited but suggest that the therapy is safe and effective for the treatment of patients suffering from COVID-19 disease.,1
7565,A systematic review of convalescent plasma treatment for COVID19,Recovery in 1-7 day or over after CP treatment until negative SARS-CoV-2 RNA detection.,1
7612,Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic,"Importantly, as we are currently uncertain how many people will contract the virus in the near/far future and therefore are unsure who will need COVID-19 medications, such considerations may apply to all new psychiatric patients currently seen by physicians.",1
7745,Development and Implementation of a COVID-19 Disease Response Protocol at a Large Academic Medical Center,"The document contains best practices and guidance for diagnosis, isolation, appropriate personal protective equipment for the care of COVID-19 patients, guidelines for transportation, diagnostic tests, investigational COVID-19 treatment options, a summary of ongoing clinical trials at our facilities, how to mitigate additional transmissions, and education for patients and families.",1
7773,Development and Implementation of a COVID-19 Disease Response Protocol at a Large Academic Medical Center,"As new data became available, including the National Institutes of Health updated recommendations for the management of COVID-19 patients on April 21, 2020, the aforementioned stakeholders were involved in determining which investigational treatment options and clinical trials were available for the health system is patient population.",1
7796,Development and Implementation of a COVID-19 Disease Response Protocol at a Large Academic Medical Center,"Before clinical trials began, AST, ID, and critical care intensivists used the treatment guidelines that were created based on previously published literature, as well as CDC and WHO recommendations.",1
7798,Development and Implementation of a COVID-19 Disease Response Protocol at a Large Academic Medical Center,"As clinical trials became available, the same group reviewed the inclusion and exclusion criteria and identified trials to meet the needs of the local patient population.",1
7812,Journal Pre-proof Best practice recommendations for point-of-care lung ultrasound in patients with suspected COVID-19 TITLE: Best practice recommendations for point-of-care lung ultrasound in patients with suspected COVID-19 AUTHORS: Best practice recommendations for point-of-care lung ultrasound in patients with suspected 1,"35 COVID-19, the clinical illness caused by SARS-CoV-2, evolved into a global pandemic 36 over a few short months .",1
7816,Journal Pre-proof Best practice recommendations for point-of-care lung ultrasound in patients with suspected COVID-19 TITLE: Best practice recommendations for point-of-care lung ultrasound in patients with suspected COVID-19 AUTHORS: Best practice recommendations for point-of-care lung ultrasound in patients with suspected 1,"41 Properties of COVID-19 which put HCWs at risk of nosocomial spread include human-to-human 42 transmission via respiratory droplets , and viral fomites which can survive on surfaces for 43 up to 72 hours .",1
7845,Journal Pre-proof Intellectual and Developmental Disability and COVID-19 Case-Fatality Trends: TriNetX Analysis Intellectual and Developmental Disability and COVID-19 Case-Fatality Trends: TriNetX Analysis,"TriNetX provides access to continuously updated, de-identified aggregate EMR data including demographics, diagnoses, procedures, medications, laboratory values, and genomics.",1
7904,Comorbidity and its Impact on Patients with COVID-19,"Coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 is a global pandemic that initially started in Wuhan, China, and spread extremely quickly, making its way to over 180 countries.",1
7905,Comorbidity and its Impact on Patients with COVID-19,"As the novel coronavirus continues to evolve, there are still many limitations to our knowledge of who exactly this virus would impact critically.",1
7928,Comorbidity and its Impact on Patients with COVID-19,"An article was selected if it included keywords such as coronavirus, COVID-19, SARS-CoV-2, clinical features, comorbidity, diabetes, and hypertension.",1
7939,Comorbidity and its Impact on Patients with COVID-19,The average incubation period for COVID-19 is approximately 5.2 days .,1
7946,Comorbidity and its Impact on Patients with COVID-19,"Also, it is important to note that COVID-19 is more infectious than SARS-CoV and MERS-CoV due to its numerous epidemiological and biological characteristics .",1
7958,Comorbidity and its Impact on Patients with COVID-19,"In Iran, a case study reported that genetic predisposition to COVID-19 can increase the probabilities of getting infected with SARS-CoV-2 and can lead to death from this virus .",1
7962,Comorbidity and its Impact on Patients with COVID-19,"According to the International Aids Society , people who are human immunodeficiency virus positive, taking antiretroviral treatment, and do not have a low CD4 count will have the same risk of having COVID-19 as one without HIV .",1
7986,Comorbidity and its Impact on Patients with COVID-19,"New York is being hit the hardest by the novel coronavirus spreading across the USA, with more cases and deaths per capita than any other state.",1
8001,Comorbidity and its Impact on Patients with COVID-19,Patients with acute respiratory distress syndrome and respiratory failure associated with the novel coronavirus may be linked to a prothrombotic coagulopathy .,1
8009,Comorbidity and its Impact on Patients with COVID-19,Authorities speculate that subjects with comorbidities were linked to a more severe disease outcome when infected with the novel coronavirus when compared with patients with no underlying disease .,1
8014,Comorbidity and its Impact on Patients with COVID-19,"As cases evolve globally, it has been noted that persons with underlying chronic illnesses are more likely to contract the virus and become severely ill. Due to SARS CoV-2 being a relatively new virus, the data available is limited.",1
8019,Comorbidity and its Impact on Patients with COVID-19,"Since there is a period where the patient is asymptomatic, and the incubation period is between 2 and 14 days, it is difficult to establish an early diagnosis, much less curb the transmission of the infection if the patient is unknowingly exposed.",1
8021,Comorbidity and its Impact on Patients with COVID-19,"Therefore, patients with comorbidities should take all necessary precautions to avoid getting infected with SARS CoV-2, as they usually have the worst prognosis.",1
8024,Surgical resection for liver cancer during the COVID-19 outbreak,"Since the beginning of 2019 novel coronavirus disease epidemic in France, caused by severe acute respiratory syndrome coronavirus 2 , hospital capacity, in the most affected regions, has rapidly exceeded.",1
8033,Surgical resection for liver cancer during the COVID-19 outbreak,"However, it has been demonstrated that SARS-COV-2 binds angiotensin converting enzyme 2 receptor to infect the cells.",1
8037,Surgical resection for liver cancer during the COVID-19 outbreak,"Thus, nascent hepatocytes expressing ACE2 receptor could be susceptible to SARS-COV-2 infection .",1
8043,Surgical resection for liver cancer during the COVID-19 outbreak,"In a similar way, once the cascade of inflammatory reactions is triggered by SARS-COV-2 or in case of related bacterial infection, COVID-19 could be responsible for the development of PHLF.",1
8055,Surgical resection for liver cancer during the COVID-19 outbreak,"Due to the risk of contamination by SARS-COV-2 before, during or after hospitalization, we believe that liver surgery for cancer should be postponed for patients at high risk of postoperative complications and severe COVID-19, including elderly patient with comorbidities and chronic liver disease.",1
8064,Surgical resection for liver cancer during the COVID-19 outbreak,Research involving human participants and/or animals This article does not contain any research with human and/or animals performed by any of the authors.,1
8067,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"Novel coronavirus disease 19 first emerged on 31 December 2019 in Wuhan city, China.",1
8071,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,Comparison of the lipid rafts of coronaviruses has indicated that the new strain COVID-19 has 80% identity with severe acute respiratory syndrome coronavirus .,1
8076,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"Over the past two decades, outbreaks of coronavirus have been observed-SARS-CoV in 2003 and Middle-East respiratory syndrome -CoV-and have been described as major public health threats.",1
8078,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"To date, it seems that the mortality rate of COVID-19 is lower than those of SARS or MERS.",1
8081,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"Some countries face an outbreak crisis and are trying to prevent the spread of COVID-19 through preventing human gatherings, imposing a curfew in cities, preventing travel between countries and closing land borders, all of which may reduce the outbreaks.",1
8082,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"The main transmission of COVID-19 starts with human-tohuman contact, including relatives and friends who have intimate contact with patients or incubating carriers.",1
8084,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,COVID-19 is related to the beta-coronavirus that infects humans and probably developed from bat coronaviruses.,1
8085,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"Structural analysis shows that COVID-19 probably derives from a bat SARS-like coronavirus, which has mutated in the spike glycoprotein and nucleocapsid N protein The positive-sense RNA genomes of COVID-19 differ from SARS-CoV and MERS-CoV, being approximately 29.9 kb, 27.9 kb and 30.1 kb, respectively .",1
8087,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"Sequence analysis revealed that COVID-19 has > 80% identity with SARS-CoV and 50% with MERS-CoV, which originated in bats .",1
8092,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"COVID-19 and COVID-19 , bat-SL-CoVZC45 and SARS-CoV BJ182b showed alignment identities of 99%, 89% and 82%, respectively.",1
8096,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,Seven complete genomes have been aligned for different coronavirus strains .,1
8103,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,COVID-19 also possesses accessory proteins that interfere with the host is innate immune response .,1
8106,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"Nucleocapsid phosphoprotein COVID-19 was aligned with NP COVID-19 and showed similarity of 100%; against NP SARS CoV CUHK-L2 and bat COV HKU5 similarities were 85% and 61%, respectively .",1
8108,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"ORF7a protein COVID-19 aligned with NS7a Bat CoV RaTG13 showed 99% similarity, aligned with hypothetical protein SARS 7 CoV it showed 89% similarity and aligned with putative uncharacterized protein 4 SARS CoV it showed 68% similarity .",1
8109,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"Alignment of ORF8 protein COVID-19 with ORF8 protein COVID-19 , hypothetical protein Bat SARS CoV Rs806/2006 and hypothetical protein Bat SARS CoV HKU3-8 showed similarities of 99%, 76% and 84%, respectively .",1
8110,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"ORF6 protein COVID-19 was aligned with ORF6 protein COVID-19 , protein 7 Rhinolophus affinis CoV and NSP 6 SARS CoV ExoN1 and showed similarities of 98%, 88% and 86%, respectively .",1
8111,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"Alignment of envelope protein COVID-19 with EP COVID-19 showed 98% similarity, with Chain A Envelope small membrane protein SARS CoV showed 90% similarity and with envelope protein Hypsugo Bat CoV HKU25 showed 56% similarity .",1
8113,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,There are obvious differences compared with other species in the coronavirus family.,1
8114,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,This may indicate that COVID-19 originated from mutations within the coronavirus family.,1
8116,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,We are unable to give reasonable explanations for the significant number of amino acid substitutions between COVID-19 and SARS-CoV or MERS-CoV due to very limited knowledge of this novel virus.,1
8117,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,The incubation period of the virus may vary with age and immune status.,1
8118,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"In general, it has been assumed that the incubation period is between 2 and 14 days, although cases have been observed up to 23 days after exposure.",1
8126,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,This period depends on the age and immune status of the individual and is shorter in those <70 years old .,1
8140,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,"COVID-19 RNA has been isolated from human saliva, nasopharynx and lower respiratory tract.",1
8150,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,Clinical trials of hydroxychloroquine treatment for COVID-19 pneumonia have shown positive preliminary outcomes in China.,1
8152,MINI-REVIEW Mutated COVID-19 may foretell a great risk for mankind in the future,Scientists have made progress in characterizing the new coronavirus but there are still many questions to be answered.,1
8162,"Italian Association of Psychogeriatrics, Italy; © Serdi and Springer-Verlag International SAS, part of Springer","In Italy, SARS-CoV-2 outbreak was catastrophic with 135,586 confirmed cases and 17,127 deaths at April, 8th .",1
8169,"Italian Association of Psychogeriatrics, Italy; © Serdi and Springer-Verlag International SAS, part of Springer",All patients admitted to COVID Wards were positive to RT-PCR for SARS-Cov-2 conducted on a nasopharyngeal specimen and presented respiratory failure.,1
8200,"To appear in: Nutrition, Metabolism and Cardiovascular Diseases","The outbreak of coronavirus disease 2019 , caused by the severe acute 68 respiratory syndrome coronavirus 2 , has been recently declared a 69 pandemic by the World Health Organization, and the disease has spread to nearly all 70 countries worldwide .",1
8239,"To appear in: Nutrition, Metabolism and Cardiovascular Diseases","Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, 860 Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, 861 Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, 862 Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: 863 implications for virus origins and receptor binding.",1
8250,Journal Pre-proof Impact of COVID-19 pandemic on patients with ST-segment elevation myocardial infarction: Insights from a British cardiac center Impact of COVID-19 Pandemic on Patients with ST-segment Elevation Myocardial Infarction: Insights from a British Cardiac Center Address for correspondence,"Since 1 st March 2020, the Coronavirus disease 2019 outbreak had been declared a ""level 4 incident"" in the United Kingdom.",1
8297,"Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China","Epidemiological evidence suggested that most of these patients had visited the Huanan seafood market in Wuhan and Proved to be caused by SARS-CoV-2, which had not been found in humans before.",1
8301,"Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China","4 Analyzing of the genome of SARS-CoV-2 isolated from human airway epithelial cells, revealed that this new virus formed another clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily.",1
8302,"Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China","5 Different from both SARS-CoV and MERS-CoV, SARS-CoV-2 is the seventh member of the family of coronaviruses that infect humans.",1
8303,"Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China","6, 7 Some researchers have found that SARS-CoV-2 has a strong affinity to a human respiratory receptor and determined the phenomenon of human to human transmission in family homes and hospitals, which suggested a potential threat to the global public health.",1
8304,"Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China","8 Research found that the incubation period is 3 to 7 days in general, and days of 14 has been suggested as a quarantine period to ensure the absence of disease from healthy.",1
8310,"Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China",Seldom information on novel coronavirus cases was known in other places of China.,1
8317,"Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China","3, 12 In this study, we did a retrospective study analysis for the confirmed cases diagnosed from 27th January to F I G U R E 2 Epidemiological analysis for COVID-19 exposure in four major cities Table 1 presented a descriptive analysis of novel coronavirus pneumonia cases from four major cities in Zhejiang.",1
8320,"Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China","Research showed the infection of COVID-19 is self-limited, people whom could recover in a strong immune system.",1
8321,"Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China",16 And the younger would be in a lower likelihood of infection because of a faster immune response mechanism.,1
8326,"Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China","23, 24 As the asymptomatic did not present any clinical signs or symptoms but still excrete coronavirus and could become a source of infection, 25, 26 it is necessary to detect the inapparent infection from population and prevent the disease from further spread.",1
8329,"Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China",27 Yang et al 28 has proved chest CT could be used to quickly assess patients with severity of the novel coronavirus.,1
8345,Impact of the COVID-19 Outbreak on the Management of Patients with Cancer,The unprecedented worldwide occurrence of the coronavirus SARS-CoV-2 pandemic is not like any other seasonal infection and is having a profound effect on the entire oncology community by impacting patients with cancer and reducing healthcare activities for a duration that cannot yet be accurately estimated .,1
8411,Impact of the COVID-19 Outbreak on the Management of Patients with Cancer,"Finally, one advantage of developing a specific registry and broad testing of patients with cancer is to obtain information on the prevalence of the disease in the patient population and facilitate inclusion of patients in COVID-19-specific clinical trials.",1
8427,Impact of the COVID-19 Outbreak on the Management of Patients with Cancer,Several antiviral therapies against COVID-19 infection have been used compassionately or as part of prospective uncontrolled and controlled clinical trials .,1
8430,Impact of the COVID-19 Outbreak on the Management of Patients with Cancer,"However, publications of upcoming clinical trials should be scrutinized for subgroup analyses of patients with cancer.",1
8431,Impact of the COVID-19 Outbreak on the Management of Patients with Cancer,"Moreover, several clinical trials specifically designed for patients with cancer are ongoing, which may help in our understanding of how patients with cancer should be treated for COVID-19 infection.",1
8432,Impact of the COVID-19 Outbreak on the Management of Patients with Cancer,The use of antiviral therapy outside clinical trials in COVID-19-infected patients remains controversial.,1
8440,Impact of the COVID-19 Outbreak on the Management of Patients with Cancer,Including patients with cancer in antiviral treatment registries and clinical trials investigating COVID-19 antiviral therapies is highly advisable.,1
8441,Impact of the COVID-19 Outbreak on the Management of Patients with Cancer,"Although very limited information is available, the use of anticancer agents concomitantly with antiviral therapy outside clinical trials is not recommended to avoid unpredicted pharmacokinetic interactions and toxicity, as previously described with antiviral agents for hepatitis B .",1
8448,Impact of the COVID-19 Outbreak on the Management of Patients with Cancer,"For instance, it has been proposed that some cancer surgeries are delayed toxicity during trials and/or because monitoring and assurance quality for safety could not be continued due to limited human resources including Clinical Research Associates or postponed using neoadjuvant therapies.",1
8503,Impact of the COVID-19 Outbreak on the Management of Patients with Cancer,"The mobilization of teams for internal reorganization to continue oncology care and/or participate in COVID-19 activities, along with transient eviction of COVID-19-positive caregivers, may result in an effective shortage of human resources to screen or include new patients in clinical trials exploring anticancer agents during the COVID outbreak .",1
8515,Impact of the COVID-19 Outbreak on the Management of Patients with Cancer,"Whenever available, serological COVID-19 diagnosis may facilitate the identification of immune patients and healthcare workers who are no longer at risk for COVID-19 infection.",1
8709,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,"The Michigan Medicine Congenital Heart Center has identified the high risk congenital cardiac conditions for COVID-19 as single ventricle patients , infants less than 12 months of age, pulmonary hypertension, oxygen saturation less than 85%, patients with unrepaired complex CHD, and patients with genetic disorders potentially associated with compromised immune systems .",1
8712,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,"14 According to recent data, SARS-CoV-2 virus has not been detected in amniotic fluid, cord blood, or breast milk of pregnant women infected with SARS-CoV-2.",1
8713,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,"The incidence of the disease is lower in neonates than in adults possibly related to the difficulty of vertical transmission of coronavirus, proper handling at birth, and timely isolation of the newborn following the birth.",1
8723,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,"To date, as SARS-CoV-2 has not been detected in breast milk, mothers with COVID-19 can express breast milk to be fed to their babies by uninfected caregivers.",1
8737,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,36 The best test for SARS-CoV-2 in the peri-operative setting is a polymerase chain reaction of respiratory secretions.,1
8740,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,The incubation period for COVID-19 is ranged between 4 and 6 days and may be as long as 14 days.,1
8745,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,"On 27 May, 2020, World Health Organisation recommended that the drugs including chloroquine and hydroxychloroquine , antivirals, immunomodulators, and plasma therapy should not be administered as treatment or prophylaxis for COVID-19, outside of the context of clinical trials.",1
8783,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,Continued invasive haemodynamic monitoring is recommended to guide fluid therapy and the use of inotropic or vasoactive medications.,1
8790,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,"Antifibrinolytic medications, preoperative haemodilution, autologous platelet-rich plasma technology, mild hypothermia or normothermia during cardiopulmonary bypass, and intraoperative blood salvage should be used to reduce the risk of transfusion-related lung injury.",1
8833,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,"43, 46, 47 SARS-CoV-2 is known to be sensitive to ultraviolet rays and heat.",1
8844,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,Anaesthesia and major surgery can produce immune-inflammatory responses in patients with CHD.,1
8849,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,"36, 41 Available evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response play important role in the pathogenesis of COVID-19.",1
8851,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,"The immune function of the patient has a major impact on the disease severity, and populations with low immune function, such as newborns, can be more susceptible.",1
8856,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,"Performing minimally invasive extracorporeal circulation and utilising the cellsaver device may both have preventive effects on the immune response, reducing the systemic cytokine load.",1
8860,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,The thymus is known to be the site of T cell development in human.,1
8873,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,"2, 14, 53 During the SARS-CoV-2 pandemic, for the health and safety of the patients, parental visiting should be limited.",1
8880,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,"As SARS-CoV-2 uses angiotensinconverting enzyme-2 receptor to enter human cells, it is supposed that angiotensin-converting enzyme inhibitors may affect the severity of coronavirus infections.",1
8883,Cardiology in the Young Perioperative care of the newborns with CHDs in the time of COVID-19,Stopping these medications may cause a worsening of the underlying heart condition.,1
8903,CE-SYSTEMATIC REVIEWS AND META-ANALYSIS Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?,"Media reports suggest that it may increase the risk of being infected with acute respiratory syndrome coronavirus 2 , the virus responsible for COVID-19.",1
8904,CE-SYSTEMATIC REVIEWS AND META-ANALYSIS Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?,SARS-CoV-2 is known to use the angiotensin converting enzyme 2 as a receptor for cell entry .,1
8909,CE-SYSTEMATIC REVIEWS AND META-ANALYSIS Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?,"Experimental data suggest that infection with SARS-CoV and SARS-CoV-2 leads to down-regulation of ACE2, and this could be detrimental due to uncontrolled ACE and angiotensin II activity, leading to inflammation, and organ damage .",1
8995,CE-SYSTEMATIC REVIEWS AND META-ANALYSIS Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?,Nicotine is an agonist of the cholinergic anti-inflammatory pathway that regulates host immune and inflammatory responses .,1
9000,CE-SYSTEMATIC REVIEWS AND META-ANALYSIS Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?,"SARS-CoV-2 activates the innate immune system and the accompanying release of a large number of cytokines, including IL-6, which can increase vascular permeability, cause migration of fluid and blood cells into the alveoli and result in dyspnea and respiratory failure .",1
9002,CE-SYSTEMATIC REVIEWS AND META-ANALYSIS Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?,"As a result, the use of medications targeting pro-inflammatory cytokines, such as IL-1 or IL-6 inhibitors, has been recommended and is already being tested in clinical trials, in an effort to treat patients with severe COVID-19 by neutralizing these key inflammatory mediators .",1
9004,CE-SYSTEMATIC REVIEWS AND META-ANALYSIS Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?,Other antiinflammatory therapeutic options that have been proposed to be tested include anti-TNF medications .,1
9005,CE-SYSTEMATIC REVIEWS AND META-ANALYSIS Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?,"Therefore, the cytokine storm is a therapeutic target in clinical trials conducted on COVID-19 patients, and nicotine has effects on the immune system that could be beneficial in reducing the intensity of the cytokine storm.",1
9011,CE-SYSTEMATIC REVIEWS AND META-ANALYSIS Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?,Data from SARS experimental studies suggest that continuous SARS-CoV-2 infection and replication induces down-regulation of ACE2 which may be implicated in organ damage and disease severity .,1
9024,CE-SYSTEMATIC REVIEWS AND META-ANALYSIS Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?,"Therefore, it is unlikely that nicotine could prevent infection with SARS-CoV-2.",1
9026,CE-SYSTEMATIC REVIEWS AND META-ANALYSIS Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?,"In conclusion, the observations of a consistently low prevalence of smoking among COVID-19 cases in China and the US, together with the potential mechanisms through which nicotine interacts with the inflammatory process and the renin-angiotensin-aldosterone axis, warrant an investigation of the clinical effects of pharmaceutical nicotine on COVID-19 susceptibility, progression, and severity through clinical trials.",1
9047,CE-SYSTEMATIC REVIEWS AND META-ANALYSIS Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?,Statements on human and animal rights Not applicable.,1
9050,Journal Pre-proof Geospatial analysis of COVID-19 and otolaryngologists above age 60 Title: Geospatial Analysis of COVID-19 and Otolaryngologists Above Age 60 Authors,The 2019 novel coronavirus is a global pandemic that has rapidly spread across the world.,1
9057,Journal Pre-proof Geospatial analysis of COVID-19 and otolaryngologists above age 60 Title: Geospatial Analysis of COVID-19 and Otolaryngologists Above Age 60 Authors,The novel coronavirus' dramatic impact on medical personnel parallels the epidemiology of the 2003 severe acute respiratory disease outbreak in which 21% of global cases were health care worker infections .,1
9102,On Lung Ultrasound Patterns Specificity in the Management of COVID-19 Patients,"We agree that the indications for an ultrasound examination are mainly those of home and hospital triage, aimed at identifying lung involvement in patients with clinical signs suggestive of COVID-19 and in whom both the chest radiographic findings and the polymerase chain reaction swab results for SARS-CoV-2 are negative .",1
9116,On Lung Ultrasound Patterns Specificity in the Management of COVID-19 Patients,The rapid onset of the coronavirus pandemic has not yet allowed us to refine alternative diagnostic options to computed tomography for this disease.,1
9121,To appear in: Infection Prevention in Practice,Severe acute respiratory syndrome coronavirus SARS-CoV-2 is the cause of the coronavirus disease 2019 that has been declared a global pandemic by the World Health Organization in 2020.,1
9122,To appear in: Infection Prevention in Practice,"SARS-CoV-2 was discovered in December 2019, in Wuhan City , China.",1
9124,To appear in: Infection Prevention in Practice,SARS-CoV-2 has phylogenetic similarity to SARS-CoV and MERS-CoV.,1
9125,To appear in: Infection Prevention in Practice,The virus was identified as a novel enveloped RNA betacoronavirus that has been named as Severe Acute Respiratory Syndrome Coronavirus 2 .,1
9145,To appear in: Infection Prevention in Practice,"The search terms included combinations of: COVID-19, SARS-COV-2, Glucocorticoids, Chloroquine, convalescent plasma, antiviral, antibacterial, Oseltamivir, Hydroxychloroquine, Chloroquine phosphate and monoclonal antibodies.",1
9163,To appear in: Infection Prevention in Practice,"Forty-one studies were included, of which clinical trials , case reports , case series , retrospective and prospective observational studies.",1
9188,To appear in: Infection Prevention in Practice,"Guan W and colleagues in their retrospective observational study reported the use of Oseltamivir in 1,099 patients; however, the study was not able to provide any solid data on the effectiveness of Oseltamivir in the prevention or treatment of COVID-19 patients.",1
9198,To appear in: Infection Prevention in Practice,"The French open label, non-randomized clinical trial was promising and the first clinical trial of these medications in COVID-19 patients.",1
9214,To appear in: Infection Prevention in Practice,"Only 41 research articles on COVID-19 and therapeutics were found eligible to be included, most conducted in China, of which only three were clinical trials.",1
9229,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,Coronavirus disease 2019 is declared a pandemic by the World Health Organization on March 11 th 2020.,1
9230,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,It is caused by severe acute respiratory syndrome coronavirus 2 .,1
9247,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,"SARS-CoV-2 infection is caused by binding of the viral surface spike protein to the human angiotensin-converting enzyme 2 receptor , which is a membrane bound aminopeptidase that is highly expressed in the heart and lungs and has a vital role in the immune system .",1
9249,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,ACE2 internalization by SARS-CoV-2 infection would theoretically cause the loss of ACE2 at the cell surface and decrease the degradation of angiotensin II into cardiovascular disease protective angiotensin 1-7.,1
9250,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,"Indeed, an increase in the overall ratio of angiotensin II to angiotension-1-7 after ACE2 internalization may exacerbate the pulmonary tissue damage initially provoked by SARS-CoV-2 infection .",1
9252,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,"If ACE2 is a functional receptor for SARS-CoV-2, the potential harmful effect and safety of ACE inhibitors or angiotensin-receptor blockers in patients with COVID-19 should be carefully considered .",1
9258,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,"To date, there is no evidence that using reninangiotensin-aldosterone inhibitors makes patients more susceptible to the SARS-CoV-2 virus infection.",1
9268,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,"In addition, many of elective patients for cardiac catheterization may have several significant comorbidities, whose prognosis may be poorer if they are actually infected by SARS-CoV-2.",1
9273,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,"Because rapid nucleic acid testing for SARS-CoV-2 infection is not available in many hospital, the treatment strategy of STEMI patients with suspected or known COVID-19 is needed to be modified .",1
9274,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,"Although primary PCI is the routine for STEMI patients in most hospital with cardiac catheterization laboratory, fibrinolytic therapy can be considered a reasonable option for the relatively stable STEMI patient with suspected or known COVID-19 in order to decrease staff exposure to possible SARS-CoV-2 infection.",1
9290,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,"For most patients with NSTEMI or unstable angina and suspected COVID-19, SARS-CoV-2 infection should be confirmed first.",1
9292,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,"After test of SARS-CoV-2 infection becomes negative, it is assessed whether further invasive interventions are needed.",1
9308,International Journal of Medical Sciences Cardiovascular disease management during the coronavirus disease 2019 pandemic,Several antiviral agents are the first medications under study for the treatment of COVID-19.,1
9326,Journal Pre-proofs Microvascular Disease Confers Additional Risk to COVID-19 Infection Microvascular Disease Confers Additional Risk to COVID-19 Infection,"Inhalation of COVID-19 onto airway epithelial cells triggers the earliest defense of the viral invasion, which is the innate immune system .",1
9327,Journal Pre-proofs Microvascular Disease Confers Additional Risk to COVID-19 Infection Microvascular Disease Confers Additional Risk to COVID-19 Infection,This initial immune response is triggered by cellular danger signals such as interleukins that in turn initiate a movement of white cells to the sites of infection.,1
9331,Journal Pre-proofs Microvascular Disease Confers Additional Risk to COVID-19 Infection Microvascular Disease Confers Additional Risk to COVID-19 Infection,Failure on this front line can lead to an ineffective adaptive immune response.,1
9333,Journal Pre-proofs Microvascular Disease Confers Additional Risk to COVID-19 Infection Microvascular Disease Confers Additional Risk to COVID-19 Infection,Failure or over exuberance of the innate immune response increases the risk of a severe or even fatal outcome.,1
9335,Journal Pre-proofs Microvascular Disease Confers Additional Risk to COVID-19 Infection Microvascular Disease Confers Additional Risk to COVID-19 Infection,This paper will explore the hypothesis that these patients are disadvantaged for a vigorous innate immune response due to underlying microvascular disease.,1
9344,Journal Pre-proofs Microvascular Disease Confers Additional Risk to COVID-19 Infection Microvascular Disease Confers Additional Risk to COVID-19 Infection,The probability is high that the patients with higher mortality rates from COVID- Neutrophils perform a significant function in the innate immune response.,1
9359,Journal Pre-proofs Microvascular Disease Confers Additional Risk to COVID-19 Infection Microvascular Disease Confers Additional Risk to COVID-19 Infection,The consequence of MVD hampering the innate immune response leads to greater risk of a severe or life-threatening infection.,1
9393,Journal Pre-proofs Microvascular Disease Confers Additional Risk to COVID-19 Infection Microvascular Disease Confers Additional Risk to COVID-19 Infection,The trade-off of potentially reducing the innate immune response to COVID-19 would need to be considered.,1
9397,""" Given the importance of timely management of myocardial infarction in COVID-19 patients, clinicians must be able to distinguish true ACS from ACS mimics among these patients. ""","Coronavirus disease 2019 was first identified in December 2019, yet within months it had spread to pandemic levels with critical global health implications to the clinical practice of all specialties.",1
9423,""" Given the importance of timely management of myocardial infarction in COVID-19 patients, clinicians must be able to distinguish true ACS from ACS mimics among these patients. ""","For those with pre-existing atherosclerotic plaque, SARS-CoV-2 may predispose to increased atherosclerotic plaque instability and coagulopathy, which are increased in the setting of cytokine storm and may manifest as thromboembolic occlusion of the coronary artery .",1
9449,""" Given the importance of timely management of myocardial infarction in COVID-19 patients, clinicians must be able to distinguish true ACS from ACS mimics among these patients. """,Certain initiatives have been made to study the epidemiology of ischemic heart disease in the SARS-CoV-2 infection; and other diagnoses should be considered in order to recognize them and better understand their pathophysiology.,1
9456,Journal Pre-proof ET-traps as a potential treatment for COVID-19 ET-traps as a potential treatment for COVID-19,COVID-19 or the coronavirus pandemic results from a novel coronavirus strain.,1
9462,Journal Pre-proof ET-traps as a potential treatment for COVID-19 ET-traps as a potential treatment for COVID-19,A coronavirus infection is found to be associated with an up regulation of different cytokines that are pro-inflammatory .,1
9475,Journal Pre-proof ET-traps as a potential treatment for COVID-19 ET-traps as a potential treatment for COVID-19,"Currently, there are different therapies for COVID-19 that are being tested for use in human clinical trials.",1
9476,Journal Pre-proof ET-traps as a potential treatment for COVID-19 ET-traps as a potential treatment for COVID-19,"This includes repurposed drugs that are already approved for human use in other disease states, as well as vaccines.",1
9479,Journal Pre-proof ET-traps as a potential treatment for COVID-19 ET-traps as a potential treatment for COVID-19,"However, a big issue here is of over stimulating the immune system, which could later lead to an autoimmune disorder .",1
9480,Journal Pre-proof ET-traps as a potential treatment for COVID-19 ET-traps as a potential treatment for COVID-19,"Given the current urgency of developing a suitable treatment for COVID-19, human testing of these treatments is being expedited and unfortunately the risk of an autoimmune condition would only appear after a few years.",1
9490,Journal Pre-proof ET-traps as a potential treatment for COVID-19 ET-traps as a potential treatment for COVID-19,"Repurposed drugs, being tested for COVID-19 have a caveat that many compromise the immune system and cause other health complications like problems with the heart and therefore should not be used as a treatment for an infection such as COVID-19 .",1
9516,Journal Pre-proof ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis,"Since first confirmed case in Wuhan in 2019, the Coronavirus Disease 2019 rapidly spread on a global scale and more than three million confirmed infections have been reported according to the World Health Organization .",1
9569,Journal Pre-proof ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis,SARS-CoV-2 binds to the extracellular domain of the transmembrane ACE2 receptor to gain entry into host cells .,1
9571,Journal Pre-proof ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis,"Contrary to this hypothesis, our analysis did not provide evidence that patients should stop or substitute the ACEI or ARB medications previously prescribed.",1
9573,Journal Pre-proof ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis,"First, the effects of ACEI/ARB on the level of human plasma ACE2 are inconsistent , and no studies evaluate their effect on lung-specific expression of ACE2 .",1
9574,Journal Pre-proof ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis,"To be relevant in SARS-CoV-2 infection, the effect on ACE2 would need to be present on respiratory epithelium.",1
9577,Journal Pre-proof ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis,"Upon binding to ACE2, SARS-CoV subsequently reduce ACE2 expression in host cells, resulting in activation of RAS, which in turn caused severe acute lung injury and exacerbated pneumonia progression .",1
9616,Journal Pre-proof Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: experiences of a general hospital Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: experiences of a general hospital,The COVID-19 Ag Respi-Strip assay is a new immunochromatographic diagnostic tool recently available for antigenic diagnosis of SARS-CoV-2.,1
9619,Journal Pre-proof Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: experiences of a general hospital Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: experiences of a general hospital,"Over a period of one month, we compared the negative results obtained with the COVID-19 Ag Respi-Strip kit with those obtained from qRT-PCR performed in a laboratory qualified for the molecular diagnosis of SARS-CoV-2.",1
9633,Journal Pre-proof Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: experiences of a general hospital Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: experiences of a general hospital,"After antigenic testing was performed, the molecular assessment of SARS-CoV-2 was outsourced to a university centre where it was carried out by qRT-PCR using E-gene SARS-CoV-2 primers/probes.",1
9634,Journal Pre-proof Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: experiences of a general hospital Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: experiences of a general hospital,"Under routine conditions, the sensitivity of the antigen detection of SARS-CoV-2 with the immunochromatographic COVID-19 Ag Respi-Strip kit was significantly lower than that announced by the manufacturer or reported by Vandenberg , although we limited ourselves to using qRT-PCR as the comparison method.",1
9671,Management of ST-Elevation Myocardial Infarction in the COVID-19 Era: The Role of Thrombosis and Anticoagulation Strategy HHS Public Access,The coronavirus disease of 2019 is a viral infection caused by the severe acute respiratory syndrome coronavirus 2 and was announced a global pandemic by the World Health Organization in 2020.,1
9676,Management of ST-Elevation Myocardial Infarction in the COVID-19 Era: The Role of Thrombosis and Anticoagulation Strategy HHS Public Access,Early studies have shown that infection occurs as a result of binding of the viral spike protein to the human angiotensin-converting enzyme 2 .,1
9710,Association of inflammatory markers with the severity of COVID-19,The ongoing worldwide pandemic of Coronavirus Disease 2019 has posed a huge threat to global public health .,1
9711,Association of inflammatory markers with the severity of COVID-19,"The pathogen has been identified as a novel single-stranded ribonucleic acid betacoronavirus named as severe acute respiratory syndrome coronavirus 2 , which share a great phylogenetic similarity with severe acute respiratory syndrome coronavirus , Zhou P. et al., 2020 .",1
9718,Association of inflammatory markers with the severity of COVID-19,"All eligible articles were retrieved, and their references of identified publications were searched for further potentially relevant articles patients could be grouped into severe COVID-19 and non-severe COVID-19, or non-intensive care unit group and ICU group, or survivors and non-survivors with COVID-19; literature sources and necessary data were available; and the diagnostic criteria of COVID-19 were clarified based on the laboratoryconfirmed SARS-CoV-2 infection.",1
9753,Association of inflammatory markers with the severity of COVID-19,"-19) , caused by SARS-CoV-2, is rapidly expanding worldwide.",1
9758,Association of inflammatory markers with the severity of COVID-19,"Also, anti-inflammatory agents for COVID-19 therapy highlights the critical role of inflammation in the progression of COVID-19 could be secreted by the active pathogenic T cell upon SARS-CoV-2 infection.",1
9760,Association of inflammatory markers with the severity of COVID-19,According to the New Coronavirus Pneumonia Prevention and Control Program published by the National All rights reserved.,1
9807,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,"Based on previous observations for SARS and other related viruses, a theoretical risk of liver damage exists with COVID-19 infection .",1
9830,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,"The risk of donor-derived infection would depend upon donor exposure, infectivity in the incubation period, degree and duration of viremia, and viability of the virus within blood or specific organ compartments .",1
9841,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,These observations are supported by evidence from the SARS epidemic in 2003 in which autopsy results could demonstrate the virus in almost all body organs .,1
9885,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,"As an example, the SARS outbreak in Toronto led to closures of 35 ICU beds for ten days, which represented 38 % of the tertiary-care university medical-surgical beds of ICU in Toronto .",1
9894,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,Possible drug-drug interactions between SARS-CoV-2 antiviral drugs and commonly used immunosuppressants for liver transplant recipients are presented in table 1 .,1
9896,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,"Despite encouraging preliminary reports, side effects, and interactions with other medications are well known .",1
9901,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,"It is an investigational drug that appears safe and may not affect other medications; however, Remdesivir concentration can be affected by enzyme inducers like Clarithromycin, Rifampin, Phenytoin, and Phenobarbital .",1
9903,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,"Favipiravir increase concentration of pioglitazone, rosiglitazone, paracetamol, oseltamivir, and hormonal replacement therapy; however, no significant interactions with immunosuppressive medications nor steroid .",1
9916,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,"Ribavirin is an old antiviral drug used in the treatment of HCV for years, and that had a role in the treatment of SARS.",1
9919,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,One of the lessons learned from MERS-CoV infections is that host inflammatory responses play a major role in disease progression.,1
9920,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,This was the base of using interferon-beta in MERS-CoV and COVID-19 infections .,1
9925,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,"As the innate immune response associated with increased serum interleukin-6 , interleukin-8 , and tumor necrosis factor-alpha levels may be the main driver for pulmonary injury due to COVID-19, immunosuppression may be protective .",1
9927,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,"More interestingly, reviewing the mortality and morbidity reports published on Coronaviruses outbreaks such SARS that emerged in 2002, MERS, and more recently COVID-19, no fatalities were reported in patients undergoing transplantations, receiving chemotherapies or other immunosuppressive treatments .",1
9929,Journal Pre-proofs Title: Liver transplantation in the era of COVID-19 Authors: Title: Liver transplantation in the era of COVID-19,"Available data on coronavirus before and during outbreaks suggest that immunosuppressed patients are not at increased risk of severe pulmonary disease compared to the general population; however, immunosuppression may prolong viral shedding in post-transplant patients with COVID-19 if they are already infected .",1
9943,Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans,"The United States has the highest number of reported symptomatic severe acute respiratory syndrome coronavirus 2 infections and related deaths in the world, accounting for one-third of global totals.",1
9944,Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans,1 There is growing concern that racial and ethnic minority communities are experiencing a disproportionate burden of morbidity and mortality from symptomatic SARS-Cov-2 infection or coronavirus disease 2019 .,1
9958,Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans,"We identified individuals tested for Covid-19 from date of first recorded test on February 8, 2020 through May 4, 2020 by using text searching of laboratory results containing terms consistent with SARS-CoV-2 or Covid-19.",1
9960,Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans,"Testing was performed in VA, state public health, and commercial reference laboratories using emergency use authorization approved SARS-CoV-2 assays.",1
9964,Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans,"If the admission began more than 14 days prior to testing, which may indicate hospital-acquired infection, we set baseline to 14 days prior to testing to better capture health status prior to SARS-CoV-2 infection.",1
10122,"Covid-19: implications for prehospital, emergency and hospital care in patients with acute coronary syndromes",Frontline services serve for the early triage of patients with Covid-19 to prevent transmission to healthcareworkers and other patients.,1
10180,"Covid-19: implications for prehospital, emergency and hospital care in patients with acute coronary syndromes",The definitive test for SARS-CoV-2 is the real-time reverse transcriptase polymerase chain reaction test.,1
10190,Case Report Coronavirus Disease 2019 With Acute Respiratory Distress Syndrome Mimicking Heart Failure Exacerbation: Time to Rethink,"Severe acute respiratory syndrome coronavirus , the causative agent of coronavirus disease 2019 was first identified in Wuhan, China in December 2019.",1
10212,Case Report Coronavirus Disease 2019 With Acute Respiratory Distress Syndrome Mimicking Heart Failure Exacerbation: Time to Rethink,"SARS CoV-2 binds to angiotensin-converting enzyme-2 receptor using spike protein, and pH, or lipid mediated endocytosis.",1
10216,Case Report Coronavirus Disease 2019 With Acute Respiratory Distress Syndrome Mimicking Heart Failure Exacerbation: Time to Rethink,"SARS CoV-2 downregulates ACE-2 receptors in the cardiopulmonary system, leading to accumulation of angiotensin-II.",1
10237,Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study,Severe acute respiratory syndrome coronavirus 2 uses the angiotensin-converting enzyme 2 as the receptor for its spike protein to invade cells and replicate.,1
10240,Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study,"These findings have led some researchers to postulate that the use of these drugs might enhance the access of SARS-CoV-2 into cells, predisposing patients to infection or increasing severity of COVID-19.",1
10260,Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study,"This hypothesis is based on two facts: these drugs have been reported to upregulate the expression of angiotensinconverting enzyme 2, the gateway used by severe acute respiratory syndrome coronavirus 2 to enter cells, and patients with severe COVID-19 have a high prevalence of cardiovascular diseases.",1
10263,Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study,"We searched PubMed on April 15, 2020, for publications in English since Jan 1, 2020, using the search terms ""COVID-19"" and ""ACE inhibitors OR angiotensin-converting enzyme inhibitors OR angiotensin receptor blockers OR RAAS inhibitors OR RAS inhibitors OR RAAS blockers OR RAS blockers"", filtering by ""human"" and ""observational study"", and no result was returned.",1
10373,Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study,"20 On the one hand, ACE2 overexpression might increase the susceptibility of cells to SARS-CoV-2, but, on the other hand, its downregulation associated with older age, male sex, and cardiovascular comorbidities, and further heightened by SARS-CoV-2 binding and internalisation 21, 22 could increase the unopposed action of angiotensin II and have a key role in the subsequent organ injury.",1
10378,Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study,"In line with this theory, recom binant soluble ACE2 has been shown in animal models of ARDS to protect subjects from lung injury, and clinical trials are underway in patients with COVID-19 .",1
10410,Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study,"Meanwhile, the data available, along with the important role of ACE inhibitors and angiotensin-receptor blockers in the management of several cardiovascular diseases, do not support their discontinuation as a preventive measure against COVID-19.",1
10416,To appear in: One Health,The fear of coronavirus disease 2019 has spread all over the world.,1
10458,Journal Pre-proof A Global Survey on the Impact of COVID-19 on Urological Services A Global Survey on the Impact of COVID-19 on Urological Services,"The novel coronavirus was first reported in Wuhan City, Hubei Province of China, in December 2019 and has spread rapidly to >200 countries and territories around the world .",1
10459,Journal Pre-proof A Global Survey on the Impact of COVID-19 on Urological Services A Global Survey on the Impact of COVID-19 on Urological Services,"The World Health Organization declared the situation a public health emergency of international concern on January 30, 2020 and subsequently named this disease coronavirus disease-19 on February 11, 2020 .",1
10559,Journal Pre-proof A Global Survey on the Impact of COVID-19 on Urological Services A Global Survey on the Impact of COVID-19 on Urological Services,A retrospective cohort study of 34 asymptomatic patients who underwent elective surgery during the COVID-19 incubation period reported that 44% required intensive care and 20% died .,1
10605,"Journal of Stroke Cerebrovascular Diseases and Cardiovascular Diseases on Mortality and Severity of COVID-19 -Systematic Review, Meta-analysis, and Meta-regression","At the time of writing this paper, Coronavirus Disease 2019 was announced as a global pandemic which has infected over 3.3 million people and cause more than 238.000 deaths, 1 these numbers are likely to increase by the time of publication.",1
10613,"Journal of Stroke Cerebrovascular Diseases and Cardiovascular Diseases on Mortality and Severity of COVID-19 -Systematic Review, Meta-analysis, and Meta-regression","We carried out a comprehensive systematic literature search from PubMed, SCOPUS, EuropePMC, and Cochrane Central Database with search terms being 1) ""COVID-19"" OR ""SARS-CoV-2"" AND ""characteristics"", 2) ""COVID-19"" OR ""SARS-CoV-2"" AND ""cerebrovascular"", 3) ""COVID-19"" OR ""SARS-CoV-2"" AND ""cardiovascular"".",1
10672,"Journal of Stroke Cerebrovascular Diseases and Cardiovascular Diseases on Mortality and Severity of COVID-19 -Systematic Review, Meta-analysis, and Meta-regression","Severe SARS-CoV-2 infection itself could induce dysfunctional haemostatic system leading to a hypercoagulable state, a condition which we commonly encounter in sepsis.",1
10676,"Journal of Stroke Cerebrovascular Diseases and Cardiovascular Diseases on Mortality and Severity of COVID-19 -Systematic Review, Meta-analysis, and Meta-regression",38 Neuroinvasion is one of the possible traits of COVID-19 because of the similarities between SARS-CoV and SARS-CoV-2.,1
10677,"Journal of Stroke Cerebrovascular Diseases and Cardiovascular Diseases on Mortality and Severity of COVID-19 -Systematic Review, Meta-analysis, and Meta-regression",The potential for neuroinvasion have been shown in human coronaviruses and in several animal coronaviruses.,1
10678,"Journal of Stroke Cerebrovascular Diseases and Cardiovascular Diseases on Mortality and Severity of COVID-19 -Systematic Review, Meta-analysis, and Meta-regression","39 However, central nervous system normally expressed very low concentrations of ACE2 or dipeptidyl peptidase 4 , which is the receptor for SARS-CoV and MERS-CoV entrance.",1
10679,"Journal of Stroke Cerebrovascular Diseases and Cardiovascular Diseases on Mortality and Severity of COVID-19 -Systematic Review, Meta-analysis, and Meta-regression","40 Possible routes for nervous system involvement after COVID-19 infection are direct invasion through blood circulation or neuronal pathway, hypoxic injury, immune system damage, ACE2 and other routes such as the lack of major histocompatibility complex antigens in nerve cells.",1
10680,"Journal of Stroke Cerebrovascular Diseases and Cardiovascular Diseases on Mortality and Severity of COVID-19 -Systematic Review, Meta-analysis, and Meta-regression","It is currently thought that SARS-CoV-2, together with host immune mechanisms, can turn these infections into persistent diseases with neurological complications, like viral encephalitis, infectious toxic encephalopathy and acute cerebrovascular disease.",1
10695,"Journal of Stroke Cerebrovascular Diseases and Cardiovascular Diseases on Mortality and Severity of COVID-19 -Systematic Review, Meta-analysis, and Meta-regression",Information regarding the use of chronic medications such as ACEI/ARB were lacking.,1
10701,Clinical Perspective,Rupsa C. Boelig 19 ) is a global pandemic caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2.,1
10703,Clinical Perspective,"Because pregnant women have a suppressed immune system, they may be at an increased risk of developing severe or critical disease associated with COVID-19, in particular pneumonia and respiratory failure.",1
10743,Clinical Perspective,"If absolutely necessary, N-95 masks should be used in setting of aerosolization, including if patient is on bilevel positive airway pressure, has a tracheostomy, requires high-flow nasal cannula O 2 , or when administering nebulized medications.",1
10819,Clinical Perspective,"Section 6: Care for the Suspected or Confirmed COVID-19ePositive Pregnant Patient in L&D Obstetric medications Two commonly used medications in obstetrics have been the source of study and controversy in the setting of COVID-19 pandemic; nonsteroidal anti-inflammatory drugs , in particular indomethacin, are commonly used for tocolysis, and steroids, specifically betamethasone or dexamethasone, are used for fetal lung maturity.",1
10856,Clinical Perspective,"C The use of a breast pump is encouraged, after review of maternal medications .",1
10874,Journal Pre-proof Acute myocardial injury in patients hospitalized with COVID-19 infection: A review Acute Myocardial Injury in Patients Hospitalized with COVID-19 Infection: A Review,"Using meta-analytic approach , the overall weighted pooled prevalence estimate of acute myocardial injury was found to be 20% markers of cellular and immune dysregulation were found to be associated with myocardial injury.",1
10892,Journal Pre-proof Acute myocardial injury in patients hospitalized with COVID-19 infection: A review Acute Myocardial Injury in Patients Hospitalized with COVID-19 Infection: A Review,"Our understanding of the pathophysiology of COVID-19 and host immune responses is still evolving, however, immunemediated inflammation plays a key role in the pathogenesis of COVID-19 .",1
10903,Journal Pre-proof Acute myocardial injury in patients hospitalized with COVID-19 infection: A review Acute Myocardial Injury in Patients Hospitalized with COVID-19 Infection: A Review,"Given the complex interplay of SARS-CoV-2 with the CV system, further investigation into potential mechanisms is needed to guide effective therapies.",1
10904,Journal Pre-proof Acute myocardial injury in patients hospitalized with COVID-19 infection: A review Acute Myocardial Injury in Patients Hospitalized with COVID-19 Infection: A Review,Epidemiological studies and randomized trials are urgently needed to investigate treatment modalities regulating immune function and inhibiting inflammatory responses to reduce the incidence and mortality associated with COVID-19 related acute myocardial injury.,1
10908,Diabetes Research and Clinical Practice Diabetes and COVID-19: IDF perspective in the Western Pacific Region,"In January 2020, a novel coronavirus from a cluster of pneumonia cases of unknown etiology was discovered in Wuhan, China 1 In people with diabetes COVID-19 can be more difficult to treat due to wide fluctuations in blood glucose levels or presence of comorbidities such as acute and chronic diabetes complications, including CVD and renal disease, which even in the general population with COVID-19 are recognized risk factors for poor outcomes, including death 2,3,4,5 .",1
10997,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study","A novel coronavirus had been isolated from these patients, and subsequently named as 2019 novel coronavirus on January 12, 2020 3 , and later as SARS-CoV-2.",1
11001,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study","Fever Clinics, mostly affiliated to the Division of Infectious Diseases in general hospitals, had been established after SARS outbreak in 2003, and since then served as the first line to monitor and manage acute febrile respiratory infections, mostly seasonal influenza in recent years.",1
11002,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study","For 2019 novel coronavirus disease , this time, patients with body temperatures≥37.2 o C were asked to firstly visit Fever Clinics, where a triage strategy was implemented 9 , and probable or possible cases were identified by experts or expert panels, and samples were sent for quick viral detection.",1
11004,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study","As far as we know, the prevalence of COVID-19 in patients with pneumonia visiting Fever Clinics has not been reported, and there is lack of data comparing the clinical features between COVID-19 and pneumonia of other etiologies.",1
11006,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study",We aimed to estimate the prevalence of COVID-19 in pneumonias during this period and to find the unique features of COVID-19 as compared to pneumonias caused by other agents.,1
11019,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study",The prevalence of COVID-19 in all these pneumonia patients was 6.14% .,1
11032,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study","An incubation period was elicited from 12 patients , ranging from 2 to 10 days with a median of 6.5 days.",1
11045,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study",Our results here provide information on the prevalence of COVID-19 in the busy Fever Clinic of a teaching hospital and differential characteristics from non-COVID-19 pneumonias.,1
11047,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study",The prevalence of COVID-19 in all these pneumonia patients was 6.14% .,1
11059,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study","Consistent to previous reports, the incubation period of our cases was in a range of 2-10 days, with a median of 6.5 days .",1
11074,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study","As a single-center, retrospective study of patients mainly from Haidian District in Beijing, the prevalence of COVID-19 in this Fever Clinic was not representative.",1
11076,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study","Furthermore, the pathogens causing pneumonia in patients without COVID-19 were not identified, therefore we were unable to evaluate the prevalence of other common viral pneumonias of this season, such as influenza pneumonia and All rights reserved.",1
11081,"Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study","During the study period when COVID-19 was epidemic, the prevalence of COVID-19 in patients with pneumonia visiting our Fever Clinic was 6.14%.",1
11104,Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak,"After an atypical viral pneumonia case cluster in late 2019, a new coronavirus was reported from these cases in Wuhan, China in January 2020.",1
11105,Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak,"With the developments that followed, this virus, called severe acute respiratory syndrome coronavirus 2 was reported to cause a respiratory disease called COVID-19 in infected people .",1
11108,Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak,"In this pandemic process, all eyes turned to cancer patients with advanced age and additional disease history due to the immune system suppression caused by cancer and/or cancer treatments .",1
11115,Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak,"It is known that lymphocytes, which are the main effector cells in the immune response against cancer, are one of the main components of the human immune system.",1
11118,Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak,"Therefore, it may be thought that the lymphopenia, which has low lymphocyte count before treatment or that occurs during treatment with temozolomide, immune-check point inhibitors, or other anti-cancer drugs, will also negatively affect the mortality with COVID-19.",1
11209,Pharmacological Research The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence,"As recommended in the Guideline on Diagnosis and Treatment of Coronavirus Disease 2019 which was officially released by National Health Commission of the People is Republic of China, TCM could exert favorable effects for patients with different syndromes and distinct stages of COVID-19, contributing to infections in the periods of both medical observation and clinical treatment .",1
11215,Pharmacological Research The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence,"Given the paucity of published English research concerning CPMs against COVID-19 currently, the present review performed a descriptive analysis of recommended CPMs from both clinical trials and published literatures, based on the following aspects: information retrieved from their instructions , medical evidence, pharmacodynamic mechanism, dominant components, applicable patients, clinical cautions and so on.",1
11219,Pharmacological Research The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence,"On the one hand, the following terms of COVID-19 were adopted: ""COVID-19 ,"" ""2019 novel coronavirus"", ""COVID19"", ""SARS-CoV-2"", ""2019-nCoV"", ""coronavirus disease 2019"", ""coronavirus disease-19"".",1
11223,Pharmacological Research The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence,"In addition, the on-going clinical trials concerning on CPMs anagist COVID-19 were supplemented to identify the potential evidence by utilizing the platform of Chinese Clinical Trial Figure 1B ).",1
11228,Pharmacological Research The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence,"It was noteworthy that early treatment was essential for suspected or mild cases, accumulated evidence of bioinformatics, pharmacodynamics and clinical findings suggested that these multiple component Chinese herbal products also exerted effects on immune regulation, symptom improvement, anti-inflammation and so on during the treatment of COVID-19.",1
11229,Pharmacological Research The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence,"The results of previously pharmacological research indicated that Huoxiang Zhengqi Capsule or other dosage forms could improve gastrointestinal dysfunction, modulate immune responses, and anti-inflammation .",1
11233,Pharmacological Research The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence,"The results of systems biology and bioinformatics revealed that the mechanism of Jinhua Qinggan granules in the treatment of COVID-19 involving multiple targets, namely MAPK1, CASP3, TP53, ALB, TNF, IL6, and multiple pathways, which might be related to antiviral, immune regulation, inflammation inhibition and apoptosis regulation via PI3K-Akt, HIF-1, TNF, MAPK, NF-κB pathways, and dominant principles including kaempferol, baicalein and oroxylin A could take participate in multiple signal pathways by binding with ACE2 .",1
11239,Pharmacological Research The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence,"In addition, prevenient Chinese research pointed out its clinical J o u r n a l P r e -p r o o f advantages that were related to improve respiratory symptoms, inhibit concurrent bacterial infection, and regulate immune function, superior clinical safety, especially certain hepatoprotective effects, suggesting it might have potentials to relieve some drug-induced liver injury during the treatment of COVID-19 for serious cases .",1
11246,Pharmacological Research The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence,"were closely correlation with the inhibition of cytokine storm in severe cases, and fatal risk of cytokine storms in the immune system of serious patients might result in organ failure and even death .",1
11249,Pharmacological Research The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence,"On the one hand, the critical targets were namely PTGS2, PTSG1, CCL2, RELA, NOS2, HMOX1, CASP3, IL6 and MAPK1, some of them belonged to chemokines, which posed the immune activation profiles of 2019-nCoV.",1
11259,Pharmacological Research The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence,"Currently, there were paucity of accessibly published evidence concerning on these CPMs and 2019-nCoV simultaneously, it was urgent and essential that subsequently clinical trials or pharmacological research to provide sufficient references for clinical recommendation.",1
11281,Pharmacological Research The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence,"Second, compared with other dosage forms of TCM medications, Chinese herbal injections were associated J o u r n a l P r e -p r o o f with the higher risk of ADRs, especially serious side effects .",1
11286,Are men who smoke at higher risk for a more severe case of COVID-19 than women who smoke? A Systematic Review,"Coronavirus, belonging to the Coronaviridae family, has been previously seen before and is known to cause a human illness with symptoms similar to the common cold .",1
11287,Are men who smoke at higher risk for a more severe case of COVID-19 than women who smoke? A Systematic Review,"Coronavirus has been shown to be a zoonotic disease in nature, and in the case of COVID-19 originating from bats .",1
11288,Are men who smoke at higher risk for a more severe case of COVID-19 than women who smoke? A Systematic Review,"In the last decade, this is the third deadliest coronavirus pandemic .",1
11289,Are men who smoke at higher risk for a more severe case of COVID-19 than women who smoke? A Systematic Review,"In 2003, there was an outbreak of coronavirus known as Severe Acute Respiratory Syndrome and in 2012 another strain of coronavirus known as Middle-East Respiratory Syndrome emerged .",1
11290,Are men who smoke at higher risk for a more severe case of COVID-19 than women who smoke? A Systematic Review,A more recent strain of coronavirus has emerged named SARS-COV-2 and is generally referred to as COVID-19 .,1
11295,Are men who smoke at higher risk for a more severe case of COVID-19 than women who smoke? A Systematic Review,Most human Coronaviruses cause mild symptoms.,1
11337,Are men who smoke at higher risk for a more severe case of COVID-19 than women who smoke? A Systematic Review,"The analysis was carried out to identify whether gender differences in smoking have an effect on the severity of the symptoms on the current coronavirus strain, COVID-19, by gathering data and calculating the odds ratios for the selected cohorts.",1
11348,Are men who smoke at higher risk for a more severe case of COVID-19 than women who smoke? A Systematic Review,"Previous strains of coronavirus outbreaks such as SARS outbreak in 2003 and MERS outbreak in 2012, determined a significantly higher death rate among males .",1
11349,Are men who smoke at higher risk for a more severe case of COVID-19 than women who smoke? A Systematic Review,The receptor used by the previous SARS-CoV viral strain to enter the host cells is the angiotensin-converting enzyme-2 receptor .,1
11350,Are men who smoke at higher risk for a more severe case of COVID-19 than women who smoke? A Systematic Review,It has been hypothesized that this receptor could be used as the novel adhesion molecule by the current SARS-CoV2 strain.,1
11386,"Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy","According to the John Hopkins Coronavirus Resource Centre , on April 3 rd , 2020 the novel Coronavirus infected more than 1,000,000 individuals with more than 50,000 deaths worldwide.",1
11462,"Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy",Results of human reading performance were computed and presented as ratios with their 95% CI.,1
11468,"Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy",Table 2 Results for the artificial intelligence and human readings of study datasets.,1
11477,"Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy","The outbreak of COVID-19 epidemic has resulted in a global health emergency, more diffuse than the coronavirus severe acute respiratory syndrome in 2003, both caused by viruses belonging to the Coronaviridae family .",1
11484,"Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy","To obtain a reference estimate, we asked human readers to assess these 110 CXRs aiming at differentiating COVID-19 from non-COVID-19 patients in suspected to be infected by this virus, being blinded to any medical history as well as clinical and biological data.",1
11486,"Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy","It is highly likely that a human reading completely informed about history and clinical data or during booming of the epidemic with an increasing prevalence would have been able to strongly increase the sensitivity, but a trade-off could be paid in terms of specificity.",1
11498,"Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy","Lastly, it is important to recognize that the role of CXR in patients' evaluation depends on the severity of infection in the individual patient, as well as on the COVID-19 prevalence in the community.",1
11511,"Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy Artificial intelligence applied on chest X-ray can aid in the diagnosis of COVID-19 infection: a first experience from Lombardy, Italy","Third, we did not include other data such as clinical conditions such as symptoms and pulse oximeter data as complementary information to be given to the AI model and the human readers, a perspective to be explored in future studies.",1
11520,Journal Pre-proof Immediate impact of COVID-19 on transplant activity in the Netherlands Immediate impact of COVID-19 on transplant activity in the Netherlands,The Coronavirus Disease 2019 pandemic is affecting societies worldwide.,1
11524,Journal Pre-proof Immediate impact of COVID-19 on transplant activity in the Netherlands Immediate impact of COVID-19 on transplant activity in the Netherlands,"Because of limited testing capacity many more, untested individuals are likely infected with SARS-CoV-2 in the Netherlands.",1
11542,Journal Pre-proof Immediate impact of COVID-19 on transplant activity in the Netherlands Immediate impact of COVID-19 on transplant activity in the Netherlands,"Health care workers involved in organ donation are at increased risk of acquiring and spreading SARS-CoV-2, since they work closely together and travel to various hospitals and visit virus hotspots.",1
11544,Journal Pre-proof Immediate impact of COVID-19 on transplant activity in the Netherlands Immediate impact of COVID-19 on transplant activity in the Netherlands,"First, SARS-CoV-2 testing of all deceased donors was implemented, since asymptomatic carriers and transmission through organ transplantation because they could not bear the extended waiting times.",1
11545,Journal Pre-proof Immediate impact of COVID-19 on transplant activity in the Netherlands Immediate impact of COVID-19 on transplant activity in the Netherlands,"So far, no donor has been tested positive for SARS-CoV-2; in one donor the retrieval procedure was cancelled because of a high suspicion of COVID-19 based on chest CT, but with a negative PCR.",1
11547,Journal Pre-proof Immediate impact of COVID-19 on transplant activity in the Netherlands Immediate impact of COVID-19 on transplant activity in the Netherlands,A CT scan provides rapid information on COVID-19 in patients with moderate to severe symptoms and is of additional value in patients with a single false negative nasopharyngeal swab for SARS-CoV-2.,1
11554,Journal Pre-proof Immediate impact of COVID-19 on transplant activity in the Netherlands Immediate impact of COVID-19 on transplant activity in the Netherlands,"To facilitate extra time needed for recipient test results to become available, allocation for liver, heart and lung transplantation is initiated before donor SARS-CoV-2 screening is known .",1
11599,We Know About COVID-19: Oral and Maxillofacial Surgeons Survey,"Infrequently, animal coronavirus can pull out and infect humans.",1
11600,We Know About COVID-19: Oral and Maxillofacial Surgeons Survey,"The novel coronavirus strain was first identified in late December 2019 due to an increase of respiratory disease cases in the city of Wuhan, Hubei, China.",1
11601,We Know About COVID-19: Oral and Maxillofacial Surgeons Survey,"Further studies revealed that the causative virus was SARS-CoV-2, being named by World Health Organization as Coronavirus Disease 2019 .",1
11626,We Know About COVID-19: Oral and Maxillofacial Surgeons Survey,"The quarantine isolation was the most preconized treatment with 95.8%, followed by symptomatic medications .",1
11627,We Know About COVID-19: Oral and Maxillofacial Surgeons Survey,"Other treatment methods as antibiotics and antiretroviral medications were cited as well, with 2.1% and 16.2%, respectively.",1
11629,We Know About COVID-19: Oral and Maxillofacial Surgeons Survey,"The analysis of the results together with the tendency lines for the community infection by the SARS-CoV2 virus in Brazil brings light to an incomparable health public problem that the OMFS in Brazil are no able to protect itself, diagnose the suspicious and probable cases, request and interpret the correct laboratorial examinations for the treatment of the COVID-19 patients.",1
11632,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"Since its initial outbreak in late 2019, Coronavirus Disease 2019 has rapidly evolved into a devastating, global pandemic Gates 2020) .",1
11634,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,COVID-19 is also having a detrimental impact on patients with underlying diseases and ongoing clinical trials.,1
11639,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"In March 2020, the U.S. Food and Drug Administration and the European Medicines Agency issued separate guidance on the conduct of clinical trials during COVID-19 .",1
11642,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"We argue that the clinical trial objective should relate to a world without ongoing COVID-19 pandemic, specifically defined through two criteria: 1) Patients do not experience severe complications due to the virus , transmission and spread of the virus are limited, and effective therapy for the virus is available; 2) No major disruption of healthcare systems, patients have access to medications, routine standard of care, and proper disease follow-up.",1
11644,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"First, that although not explicitly stated in protocols, clinical trials started before COVID-19 were designed with the intention to inform clinical practice in a world absent of the pandemic as defined above.",1
11646,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"To assess the impact of COVID-19 on ongoing clinical trials, the ICH E9 addendum on estimands and sensitivity analysis provides a helpful framework for discussion .",1
11647,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"Under this framework, clinical trials provide a precise description of the treatment effect reflecting the clinical question posed by a given trial objective.",1
11657,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"By having a precise definition of the initial target of estimation, sponsors of ongoing clinical trials can better identify potential sources of bias due to the pandemic.",1
11664,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"Recognizing the useful role that estimands may play in analysing clinical trial data affected by COVID-19, the industry working group on estimands in oncology convened in March 2020 to share experiences in dealing with emerging challenges to ongoing clinical trials .",1
11667,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,Our intention in this article is to support discussions between various stakeholders regarding the impact of COVID-19 on individual clinical trials.,1
11669,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"While our focus will be on the impact of COVID-19 on randomized superiority clinical trials in oncology, we comment on other settings and hope that this discussion will be informative for future public health crises, should there be more that cause similar disruptions to health care systems.",1
11674,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"In Section 2, we assess the potential impact of COVID-19 on interpretation of randomized superiority clinical trials with a focus on time-to-event endpoints.",1
11690,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"a NOTE: ""Blood cancers often directly compromise the immune system, so those patients are probably most at risk, whereas cancers such as colon cancer, breast cancer, and lung cancer do not typically cause immune suppression that is not treatment-related.""",1
11706,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"patients with compromised immune systems, elderly patients at high risk .",1
11745,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,Typical population-level summaries for time-to-event endpoints in oncology clinical trials are the hazard ratio and survival probability.,1
11853,Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -Application of the Estimand Framework on behalf of the industry working group on estimands in oncology z Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials -Application of the Estimand,"In this paper, we have illustrated how the estimand framework can help to structure discussions about the impact of COVID-19 on the interpretation of results from ongoing oncology clinical trials, with a focus on time-to-event endpoints in randomized superiority trials.",1
11880,THE MUC5B PROMOTOR POLYMORPHISM ASSOCIATES WITH SEVERE COVID-19,The current coronavirus disease COVID-19 pandemic illustrates the diversity in response to exposition to severe acute respiratory syndrome coronavirus 2 .,1
11884,THE MUC5B PROMOTOR POLYMORPHISM ASSOCIATES WITH SEVERE COVID-19,Diversity in response to exposition to SARS-CoV-2 may be related to host factors associated with airway defense.,1
11907,THE MUC5B PROMOTOR POLYMORPHISM ASSOCIATES WITH SEVERE COVID-19,Diagnosis of COVID-19 were made on the basis of a positive SARS-CoV-2 PCR except for three cases with clinical characteristics and a high-resolution computed tomography congruent with COVID-19 disease.,1
11938,THE MUC5B PROMOTOR POLYMORPHISM ASSOCIATES WITH SEVERE COVID-19,"In the human respiratory system, MUC5B is secreted throughout the lung by submucosal glands and the superficial epithelium of trachea, bronchi, bronchioles and alveoli, and by salivary glands and nasal mucosa 3, 5, 18, 19 .",1
12105,An artificial intelligence-based first-line defence against COVID-19: digitally screening citizens for risks via a chatbot,"Currently, the world is facing an unprecedented health crisis caused by the novel coronavirus disease .",1
